

# CITATION REPORT

List of articles citing

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

DOI: 10.1056/nejm199704033361401

New England Journal of Medicine, 1997, 336, 973-9.

**Source:** <https://exaly.com/paper-pdf/28254397/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2266	Oversight Hearings Promote NSF Insight. <b>1979</b> , 29, 433-434		
2265	Is managed care here to stay?. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 1013-4	59.2	17
2264	Adjuvant therapy for rectal cancer--a good first step. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 1016-7	59.2	50
2263	Managed care--a look back and a look ahead. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 1018-20	59.2	52
2262	Inflammation, aspirin, and the risk of cardiovascular disease. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 422; author reply 423-4	59.2	12
2261	Immunologic Aspects of Vasculitis and Cardiovascular Disease. <b>1997</b> , 278, 1962		14
2260	Maternal Infection and Cerebral Palsy in Infants of Normal Birth Weight. <b>1997</b> , 278, 207		498
2259	Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 1014-6	59.2	197
2258	Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 1360-9	59.2	1070
2257	Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. <b>1997</b> , 27 Suppl 1, 2-11		5
2256	C-reactive protein as a marker for acute coronary syndromes. <b>1997</b> , 18, 1897-902		38
2255	Unstable angina: integrating new treatments. <b>1997</b> , 32, 139-42, 144, 146-50		
2254	Classification, diagnosis and treatment of vascular dementia. <b>1997</b> , 11, 361-73		41
2253	Hemostatic risk factors in arterial thrombosis and atherosclerosis: the thrombin-fibrin and platelet-vWF axis. <b>1997</b> , 88, 1-25		13
2252	Chronic infections and coronary heart disease: is there a link?. <b>1997</b> , 350, 430-6		1028
2251	C-Reactive Protein Undervalued, Underutilized. <b>1997</b> , 43, 2017-2018		10
2250	The prognostic value of the acute-phase response in stroke recurrence. <b>1997</b> , 4, 491-497		6

2249	Aspirin for the second hundred years: new uses for an old drug. <b>1997</b> , 81, 151-2	30
2248	Pharmaceutical biotechnology. <b>1997</b> , 8, 763-825	
2247	Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. <b>1997</b> , 3, 1346-53	200
2246	Role of C-reactive protein in acute lung injury. <b>1997</b> , 3, 539-45	20
2245	Coronary angioplasty induces a systemic inflammatory response. <b>1997</b> , 80, 1476-8	76
2244	Increased adhesiveness of white blood cells in patients with unstable angina: additional evidence for an involvement of the immune-inflammatory system. <b>1997</b> , 20, 1017-20	4
2243	Current and Practical Management of Acute Myocardial Infarction. <b>1997</b> , 4, 375-396	
2242	The diagnosis of polymyalgia rheumatica in patients with a low erythrocyte sedimentation rate: comment on the article by Helfgott and Kieval. <b>1997</b> , 40, 1726-7; author reply 1727-8	6
2241	[Antithrombotic therapy in chronic coronary syndromes--value of thrombocyte aggregation inhibition, anticoagulation and chronic thrombolysis]. <b>1998</b> , 87 Suppl 2, 145-51	2
2240	Management strategies for a better outcome in unstable coronary artery disease. <b>1998</b> , 21, 314-22	31
2239	Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. <b>1998</b> , 21, 879-84	18
2238	Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. <b>1998</b> , 7, 113-74	172
2237	New antiplatelet agents. <b>1998</b> , 28, 558-64	2
2236	Recurrent urinary infection, raised serum levels of C-reactive protein, and the risk of cardiovascular disease in patients with spinal cord injury: a hypothesis. <b>1998</b> , 36, 868-9	3
2235	Interactions between periodontal disease, medical diseases and immunity in the older individual. <b>1998</b> , 16, 80-105	94
2234	Autoimmune and inflammatory responses may have an additive effect in postpercutaneous transluminal coronary angioplasty restenosis. <b>1998</b> , 81, 339-41	16
2233	Complications associated with combined use of abciximab and an intracoronary thrombolytic agent (urokinase or tissue-type plasminogen activator). <b>1998</b> , 82, 518-9	5
2232	Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. <b>1998</b> , 82, 515-8	177

2231	Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. <b>1998</b> , 82, 845-50	84
2230	Atherogenesis and its relationship to coronary risk factors. <b>1998</b> , 1, 3-14	4
2229	Is infection with Chlamydia pneumoniae a causative agent in atherosclerosis?. <b>1998</b> , 4, 426-30	35
2228	Fundamentals of clinical methodology: 2. Etiology. <b>1998</b> , 12, 227-70	16
2227	Hypoxia and molecular cardiovascular medicine. <b>1998</b> , 8, 24-33	13
2226	NF- $\kappa$ B Mediated Transcription in Human Monocytic Cells and Endothelial Cells. <b>1998</b> , 8, 138-42	16
2225	Vascular surgery. <b>1998</b> , 186, 247-62	1
2224	Neonatal cytokines and coagulation factors in children with cerebral palsy. <b>1998</b> , 44, 665-75	460
2223	Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. <b>1998</b> , 187, 23-42	334
2222	[New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase]. <b>1998</b> , 93, 407-15	5
2221	T-lymphocytes and monocytes in atherogenesis. <b>1998</b> , 23, 168-77	41
2220	[Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection]. <b>1998</b> , 23, 185-92	9
2219	Medikamentöse Therapie der chronischen Myokardischämie bei koronarer Herzkrankheit. <b>1998</b> , 39, 728-738	1
2218	The activated immune system in congestive heart failure--from dropsy to the cytokine paradigm. <b>1998</b> , 243, 87-92	35
2217	Recent advances in the management of unstable angina and non-Q-wave myocardial infarction. <b>1998</b> , 46, 335-41	
2216	Marqueurs protéiques et infection. <b>1998</b> , 1998, 133-135	
2215	C-reactive protein: a cardiovascular risk factor report on the CRP hot-topic workshop October 1, 1997. <b>1998</b> , 12, 323-327	10
2214	Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. <b>1998</b> , 88, 9-12	27

2213	Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. <b>1998</b> , 351, 88-92		1031
2212	Altering molecular mechanisms to prevent sudden arrhythmic death. <b>1998</b> , 351, 1276-8		30
2211	Acute respiratory-tract infections and risk of first-time acute myocardial infarction. <b>1998</b> , 351, 1467-71		297
2210	The identification of salicylates as normal constituents of serum: a link between diet and health?. <b>1998</b> , 51, 502-5		24
2209	Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. <i>Circulation</i> , <b>1998</b> , 97, 1195-206	16.7	265
2208	Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. <i>Circulation</i> , <b>1998</b> , 98, 731-3	16.7	1329
2207	Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. <i>Circulation</i> , <b>1998</b> , 97, 425-8	16.7	770
2206	Elevated concentrations of soluble intercellular adhesion molecule-1 were associated with increased risk of MI. <b>1998</b> , 2, 66		
2205	Secondary prevention of coronary heart disease. <b>1998</b> , 79, 1006-17		8
2204	Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. <b>1998</b> , 31, 1217-25		256
2203	C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. <b>1998</b> , 31, 1460-5		626
2202	Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. <b>1998</b> , 32, 35-41		187
2201	Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. <b>1998</b> , 32, 655-62		294
2200	Long-term (10-year) outcome in patients with unstable angina pectoris treated by coronary balloon angioplasty. <b>1998</b> , 32, 1603-9		18
2199	Cost-effective pharmacological prevention of acute coronary syndromes. <b>1998</b> , 37, 469-75		
2198	Pathobiology of thrombin in acute coronary syndromes. <b>1998</b> , 136, S19-31		13
2197	Inflammation in cardiovascular disease: cart, horse, or both?. <i>Circulation</i> , <b>1998</b> , 97, 2000-2	16.7	127
2196	Risk Assessment and Physical Examination in Vascular Disease. <b>1998</b> , 9, 264-269		1

2195	The role of cytokines in unstable angina. <b>1998</b> , 7, 1667-72	10
2194	Persistent infection and vascular disease: a systematic review. <b>1998</b> , 7, 691-713	33
2193	Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers. <b>1998</b> , 33, 785-9	14
2192	Pharmacokinetics, Pharmacodynamics, and Tolerability Profile of Clinafloxacin. <b>1998</b> , 15, 19-34	2
2191	Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. <b>1998</b> , 158, 1709-14	225
2190	Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina. <b>1998</b> , 136, 884-93	35
2189	Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. <b>1998</b> , 56, 965-76	17
2188	Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. <b>1998</b> , 139, 307-15	198
2187	Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. <b>1998</b> , 140, 199-270	422
2186	The pathophysiologic roles of interleukin-6 in human disease. <b>1998</b> , 128, 127-37	781
2185	The actions of exogenous dehydroepiandrosterone in experimental animals and humans. <b>1998</b> , 218, 174-91	116
2184	The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. <b>1998</b> , 55, 580-92	1167
2183	Dental plaque, platelets, and cardiovascular diseases. <b>1998</b> , 3, 151-60	159
2182	Ethnic differences in correlates of microalbuminuria in NIDDM. The role of the acute-phase response. <b>1998</b> , 21, 385-8	11
2181	Association of virulent <i>Helicobacter pylori</i> strains with ischemic heart disease. <i>Circulation</i> , <b>1998</b> , 97, 1675-87	255
2180	<i>Chlamydia pneumoniae</i> in atheroma: consideration of criteria for causality. <b>1998</b> , 51, 812-7	34
2179	C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. <i>Circulation</i> , <b>1998</b> , 97, 2007-11	16.7 789
2178	Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. <i>Circulation</i> , <b>1998</b> , 98, 839-44	16.7 1104

2177	Medical Therapy for Coronary Artery Disease: Primary and Secondary Prevention. <b>1998</b> , 6, 245-249		
2176	Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris. <i>Circulation</i> , <b>1998</b> , 98, 1707-13	16.7	147
2175	Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention. <b>1998</b> , 3, 77-84		0
2174	Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. <i>Circulation</i> , <b>1998</b> , 97, 1095-102	16.7	205
2173	Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. <b>1998</b> , 279, 1477-82		1443
2172	Gene therapy for restenosis: are we ready?. <b>1998</b> , 82, 306-13		65
2171	Stroke risk factors and stroke prevention. <b>1998</b> , 18, 429-40		83
2170	Is clopidogrel markedly superior to aspirin in patients with peripheral vascular disease?. <b>1998</b> , 9, 273-8		17
2169	Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. <b>1998</b> , 35 ( Pt 6), 745-53		274
2168	Assessing the relationship between dental disease and coronary heart disease in elderly U.S. veterans. <b>1998</b> , 129, 301-11		106
2167	Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. <b>1998</b> , 18, 1634-42		34
2166	Inflammation, infection, and cardiovascular risk: how good is the clinical evidence?. <i>Circulation</i> , <b>1998</b> , 97, 1671-4	16.7	117
2165	Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. <i>Circulation</i> , <b>1998</b> , 98, 2370-6	16.7	265
2164	Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. <b>1998</b> , 158, 1434-9		76
2163	Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. <i>Circulation</i> , <b>1998</b> , 98, 2796-9	16.7	147
2162	Acute phase and opsonin response in cardiac surgery patients: influence of underlying cardiac disease. <b>1998</b> , 13, 447-54		4
2161	Persistent inflammatory response in stroke survivors. <b>1998</b> , 50, 1722-8		97
2160	Atherosclerosis and the immune system. <b>1998</b> , 158, 1395-6		10

2159	Enhanced upregulation of the Fc gamma receptor IIIa (CD16a) during in vitro differentiation of ApoE4/4 monocytes. <b>1998</b> , 18, 1424-32	36
2158	Evaluation of a latex-enhanced immunoturbidimetric assay for measuring low concentrations of C-reactive protein. <b>1998</b> , 35 ( Pt 5), 671-3	22
2157	Periodontal disease and mortality from all causes in the VA Dental Longitudinal Study. <b>1998</b> , 3, 339-49	86
2156	Infections and atherosclerosis: new clues from an old hypothesis?. <b>1998</b> , 148, 937-48	157
2155	Informed consent: edging forwards (and backwards). <b>1998</b> , 316, 949-51	29
2154	C-reactive protein and risks of future myocardial infarction and thrombotic stroke. <b>1998</b> , 19, 1-3	47
2153	Concordant message of different inflammatory markers in patients with rheumatoid arthritis. <b>1998</b> , 103, 35-42	15
2152	Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. <b>1998</b> , 19, 1434-503	757
2151	Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats. <b>1998</b> , 37, 108-14	23
2150	The role of blood platelets in coronary atherosclerosis and thrombosis. <b>1998</b> , 58, 1-10	10
2149	Antibodies to oxidized lipoproteins and their relationship to myocardial infarction. <b>1998</b> , 91, 411-5	13
2148	Communicating the risk reduction achieved by cholesterol reducing drugs. <b>1998</b> , 316, 1956-8	72
2147	Maximizing the cost-effectiveness of lipid-lowering therapy. <b>1998</b> , 158, 1977-89	54
2146	Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. <b>1998</b> , 8, 310-7	56
2145	Acute coronary syndromes: 2. Antiplatelet agents. <b>1998</b> , 33, 107-10, 115-8, 121-4 passim	
2144	Intercellular adhesion molecule (ICAM-1) and the risks of developing atherosclerotic disease. <b>1998</b> , 19, 1119-21	24
2143	Functional food science and the cardiovascular system. <b>1998</b> , 80 Suppl 1, S113-46	39
2142	NIH-FDA Conference: Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Abstracts. <b>1998</b> , 14, 187-334	14



2141	Monocyte Activation and Humoral Immune Response to Endotoxins in Patients Receiving On-Line Hemodiafiltration Therapy. <b>1998</b> , 21, 335-340	13
2140	Antithrombotic drugs: insights from cardiology. <b>1998</b> , 8 Suppl 5, 19-27	29
2139	Exposure to dioxin and nonneoplastic mortality in the expanded IARC international cohort study of phenoxy herbicide and chlorophenol production workers and sprayers. <b>1998</b> , 106 Suppl 2, 645-53	103
2138	Endothelium and acute coronary syndromes. <b>1998</b> , 44, 1799-1808	76
2137	Rapid Automated High Sensitivity Enzyme Immunoassay of C-Reactive Protein. <b>1998</b> , 44, 1358-1361	116
2136	Biochemical markers of the acute coronary syndromes. <b>1998</b> , 44, 1855-1864	114
2135	The atheromatous lipid core. <b>1998</b> , 19, 16-8	35
2134	Effects of acidosis on acute phase protein metabolism in liver cells. <b>1999</b> , 25, 228-33	6
2133	Increased Levels of Factor VIII and Fibrinogen in Patients with Venous Thrombosis Are not Caused by Acute Phase Reactions. <b>1999</b> , 81, 680-683	187
2132	Central injection of nicotine increases hepatic and splenic interleukin 6 (IL-6) mRNA expression and plasma IL-6 levels in mice: involvement of the peripheral sympathetic nervous system. <b>1999</b> , 13, 1259-67	25
2131	Stroke prediction and prevention by carotid endarterectomy: keep an eye on the doughnut and not just the hole. <b>1999</b> , 9, 345-50	5
2130	The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. <b>1999</b> , 14, 1961-7	55
2129	Vegetarians and Cardiovascular Risk Factors: Hemostasis, Inflammatory Markers and Plasma Homocysteine. <b>1999</b> , 81, 913-917	63
2128	Vitamin E and vascular homeostasis: implications for atherosclerosis. <b>1999</b> , 13, 965-75	130
2127	Suppressive Effects of Anti-inflammatory Agents on Human Endothelial Cell Activation and Induction of Heat Shock Proteins. <b>1999</b> , 5, 117-128	42
2126	Genetic Polymorphism of 5,10-MTHFR Reductase Gene in Offspring of Patients with Myocardial Infarction. <b>1999</b> , 82, 19-23	64
2125	Markers of chronic infection and inflammation. Are they important in cases with chronic coronary heart disease. <b>1999</b> , 40, 275-80	5
2124	Industry Proposals. <b>1999</b> , 22, 281-286	

2123	National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases. <b>1999</b> , 45, 1104-1121	513
2122	Malnutrition, Cardiac Disease, and Mortality. <b>1999</b> , 19, 309-314	19
2121	Gene-Environment Interaction in the Determination of Levels of Plasma Fibrinogen. <b>1999</b> , 82, 818-825	33
2120	Inflammatory Markers in Men with Angiographically Documented Coronary Heart Disease. <b>1999</b> , 45, 1967-1973	114
2119	C-reactive protein and coronary artery disease-what is the link?. <b>1999</b> , 14, 2798-800	20
2118	Nontraditional Cardiovascular Risk Factors. <b>1999</b> , 317, 193-207	14
2117	Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. <b>1999</b> , 20, 567-74	53
2116	Chronic Infection, Chlamydia And Coronary Heart Disease. <b>1999</b> ,	3
2115	Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. <b>1999</b> , 19, 2355-63	247
2114	A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. <b>1999</b> , 19, 932-8	145
2113	Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. <b>1999</b> , 19, 493-8	220
2112	Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. <b>1999</b> , 19, 499-504	60
2111	Mathematical treatment of autonomic oscillations. <i>Circulation</i> , <b>1999</b> , 100, e63-4	16.7 85
2110	C(-260)-->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. <i>Circulation</i> , <b>1999</b> , 99, 3218-20	16.7 286
2109	The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. <b>1999</b> , 19, 1776-83	172
2108	Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. <b>1999</b> , 19, 1695-9	93
2107	Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. <i>Circulation</i> , <b>1999</b> , 100, e95	16.7 7
2106	Novel inflammatory markers of coronary risk: theory versus practice. <i>Circulation</i> , <b>1999</b> , 100, 1148-50	16.7 331

2105	Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. <b>1999</b> , 274, 34111-5		43
2104	Evaluation of platelet membrane glycoproteins in coronary artery disease : consequences for diagnosis and therapy. <i>Circulation</i> , <b>1999</b> , 99, E1-E11	16.7	76
2103	Angiotensin induces inflammatory activation of human vascular smooth muscle cells. <b>1999</b> , 19, 1623-9		395
2102	C-Reactive protein, serum amyloid A protein, and coronary events. <i>Circulation</i> , <b>1999</b> , 100, e66	16.7	1
2101	Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. <b>1999</b> , 19, 1368-77		244
2100	Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. <i>Circulation</i> , <b>1999</b> , 100, 832-7	16.7	75
2099	Mathematical treatment of autonomic oscillations. <i>Circulation</i> , <b>1999</b> , 100, e64	16.7	
2098	Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. <b>1999</b> , 281, 1722-7		296
2097	Emerging noninvasive biochemical measures to predict cardiovascular risk. <b>1999</b> , 159, 237-45		42
2096	Reenvisioning Medical Education for the New Millennium. <b>1999</b> , 282, 2171		1
2095	Interleukin-6 exacerbates early atherosclerosis in mice. <b>1999</b> , 19, 2364-7		417
2094	Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. <i>Circulation</i> , <b>1999</b> , 99, 1161-4	16.7	178
2093	Elevated C-reactive protein levels in overweight and obese adults. <b>1999</b> , 282, 2131-5		1621
2092	Inhibition of mouse mammary adenocarcinoma (EMT6) growth and metastases in mice by a modified form of C-reactive protein. <b>1999</b> , 20, 72-87		13
2091	Inflammation, the acute phase response and atherosclerosis. <b>1999</b> , 37, 495-503		56
2090	von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. <b>1999</b> , 19, 3071-8		253
2089	Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. <i>Circulation</i> , <b>1999</b> , 100, 230-5	16.7	1259
2088	Inhibition of arteriosclerosis by T-cell depletion in normocholesterolemic rabbits immunized with heat shock protein 65. <b>1999</b> , 19, 1905-11		46

2087	Smoldering arteries? Low-grade inflammation and coronary heart disease. <b>1999</b> , 282, 2169-71		25
2086	Hormone replacement therapy, inflammation, and hemostasis in elderly women. <b>1999</b> , 19, 893-9		185
2085	High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coronary artery bypass graft surgery. <b>1999</b> , 81, 488-94		8
2084	Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. <b>1999</b> , 19, 1986-91		400
2083	A rapid and sensitive automated light scattering immunoassay for serum C-reactive protein and the definition of a reference range in healthy blood donors. <b>1999</b> , 37, 109-13		11
2082	Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. <b>1999</b> , 19, 617-24		297
2081	Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. <b>1999</b> , 19, 54-8		94
2080	Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. <i>Circulation</i> , <b>1999</b> , 99, 861-6	16.7	198
2079	Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. <b>1999</b> , 19, 646-55		251
2078	MicroCRP: a highly sensitive CRP method applied in the monitoring of renal allograft recipients. <b>1999</b> , 59, 405-16		8
2077	Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. <i>Circulation</i> , <b>1999</b> , 99, 1540-7	16.7	278
2076	Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. <i>Circulation</i> , <b>1999</b> , 99, 855-60	16.7	455
2075	Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. <b>1999</b> , 19, 2993-3000		144
2074	C-reactive protein and outcome after ischemic stroke. <b>1999</b> , 30, 981-5		271
2073	Infection and atherosclerosis: emerging mechanistic paradigms. <i>Circulation</i> , <b>1999</b> , 100, e20-8	16.7	324
2072	Independent prognostic value of elevated C-reactive protein in unstable angina. <i>Circulation</i> , <b>1999</b> , 100, 1958-63	16.7	186
2071	Increasing plasma neopterin and persistent plasma endothelin during follow-up after acute cerebral ischemia. <b>1999</b> , 50, 1-8		20
2070	Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. <b>1999</b> , 96, 8247-52		206

2069	Cardiac neural changes before vasovagal syncope. <i>Circulation</i> , <b>1999</b> , 100, e67	16.7
2068	Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. <i>Circulation</i> , <b>1999</b> , 100, 736-42	16.7 350
2067	Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study. <b>1999</b> , 51, 173-9	14
2066	Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. <b>1999</b> , 55, 648-58	1071
2065	Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. <b>1999</b> , 55, 1945-51	260
2064	Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. <b>1999</b> , 55, 1899-911	1196
2063	Interactions Between Hemodialysis Adequacy and Nutrition in Dialysis Patients. <b>1999</b> , 12, 112-116	3
2062	Thrombogenic Risk Factors for Cardiovascular Disease in Dialysis Patients. <b>1999</b> , 12, 117-125	8
2061	Periodontitis-atherosclerosis syndrome: an expanded model of pathogenesis. <b>1999</b> , 34, 346-52	65
2060	Arteriosklerose – eine chronische Infektionskrankheit durch Chlamydia pneumoniae. <b>1999</b> , 4, 185-193	
2059	Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. <b>1999</b> , 22, A27	
2058	Future directions in thrombolysis. <b>1999</b> , 22, IV44-53	11
2057	Protective role of interleukin-10 in atherosclerosis. <b>1999</b> , 85, e17-24	505
2056	Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. <b>1999</b> , 24, 51-6	18
2055	[Angiology update]. <b>1999</b> , 94, 251-63	0
2054	Cardiac markers: present and future. <b>1999</b> , 29, 56-63	22
2053	Urinary hypoxanthine and xanthine levels in acute coronary syndromes. <b>1999</b> , 29, 162-5	20
2052	[Blood coagulation and fibrinolysis in arteriosclerosis]. <b>1999</b> , 88, 315-23	5

2051	The anti-inflammatory properties of rose-hip. <b>1999</b> , 7, 63-8	36
2050	Rose hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain inflammatory parameters in vivo. <b>1999</b> , 7, 377-86	48
2049	Diet and hemostatic factors. <b>1999</b> , 1, 243-8	10
2048	Inflammation and lipid-lowering treatment. <b>1999</b> , 1, 251-5	1
2047	The role of C-reactive protein in cardiovascular disease risk. <b>1999</b> , 1, 99-104	56
2046	Anaerobic Periodontal Infections as Risk Factors for Medical Diseases. <b>1999</b> , 1, 33-38	6
2045	Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. <b>1999</b> , 133, 321-5	117
2044	Interleukin-6 production by endothelial cells after infection with influenza virus and cytomegalovirus. <b>1999</b> , 134, 623-30	32
2043	Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. <b>1999</b> , 83, 515-8	35
2042	Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. DAVIT Study Group. Danish Verapamil Infarction Trial. <b>1999</b> , 83, 1263-5, A9	14
2041	C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. <b>1999</b> , 83, 1595-9	76
2040	White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]). <b>1999</b> , 84, 252-7	73
2039	Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. <b>1999</b> , 84, 459-61, A9	84
2038	Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. <b>1999</b> , 84, 595-8, A8	45
2037	Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. <b>1999</b> , 84, 1018-22	278
2036	Diagnosis and management of patients with unstable angina. <b>1999</b> , 24, 681-744	8
2035	The physiological structure of human C-reactive protein and its complex with phosphocholine. <b>1999</b> , 7, 169-77	536
2034	Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. <b>1999</b> , 42, 51-60	427

2033	Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. <b>1999</b> , 13, 273-9	195
2032	Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. <b>1999</b> , 29, 122-7; discussion 127-9	147
2031	A high plasma concentration of TNF-alpha is associated with dementia in centenarians. <b>1999</b> , 54, M357-64	335
2030	Role of inflammation in the pathogenesis of unstable coronary artery diseases. <b>1999</b> , 59, 12-22	10
2029	A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary heart disease. <b>1999</b> , 59, 32-35	17
2028	Increasing neopterin and decreasing endothelin-1 in plasma during insulin infusion in women. <b>1999</b> , 59, 417-24	9
2027	Do age-related macular degeneration and cardiovascular disease share common antecedents?. <b>1999</b> , 6, 125-43	211
2026	C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. <b>1999</b> , 19, 972-8	1914
2025	C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. <b>1999</b> , 137, 346-51	99
2024	Infectious causes of atherosclerosis. <b>1999</b> , 137, 216-26	49
2023	Newer antiplatelet agents in acute coronary syndromes. <b>1999</b> , 138, S570-6	10
2022	Oral contraceptive use is associated with a systemic acute phase response. <b>1999</b> , 13, 239-244	20
2021	Pro-inflammatory effect of oestrogens. <b>1999</b> , 13, 217-219	4
2020	Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. <b>1999</b> , 52, 465-77	187
2019	The altered homeostatic theory: a holistic approach to multiple diseases, including atherosclerosis, ischemic diseases, and hypertension. <b>1999</b> , 53, 194-9	10
2018	Occlusions of epicardial arteries might not directly induce symptoms in ischemic heart disease. <b>1999</b> , 53, 533-42	9
2017	The possible role of infections in acute myocardial infarction. <b>1999</b> , 53, 397-404	7
2016	High levels of plasma C-reactive protein and future risk of age-related cataract. <b>1999</b> , 9, 166-71	63

2015	[Primary nutritional and drug prevention of atherosclerosis]. <b>1999</b> , 20 Suppl 3, 360s-370s		2
2014	Infection, immunisation and atherosclerosis: is there a link?. <b>1999</b> , 17, 559-64		7
2013	Atherosclerosis--an inflammatory disease. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 115-26	59.2	17316
2012	C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. <i>Circulation</i> , <b>1999</b> , 100, 96-102	16.7	665
2011	C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. <i>Circulation</i> , <b>1999</b> , 99, 237-42	16.7	1410
2010	Acute-phase proteins and other systemic responses to inflammation. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 448-54	59.2	4765
2009	Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk. <b>1999</b> , 33, 261-6		61
2008	Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. <b>1999</b> , 95, 75-82		48
2007	The effect of red wine on the fibrinolytic system and the cellular activation reactions before and after exercise. <b>1999</b> , 96, 355-63		14
2006	Management of high-risk subsets in unstable angina. <b>1999</b> , 17, 415-37, x		2
2005	C-Reactive protein, serum amyloid A protein, and coronary events. <i>Circulation</i> , <b>1999</b> , 100, e65-6	16.7	12
2004	Histopathology of plaque rupture. <b>1999</b> , 17, 263-70, vii		40
2003	Risk Assessment and Physical Examination in Vascular Disease. <b>1999</b> , 10, 311-316		
2002	[Ischemic cardiopathy: inflammation markers and the cardiovascular risk]. <b>1999</b> , 52, 990-1003		9
2001	Antibiotics for myocardial infarction? A possible role of infection in atherogenesis and acute coronary syndromes. <b>1999</b> , 57, 283-91		25
2000	ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). <b>1999</b> , 33, 2092-197		482
1999	Volumetric remodeling of the proximal left coronary artery: early versus late after heart transplantation. <b>1999</b> , 34, 197-203		48
1998	Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. <b>1999</b> , 34, 1738-43		141



1997	Enhanced inflammatory response in patients with preinfarction unstable angina. <b>1999</b> , 34, 1696-703	126
1996	Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. <b>1999</b> , 34, 1975-81	379
1995	Endotoxin: another phantom menace?. <b>1999</b> , 34, 1982-4	5
1994	Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease. <b>1999</b> , 34, 1995-2001	54
1993	Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. <b>1999</b> , 71, 663-70	102
1992	Endotoxin and interleukin-1 decrease hepatic lipase mRNA levels. <b>1999</b> , 142, 379-87	45
1991	Immunization with bacillus Calmette-Guerin vaccine increases aortic atherosclerosis in the cholesterol-fed rabbit. <b>1999</b> , 143, 105-13	35
1990	Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. <b>1999</b> , 143, 383-8	49
1989	Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. <b>1999</b> , 145, 51-60	112
1988	A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. <b>1999</b> , 144, 251-61	65
1987	Plasma sialic acid and coronary artery atheromatous load in patients with stable chest pain. <b>1999</b> , 145, 261-6	15
1986	Plasma levels of interleukin 2, 6, 10 and phenotypic characterization of circulating T lymphocytes in ischemic heart disease. <b>1999</b> , 145, 369-74	67
1985	Coronary C-reactive protein distribution: its relation to development of atherosclerosis. <b>1999</b> , 145, 375-9	160
1984	C-reactive protein (CRP) in cerebro-vascular events. <b>1999</b> , 147, 49-53	46
1983	Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. <b>1999</b> , 147 Suppl 1, S3-10	41
1982	Haemostatic function, arterial disease and the prevention of arterial thrombosis. <b>1999</b> , 12, 577-99	8
1981	Hormone replacement therapy and increased plasma concentration of C-reactive protein. <i>Circulation</i> , <b>1999</b> , 100, 713-6	16.7 380
1980	Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. <i>Circulation</i> , <b>1999</b> , 100, 717-22	16.7 576

1979	Extradigestive manifestations of <i>Helicobacter pylori</i> gastric infection. <b>1999</b> , 45 Suppl 1, I9-I12	72
1978	Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis. <b>1999</b> , 138, 555-9	32
1977	Stable versus unstable atherosclerosis: clinical aspects. <b>1999</b> , 138, S421-5	76
1976	Viruses and atherosclerosis: a critical review of the epidemiologic evidence. <b>1999</b> , 138, S453-60	18
1975	<i>Chlamydia pneumoniae</i> and atherosclerosis: links to the disease process. <b>1999</b> , 138, S488-90	46
1974	The association of chronic cough with the risk of myocardial infarction: the Framingham Heart Study. <b>1999</b> , 106, 279-84	29
1973	Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. <b>1999</b> , 106, 506-12	1225
1972	Cellular adhesion molecules and atherogenesis. <b>1999</b> , 107, 85-97	280
1971	Expression of cytokine and adhesion molecule mRNA in atherectomy specimens from patients with coronary artery disease. <b>1999</b> , 63, 249-54	11
1970	Fibrinolytic factors, serum lipid and C-reactive protein predicting cardiac events in Japanese patients with coronary atherosclerotic lesions. <b>1999</b> , 63, 976-80	7
1969	Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis. <b>1999</b> , 344, 7-13	18
1968	Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis. <b>1999</b> , 344, 7	8
1967	Plasma C-reactive protein in haemodialysis. <b>1999</b> , 17, 142-8	21
1966	Emerging evidence for inflammation in conditions frequently affecting older adults: report of a symposium. <b>1999</b> , 47, 1016-25	28
1965	Serum IL-6 level and the development of disability in older persons. <b>1999</b> , 47, 639-46	611
1964	Is vasculitis a significant component of atherosclerosis?. <b>1999</b> , 11, 3-10	11
1963	Cytomegalovirus infection and coronary heart disease. <i>Circulation</i> , <b>1999</b> , 100, e139	16.7 9
1962	Genetics and molecular biology. <b>1999</b> , 10, 471-474	

1961	Inflammation markers and coronary heart disease. <b>1999</b> , 10, 435-41	87
1960	Evaluating novel cardiovascular risk factors: can we better predict heart attacks?. <b>1999</b> , 130, 933-7	210
1959	Biochemical Markers of Acute Coronary Syndromes. <b>2000</b> ,	
1958	Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. <b>2000</b> , 133, 111-22	180
1957	Aspirin in the treatment and prevention of cardiovascular disease. <b>2000</b> , 30 Suppl 3, 1-13	1
1956	Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993-1998. <b>2000</b> , 64, 303-8	32
1955	Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. <b>2000</b> , 352, 693	16
1954	Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. <b>2000</b> , 98, 531-535	159
1953	Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. <b>2000</b> , 98, 531	81
1952	Trends in patient and technique survival in peritoneal dialysis and strategies: how are we doing and how can we do better?. <b>2000</b> , 7, 324-37	15
1951	Recurrent Venous Thrombosis and Markers of Inflammation. <b>2000</b> , 83, 536-539	110
1950	Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. <b>2000</b> , 10, 97-101	45
1949	Ischaemic heart disease following renal transplantation. <b>2000</b> , 15, 269-77	19
1948	Interpretation of plasma protein measurements in end-stage renal disease. <b>2000</b> , 18, 337-42	10
1947	The effect of anti-platelet aggregation to prevent pressure ulcer development: a retrospective study of 132 elderly patients. <b>2000</b> , 46, 311-7	7
1946	American Diabetes Association Annual Meeting, 1999: more on cardiovascular disease. <b>2000</b> , 23, 845-52	9
1945	Obesity and diabetes. <b>2000</b> , 23, 1584-90	38
1944	New emerging risk factors for cardiovascular disease: their relation with menopause and hormone therapy. <b>2000</b> , 6, 27-33	1

1943	C-reactive protein as a marker of chronic inflammation in uremic patients. <b>2000</b> , 18, 183-90	36
1942	The inflammatory process in aging. <b>2000</b> , 10, 207-222	36
1941	Diabetes mellitus, cardiovascular disease and hormone replacement therapy. <b>2000</b> , 8, 153-172	1
1940	Renin angiotensin system and ASCVD. <b>2000</b> , 15, 141-50	13
1939	Microinflammatory state in CRI, PD-/HD-patients. <b>2000</b> , 15, 149-154	1
1938	Effect of the inflammatory response on trace element and vitamin status. <b>2000</b> , 37 ( Pt 3), 289-97	149
1937	Reference distributions for the positive acute phase serum proteins, alpha1-acid glycoprotein (orosomuroid), alpha1-antitrypsin, and haptoglobin: a practical, simple, and clinically relevant approach in a large cohort. <b>2000</b> , 14, 284-92	26
1936	Is there an antigenic mimicry between arteriosclerotic lesions and H. pylori antigens?. <b>2000</b> , 33, 419-21	5
1935	High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. <b>2000</b> , 33, 601-10	67
1934	The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. <b>2000</b> , 58, 346-52	158
1933	Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. <b>2000</b> , 58, 1703-10	257
1932	The link of biocompatibility to cytokine production. <b>2000</b> , 76, S96-103	70
1931	Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. <b>2000</b> , 121, 255-60	249
1930	Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects - The Hoorn Study. <b>2000</b> , 30, 763-70	24
1929	Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. <b>2000</b> , 247, 205-12	47
1928	The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. <b>2000</b> , 247, 341-5	63
1927	C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. <b>2000</b> , 248, 406-14	33
1926	Are statins anti-inflammatory?. <b>2000</b> , 1, 161-165	69

1925	Periodontal medicine: the emergence of a new branch of periodontology. <b>2000</b> , 23, 9-12	103
1924	Oral disease, cardiovascular disease and systemic inflammation. <b>2000</b> , 23, 110-20	116
1923	Du bon usage du dialogue m�decin-patient : ce n'est pas que pour le m�decin. <b>2000</b> , 2000, 8-9	
1922	CRP : un param�tre biologique pr�dictif des �v�nements cardio-vasculaires futurs. <b>2000</b> , 2000, 9	
1921	Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults--the ARIC study. Atherosclerosis Risk in Communities. <b>2000</b> , 8, 279-86	96
1920	Central injection of nitric oxide synthase inhibitors increases peripheral interleukin-6 and serum amyloid A: involvement of adrenaline from adrenal medulla. <b>2000</b> , 130, 41-8	5
1919	Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. <b>2000</b> , 20, 146-52	75
1918	Ceruloplasmin and cardiovascular disease. <b>2000</b> , 28, 1735-44	123
1917	FORUM: oxidation and atherosclerosis. <b>2000</b> , 28, 1681-2	17
1916	Vitamin E and heart disease: basic science to clinical intervention trials. <b>2000</b> , 28, 141-64	353
1915	Increased plasma fibrinogen level and future risk of coronary artery disease after repair of abdominal aortic aneurysm. <b>2000</b> , 191, 619-25	7
1914	Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: chronic infections and coronary heart disease. <b>2000</b> , 20, 52-63	3
1913	Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors. <b>2000</b> , 20, 698-710	16
1912	Periodontal disease and atherosclerotic cardiovascular disease: confounding effects or epiphenomenon?. <b>2000</b> , 20, 805-18	7
1911	Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. <b>2000</b> , 85, 140-6	239
1910	Prevalence of autoantibodies against contractile proteins in coronary artery disease and their clinical implications. <b>2000</b> , 85, 870-2, A6, A9	20
1909	Relation of C-reactive protein to extent and severity of coronary narrowing in patients with stable angina pectoris or abnormal exercise tests. <b>2000</b> , 86, 205-7	42
1908	Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. <b>2000</b> , 86, 682-4, A8	66

1907	Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?. <b>2000</b> , 86, 35J-42J; discussion 42J-43J	4
1906	Effect of short-term aspirin use on C-reactive protein. <b>2000</b> , 9, 37-41	62
1905	Circulating levels of IL-1beta, a prothrombotic cytokine, are elevated in unstable angina versus stable angina. <b>2000</b> , 9, 217-22	40
1904	Statin therapy and plasma C-reactive protein levels in primary prevention. <b>2000</b> , 14, 699-700	1
1903	Lipopolysaccharide induction of gene expression in human monocytic cells. <b>2000</b> , 21, 247-51	31
1902	The prediction of coronary atherosclerosis employing artificial neural networks. <b>2000</b> , 23, 453-6	16
1901	Chlamydia pneumoniae and atherosclerosis. <b>2000</b> , 2, 218-25	6
1900	Novel risk factors for stroke: homocysteine, inflammation, and infection. <b>2000</b> , 2, 110-4	11
1899	Basic mechanisms of stroke prevention with lipid-lowering therapy. <b>2000</b> , 2, 120-5	2
1898	Oral platelet glycoprotein IIb/IIIa inhibition. <b>2000</b> , 2, 372-7	8
1897	Global risk assessment for lipid therapy to prevent coronary heart disease. <b>2000</b> , 2, 424-32	
1896	Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. <b>2000</b> , 2, 269-73	15
1895	The role of C-reactive protein in cardiovascular disease risk. <b>2000</b> , 2, 274-9	27
1894	Weighing the evidence for infection as a risk factor for coronary heart disease. <b>2000</b> , 2, 280-7	9
1893	Inflammation and acute coronary syndromes. <b>2000</b> , 25, 108-12	25
1892	Atherosclerosis--an autoimmune disease due to an immune reaction against heat-shock protein 60. <b>2000</b> , 25, 87-90	49
1891	[C-reactive protein as an independent marker of prognosis in acute coronary syndrome: comparison with troponin T]. <b>2000</b> , 89, 658-66	3
1890	Coronary artery disease: an inflammatory or infectious process. <i>Basic Research in Cardiology</i> , <b>2000</b> , 95 Suppl 1, I59-64	11.8 4

1889	New Strategies for Management of Malnutrition in Peritoneal Dialysis Patients. <b>2000</b> , 20, 271-275	5
1888	Evaluation of Four Automated High-Sensitivity C-Reactive Protein Methods: Implications for Clinical and Epidemiological Applications. <b>2000</b> , 46, 461-468	197
1887	Indications for Treatment of Asymptomatic Carotid Stenosis. <b>2000</b> , 11, 247-264	2
1886	Immunoradiometric Assay of Circulating C-Reactive Protein: Age-related Values in the Adult General Population. <b>2000</b> , 46, 934-938	199
1885	Inflammation influences vascular remodeling through AT2 receptor expression and signaling. <b>2000</b> , 2, 13-20	128
1884	Images in cardiology. Saddle pulmonary embolism: diagnosis by spiral computed tomography. <b>2000</b> , 84, 10	
1883	The Role of Chronic Infection and Inflammation in Korean Patients with Coronary Artery Disease. <b>2000</b> , 30, 1107	8
1882	Direct effects of statins on cells primarily involved in atherosclerosis. <b>2000</b> , 23, 187-92	38
1881	Inflammation, insulin resistance, infection, diabetes, and atherosclerosis. <b>2000</b> , 6, 272-6	21
1880	Causes of Low Serum Albumin in Peritoneal Dialysis Patients. <b>2000</b> , 23, 149-153	1
1879	C-reactive protein: a new cardiovascular risk factor?. <b>2000</b> , 173, 117-8	2
1878	C-Reactive Protein and Cardiac Troponin T in Risk Stratification: Differences in Optimal Timing of Tests Early after the Onset of Chest Pain. <b>2000</b> , 46, 1597-1603	32
1877	Systemic diseases caused by oral infection. <b>2000</b> , 13, 547-58	649
1876	Marshaling the Anti-Inflammatory Influence of the Neuroimmunomodulator alpha-MSH. <b>2000</b> , 15, 192-195	4
1875	Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). <b>2000</b> , 15, 953-60	599
1874	Direct proinflammatory effect of C-reactive protein on human endothelial cells. <i>Circulation</i> , <b>2000</b> , 102, 2165-8	16.7 1539
1873	Acute-phase inflammatory response to periodontal disease in the US population. <b>2000</b> , 79, 49-57	314
1872	Plasma C-reactive protein in hemodialysis patients: a cross-sectional, longitudinal clinical survey. <b>2000</b> , 18, 30-6	52

1871	Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 1139-47	59.2	963
1870	HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. <b>2000</b> , 54, 790-6		101
1869	Opinion: Oxidized Lipoproteins, Inflammation, and Acute Phase Reactants as Markers for Coronary Artery Disease. Oxidierte Lipoproteine, Entzündung und Akute Phase-Reaktanden als Marker für Koronararterienkrankung: Persönlicher Standpunkt. <b>2000</b> , 24, 5-13		
1868	Production of hepatocyte growth factor during acute myocardial infarction. <b>2000</b> , 83, 450-5		34
1867	Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. <i>Circulation</i> , <b>2000</b> , 101, E16-22	16.7	485
1866	Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. <b>2000</b> , 20, 298-308		71
1865	Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. <b>2000</b> , 20, 1417-20		161
1864	C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. <b>2000</b> , 20, 2094-9		469
1863	Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. <i>Circulation</i> , <b>2000</b> , 102, 2100-4	16.7	75
1862	The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). <b>2000</b> , 181 Suppl 3, S569-71		13
1861	Plasma levels of C-reactive protein after coronary stent implantation. <b>2000</b> , 21, 1152-8		86
1860	Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. <b>2000</b> , 21, 1574-83		154
1859	Clinical and research challenges in risk factors for cardiovascular diseases. <b>2000</b> , 21, 1917-21		5
1858	C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. <b>2000</b> , 21, 1598-606		42
1857	C-reactive protein and dangerous liaisons. <b>2000</b> , 21, 1560-2		
1856	Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. <b>2000</b> , 21, 1614-20		85
1855	Antihypertensive management in PD- and HD-patients. <b>2000</b> , 15, 135-136		
1854	Management of acute ischaemic heart disease. <b>2000</b> , 15, 143-144		2



1853	C-reactive protein, inflammation and atherosclerosis: do we really understand it yet?. <b>2000</b> , 21, 958-60		13
1852	Management of diabetic patients on dialysis. <b>2000</b> , 15, 141-142		
1851	Management of heart failure. <b>2000</b> , 15, 147-148		13
1850	Management of dyslipidaemia. <b>2000</b> , 15, 129-130		1
1849	Management of patients with diabetic nephropathy. <b>2000</b> , 15, 139-140		5
1848	Examination of the relation between periodontal health status and cardiovascular risk factors: serum total and high density lipoprotein cholesterol, C-reactive protein, and plasma fibrinogen. <b>2000</b> , 151, 273-82		219
1847	Management of diabetic patients with microalbuminuria. <b>2000</b> , 15, 137-138		
1846	Endothelial apoptosis: could it have a role in the pathogenesis and treatment of disease?. <b>2000</b> , 117, 841-54		139
1845	C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. <b>2000</b> , 21, 1000-8		66
1844	Assessment of cardiovascular risk factors. <b>2000</b> , 15, 127-128		1
1843	General management of hypertension. <b>2000</b> , 15, 131-132		1
1842	Serum carotenoids and markers of inflammation in nonsmokers. <b>2000</b> , 152, 1065-71		141
1841	Inflammatory markers of coronary risk. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 1179-82	59.2	198
1840	C-reactive protein in the prediction of cardiovascular disease. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 512-3	59.2	14
1839	Acute systemic inflammation impairs endothelium-dependent dilatation in humans. <i>Circulation</i> , <b>2000</b> , 102, 994-9	16.7	481
1838	[ <i>Helicobacter pylori</i> and coronary heart diseases--hypotheses and facts]. <b>2000</b> , 38, 315-23		3
1837	C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. <b>2000</b> , 21, 1584-90		245
1836	Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels. <b>2000</b> , 32, 515-8		38

1835	Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. <b>2000</b> , 21, 21-4		239
1834	Claudication in the Young Patient. <b>2000</b> , Volume 13, 0027-0038		
1833	Thyrotropin regulation of cyclic adenosine monophosphate production in human coronary artery smooth muscle cells. <b>2000</b> , 10, 219-25		39
1832	Reference interval for serum C-reactive protein in healthy blood donors using the Dade Behring N Latex CRP mono assay. <b>2000</b> , 60, 37-43		36
1831	Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. <b>2000</b> , 275, 10077-84		140
1830	On the association of elevated tPA/PAI-1 complex and von Willebrand factor with recurrent myocardial infarction. <b>2000</b> , 20, 1857-9		10
1829	Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. <i>Circulation</i> , <b>2000</b> , 102, 2329-34	16.7	294
1828	Recognition of the importance of embolization in atherosclerotic vascular disease. <i>Circulation</i> , <b>2000</b> , 101, 570-80	16.7	634
1827	Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. <i>Circulation</i> , <b>2000</b> , 101, 1758-9	16.7	72
1826	Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. <i>Circulation</i> , <b>2000</b> , 101, 2149-53	16.7	765
1825	Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure. <b>2000</b> , 275, 24583-9		98
1824	Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. <i>Circulation</i> , <b>2000</b> , 102, 1227-32	16.7	190
1823	Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. <i>Circulation</i> , <b>2000</b> , 102, 1000-6	16.7	562
1822	The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. <b>2000</b> , 182, 1583-7		79
1821	Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. <i>Circulation</i> , <b>2000</b> , 101, 1785-91	16.7	132
1820	Atherogenesis: current understanding of the causes of atheroma. <b>2000</b> , 83, 247-52		50
1819	Significant association of cagA positive Helicobacter pylori strains with risk of premature myocardial infarction. <b>2000</b> , 84, 267-71		57
1818	Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. <b>2000</b> , 181 Suppl 3, S572-8		49

1817	Comparison of laboratory parameters as risk factors for the presence and the extent of coronary or carotid atherosclerosis: the significance of apolipoprotein B to apolipoprotein all ratio. <b>2000</b> , 38, 529-38	16
1816	Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. <b>2000</b> , 20, 2657-62	189
1815	C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. <b>2000</b> , 20, 1047-51	136
1814	Brugada syndrome: an electrocardiographic diagnosis not to be missed. <b>2000</b> , 84, 1-2	10
1813	C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. <b>2000</b> , 20, 198-203	42
1812	C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. <b>2000</b> , 20, 1057-60	183
1811	C-reactive protein as cardiovascular risk factor. A discovery by ECAT. <b>2000</b> , 38, 1055	3
1810	Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. <b>2000</b> , 20, 1052-6	119
1809	Plasma sphingomyelin level as a risk factor for coronary artery disease. <b>2000</b> , 20, 2614-8	287
1808	The role of inflammation in cardiovascular disease. <b>2000</b> , 20, 901	18
1807	Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. <i>Circulation</i> , <b>2000</b> , 102, 1634-8	16.7 228
1806	Adhesion of monocyte very late antigen-4 to endothelial vascular cell adhesion molecule-1 induces interleukin-1beta-dependent expression of interleukin-6 in endothelial cells. <b>2000</b> , 20, 353-9	25
1805	Inflammation-mediated rheumatic diseases and atherosclerosis. <b>2000</b> , 59, 321-5	132
1804	Recent advances in ischaemic heart disease. <b>2000</b> , 76, 542-6	3
1803	Aspirin triggered lipid mediators: novel inhibitors of leucocyte trafficking. <b>2000</b> , 55 Suppl 2, S10-2	3
1802	Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. <b>2000</b> , 20, 529-37	123
1801	C-reactive protein as a clinical marker of risk. <i>Circulation</i> , <b>2000</b> , 102, E63-4	16.7 2
1800	Description and status of the azithromycin and coronary events study (ACES). <b>2000</b> , 181 Suppl 3, S579-81	42

1799	A neuronal NO synthase (NOS1) gene polymorphism is associated with asthma. <b>2000</b> , 272, 391-4	68
1798	Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. <b>2000</b> , 32, 43-52	80
1797	Comparison of sibralfiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. <b>2000</b> , 355, 337-345	190
1796	Plaque stabilization: the role of lipid lowering. <b>2000</b> , 74 Suppl 1, S11-5	10
1795	Local cytokine production and acute coronary events. <b>2000</b> , 73, 79-81	2
1794	C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. <b>2000</b> , 35, 469-76	696
1793	Cardiovascular disease and chronic renal disease: a new paradigm. <b>2000</b> , 35, S117-31	396
1792	Activation of the acute phase response and complement C3 in patients with IgA nephropathy. <b>2000</b> , 35, 21-8	33
1791	Prospective crossover trial of the influence of vitamin E-coated dialyzer membranes on T-cell activation and cytokine induction. <b>2000</b> , 35, 95-104	52
1790	Diseases of aging. <b>2000</b> , 18, 1567-83	99
1789	Albumin, fibrinogen, von Willebrand factor, factor VIII activity, and leukocyte count are significant nontraditional risk factors for CHD in patients with diabetes. <b>2000</b> , 4, 89-91	
1788	Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study. <b>2000</b> , 140, 249-52	23
1787	Cardiac marker testing: where should we focus?. <b>2000</b> , 140, 351-3	4
1786	Importance of microembolization and inflammation in atherosclerotic heart disease. <b>2000</b> , 140, S90-102	23
1785	Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: findings from National Health and Nutrition Examination Survey III. <b>2000</b> , 53, 95-102	57
1784	Estrogens and women's health: interrelation of coronary heart disease, breast cancer and osteoporosis. <b>2000</b> , 74, 297-309	30
1783	The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. <b>2000</b> , 68, 457-65	41
1782	Markers of inflammation as predictors in cardiovascular disease. <b>2000</b> , 293, 31-52	52

1781	Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors. <b>2000</b> , 46, 1-123		2
1780	Long-term prevention of ischaemic stroke and stroke recurrence. <b>2000</b> , 98, 83-96		8
1779	Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. <b>2000</b> , 100, 373-9		42
1778	Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. <i>Circulation</i> , <b>2000</b> , 101, 1767-72	16.7	1852
1777	Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. <b>2000</b> , 71, 1528-34		560
1776	Chlamydia pneumoniae-induced transactivation of the major immediate early promoter of cytomegalovirus: potential synergy of infectious agents in the pathogenesis of atherosclerosis. <b>2000</b> , 181, 787-90		13
1775	Association between C-reactive protein and features of the metabolic syndrome: a population-based study. <b>2000</b> , 23, 1835-9		510
1774	Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. <i>Circulation</i> , <b>2000</b> , 102, 2522-7	16.7	75
1773	Aspirin. <i>Circulation</i> , <b>2000</b> , 101, 1206-18	16.7	612
1772	Hypothesis: the recent decline in coronary heart disease mortality--mainly a shift from fatal to non-fatal events?. <b>2000</b> , 34, 468-74		7
1771	Report on the Royal Society of Medicine one day meeting on coronary artery disease--'Bench to Bedside'. 29th June 2000, London, UK. <b>2000</b> , 1, 1469-73		
1770	Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. <b>2000</b> , 9, 194-201		31
1769	Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. <b>2000</b> , 55, M709-15		305
1768	PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. <i>Circulation</i> , <b>2000</b> , 102, 636-41	16.7	345
1767	The pathophysiology of acute coronary syndromes. <b>2000</b> , 83, 361-6		387
1766	Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. <b>2000</b> , 321, 199-204		1106
1765	Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 1148-55	59.2	708
1764	Novel risk factors for atherosclerosis. <b>2000</b> , 75, 369-80		127

1763	Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. <b>2000</b> , 84, 163-79, ix		24
1762	Chronic infection and coronary artery disease. <b>2000</b> , 84, 123-48		39
1761	C-reactive protein, inflammation, and coronary risk. <b>2000</b> , 84, 149-61, ix		111
1760	Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). <i>Circulation</i> , <b>2000</b> , 102, 42-7	16.7	1841
1759	Multiple complex coronary plaques in patients with acute myocardial infarction. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 915-22	59.2	769
1758	Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. <b>2000</b> , 192, 1197-204		910
1757	Premature atherosclerosis in systemic lupus erythematosus. <b>2000</b> , 26, 257-78		101
1756	<i>Helicobacter pylori</i> is an aetiological factor for ischaemic heart disease: the case against. <b>2000</b> , 32, 65-8		14
1755	Inflammation, infection and atherosclerosis: do antibacterials have a role in the therapy of coronary artery disease?. <b>2000</b> , 59, 159-70		9
1754	Induction of early atherosclerosis in CBA/J mice by combination of <i>Trypanosoma cruzi</i> infection and a high cholesterol diet. <b>2000</b> , 153, 273-82		17
1753	Antibodies to <i>Chlamydia pneumoniae</i> and clinical course in patients with unstable angina pectoris. <b>2000</b> , 153, 499-504		6
1752	Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. <b>2000</b> , 148, 179-88		43
1751	C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. <b>2000</b> , 149, 139-50		339
1750	Relation of inflammation to vascular function in patients with coronary heart disease. <b>2000</b> , 149, 403-11		88
1749	Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. <b>2000</b> , 148, 209-14		1425
1748	The role of plaque rupture and thrombosis in coronary artery disease. <b>2000</b> , 149, 251-66		197
1747	Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. <b>2000</b> , 35, 1535-42		332
1746	Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. <b>2000</b> , 35, 1628-37		704

1745	Techniques characterizing the coronary atherosclerotic plaque: influence on clinical decision making?. <b>2000</b> , 36, 13-21		123
1744	Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. <b>2000</b> , 36, 39-43		112
1743	Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. <b>2000</b> , 36, 423-6		131
1742	ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). <b>2000</b> , 36, 970-1062		731
1741	Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. <b>2000</b> , 36, 1774-80		107
1740	Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. <b>2000</b> , 35, 358-62		108
1739	Reply. <b>2000</b> , 35, 815-816		
1738	Mechanism of protection against vascular smoking-induced changes by hormone replacement therapy. <b>2000</b> , 35, 815-6		1
1737	C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 836-43	59.2	4551
1736	Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. <b>2000</b> , 37, 431-502		194
1735	Periodontal infections contribute to elevated systemic C-reactive protein level. <b>2001</b> , 72, 1221-7		480
1734	Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. <b>2001</b> , 154, 681-9		307
1733	Helicobacter pylori heat shock protein 60 and risk of coronary heart disease: a case control study with focus on markers of systemic inflammation and lipids. <b>2001</b> , 156, 193-9		21
1732	A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. <b>2001</b> , 154, 699-702		56
1731	Fibrinogen and C-reactive protein on admission as markers of final infarct size after primary angioplasty for acute myocardial infarction. <b>2001</b> , 157, 189-96		22
1730	Autoantibodies and endothelial dysfunction in well-controlled, uncomplicated insulin-dependent diabetes mellitus patients. <b>2001</b> , 158, 241-6		26
1729	C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. <b>2001</b> , 158, 495-8		50
1728	Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. <b>2001</b> , 37, 839-46		181

1727	The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. <b>2001</b> , 37, 1266-70	86
1726	Increased local temperature in human coronary atherosclerotic plaques: an independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention. <b>2001</b> , 37, 1277-83	132
1725	Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. <b>2001</b> , 37, 2036-41	154
1724	Plaque burden, arterial remodeling and plaque vulnerability: determined by systemic factors?. <b>2001</b> , 38, 718-23	61
1723	C-reactive protein is increased in patients with degenerative aortic valvular stenosis. <b>2001</b> , 38, 1078-82	138
1722	A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. <b>2001</b> , 38, 1302-6	186
1721	Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. <b>2001</b> , 38, 2006-12	102
1720	[C-reactive protein as a coronary risk factor]. <b>2001</b> , 117, 303-8	4
1719	[Inflammation and infection in stable coronary disease and acute coronary syndrome]. <b>2001</b> , 54, 453-9	5
1718	Tratamiento hipolipemiante en ancianos. <b>2001</b> , 36, 195-209	
1717	[The role of inflammation and infection in acute coronary syndrome]. <b>2001</b> , 26 Suppl 1, 9-18	2
1716	Associations of subclinical cardiovascular disease with frailty. <b>2001</b> , 56, M158-66	539
1715	Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1022-9	59.2 444
1714	Mechanisms of acute coronary syndromes and the potential role of statins. <b>2001</b> , 2, 9-14	13
1713	Effect of the inflammation, chronic hyperglycemia, or malabsorption on the apolipoprotein A-IV concentration in type 1 diabetes mellitus and in diabetes secondary to chronic pancreatitis. <b>2001</b> , 50, 1019-24	11
1712	Cholesterol: an important but relatively overemphasized risk factor for ischemic heart disease. <b>2001</b> , 57, 593-601	5
1711	Established and emerging cardiovascular risk factors. <b>2001</b> , 141, S49-57	105
1710	C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. <b>2001</b> , 141, 206-10	100



1709	Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. <b>2001</b> , 141, 342-7		17
1708	Joint effects of C-reactive protein and other risk factors on acute coronary events. <b>2001</b> , 141, 580-5		46
1707	The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. <b>2001</b> , 141, 893-8		45
1706	PRINCE's prospects: statins, inflammation, and coronary risk. <b>2001</b> , 141, 881-3		20
1705	Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. <b>2001</b> , 142, 248-53		57
1704	Highlights from the American College of Cardiology Forty-Ninth Annual Scientific Sessions: March 18 to 21, 2001. <b>2001</b> , 142, 363-374		3
1703	C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. <b>2001</b> , 138, 486-92		171
1702	Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. <b>2001</b> , 77, 247-53		151
1701	Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. <b>2001</b> , 80, 55-60		56
1700	Hippocrates, cardiology, Confucius and the Yellow Emperor. <b>2001</b> , 81, 219-33		8
1699	Insulin Resistance and Cardiovascular Disease. <b>2001</b> , 86, 713-718		193
1698	Current concepts of the pathogenesis of the acute coronary syndromes. <i>Circulation</i> , <b>2001</b> , 104, 365-72	16.7	1205
1697	High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. <i>Circulation</i> , <b>2001</b> , 103, 1813-8	16.7	1051
1696	CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction?. <b>2001</b> , 1, 403-14		37
1695	The response of serum sialic acid and other acute phase reactants to an oral fat load in healthy humans. <b>2001</b> , 12, 510-4		18
1694	C-reactive protein and primary prevention of ischemic heart disease. <b>2001</b> , 311, 45-8		10
1693	Obesity and preeclampsia: the potential role of inflammation. <b>2001</b> , 98, 757-62		114
1692	Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users. <b>2001</b> , 101, 35-43		39

1691	Ischemic stroke among inpatients with preceding inflammatory response. <b>2001</b> , 104, 375-7		
1690	Plasma ascorbic acid and risk of heart disease and cancer. <b>2001</b> , 357, 2134		
1689	ANTIPLATELET AND ANTICOAGULANT THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC HEART DISEASE. <b>2001</b> , 19, 253-265		
1688	Comorbidity in rheumatoid arthritis. <b>2001</b> , 27, 283-303		54
1687	Development of Definitions for Acute Illness in Nursing Home Residents Based on Chart-Recorded Physical Exam Findings. <b>2001</b> , 2, 279-284		5
1686	[Diabetes mellitus, inflammation and coronary atherosclerosis: current and future perspectives]. <b>2001</b> , 54, 751-63		19
1685	[Current topics in vascular biology: an update for the 21st century]. <b>2001</b> , 54, 635-42		0
1684	The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. <b>2001</b> , 6, 30-40		109
1683	Health consequences of visceral obesity. <b>2001</b> , 33, 534-41		229
1682	Statins in the 21st century: end of the simple story?. <b>2001</b> , 10, 1755-66		17
1681	Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. <i>Circulation</i> , <b>2001</b> , 104, 1598-603	16.7	474
1680	Insulin resistance and cardiovascular disease. <b>2001</b> , 86, 713-8		357
1679	Association between physical activity and markers of inflammation in a healthy elderly population. <b>2001</b> , 153, 242-50		435
1678	Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. <b>2001</b> , 167, 5355-61		71
1677	C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. <b>2001</b> , 33, 37-47		152
1676	Platelets and atherosclerosis. <b>2001</b> , 293-307		
1675	Prevention of a first myocardial infarction. <b>2001</b> , 41, 359-67		3
1674	Role of inflammation in stable angina patients without hypercholesterolemia. <b>2001</b> , 31, 620		2

1673	Vitamin E and macrophage cyclooxygenase regulation in the aged. <b>2001</b> , 131, 382S-8S	65
1672	High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , <b>2001</b> , 104,	16.7 10
1671	Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. <b>2001</b> , 161, 2474-80	100
1670	A Prospective Evaluation of the Interleukin-1 Receptor Antagonist Intron 2 Gene Polymorphism and the Risk of Myocardial Infarction. <b>2001</b> , 86, 1141-1143	10
1669	Absence of Diurnal Variation of C-Reactive Protein Concentrations in Healthy Human Subjects. <b>2001</b> , 47, 426-430	284
1668	Proposed Cardiovascular Risk Assessment Algorithm Using High-Sensitivity C-Reactive Protein and Lipid Screening. <b>2001</b> , 47, 28-30	151
1667	Evaluation of Nine Automated High-Sensitivity C-Reactive Protein Methods: Implications for Clinical and Epidemiological Applications. Part 2. <b>2001</b> , 47, 418-425	406
1666	Vasculitis of the Coronary Arteries and Atherosclerosis. <b>2001</b> , 315-327	10
1665	Malnutrition, Inflammation, and Atherosclerosis in Peritoneal Dialysis Patients. <b>2001</b> , 21, 157-162	76
1664	Variability and Classification Accuracy of Serial High-Sensitivity C-Reactive Protein Measurements in Healthy Adults. <b>2001</b> , 47, 444-450	323
1663	5?-Nucleotidase in the Detection of Increased Activity of the Liver Form of Alkaline Phosphatase in Serum. <b>2001</b> , 47, 2046-2048	11
1662	GMC: approaching the abyss. <b>2001</b> , 322, 1599-1599	
1661	Different Effects of Oral and Transdermal Hormone Replacement Therapies on Factor IX, APC Resistance, t-PA, PAI and C-reactive Protein. <b>2001</b> , 86, 550-556	130
1660	PlateletLeukocyteEndothelium cross talk. <b>2001</b> , 106-123	3
1659	Redesigning the map of uremic toxins. <b>2001</b> , 133, 42-70	18
1658	Aspirin intake and the use of serum ferritin as a measure of iron status. <b>2001</b> , 74, 219-26	47
1657	Performance Characteristics of an Automated Method for High-sensitivity CRP on the Roche Cobas Mira Analyzer. <b>2001</b> , 6, 30-31	1
1656	Effects of Fluvastatin and Bezafibrate Combination on Plasma Fibrinogen, t-Plasminogen Activator Inhibitor and C Reactive Protein Levels in Coronary Artery Disease Patients with Mixed Hyperlipidaemia (FACT Study) [A Rebuttal]. <b>2001</b> , 85, 189-189	2

1655	Evaluation of Turbidimetric High-Sensitivity C-Reactive Protein Assays for Cardiovascular Risk Estimation. <b>2001</b> , 47, 2044-2046	25
1654	Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice. <b>2001</b> , 19, 1083-8	18
1653	Targeting the central nervous system inflammatory response in ischemic stroke. <b>2001</b> , 14, 349-53	58
1652	Issues surrounding age: vascular disease in the elderly. <b>2001</b> , 12, 601-9	24
1651	Hypercoagulability in Obstructive Sleep Apnea. <b>2001</b> , 8, 238-241	2
1650	Coronary vascular endothelial function and myocardial ischemia: why should we worry about endothelial dysfunction?. <b>2001</b> , 12, 475-84	11
1649	Dietary carbohydrates, physical inactivity, obesity, and the 'metabolic syndrome' as predictors of coronary heart disease. <b>2001</b> , 12, 395-404	106
1648	Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. <b>2001</b> , 10, 377-83	15
1647	Amyloid precursors and amyloidosis in inflammatory arthritis. <b>2001</b> , 13, 67-73	65
1646	Obesity and Preeclampsia. <b>2001</b> , 98, 757-762	82
1645	Prognostic implications of endothelial dysfunction: does it mean anything?. <b>2001</b> , 12, 435-43	32
1644	Inflammation and coronary heart disease: an overview. <b>2001</b> , 9, 31-5	87
1643	Platelet-active drugs : the relationships among dose, effectiveness, and side effects. <b>2001</b> , 119, 39S-63S	380
1642	Differences in inflammatory activity at the onset of acute myocardial infarction according to the clinical presentation of preinfarction angina. <b>2001</b> , 65, 707-10	
1641	Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. <b>2001</b> , 3, 326-32	41
1640	Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors. <b>2001</b> , 11 Suppl 1, 85-95	29
1639	Inflammatory and atherosclerotic interactions in the depleted uremic patient. <b>2001</b> , 19, 53-61	168
1638	Hormone Replacement Therapy in Primary and Secondary Prevention of Coronary Artery Disease: Cardiologist and Geriatric Specialist Perspectives. <b>2001</b> , 23, 409-416	

1637	Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. <b>2001</b> , 101, 523-531	19
1636	Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. <b>2001</b> , 101, 523	12
1635	A prospective study of Helicobacter pylori seropositivity and the risk for future myocardial infarction among socioeconomically similar U.S. men. <b>2001</b> , 135, 184-8	59
1634	Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. <b>2001</b> , 134, 224-38	201
1633	Relationship between systemic markers of inflammation and serum beta-carotene levels. <b>2001</b> , 161, 1903-8	78
1632	Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. <b>2001</b> , 116 Suppl, S108-15	32
1631	Perspectives on vascular biology and diabetes. <b>2001</b> , 49, 100-3	0
1630	Cell Adhesion Molecules in Cardiovascular Pathology [A Glance into the Future?]. <b>2001</b> , 1, 225-235	2
1629	Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. <b>2001</b> , 32, 280-99	341
1628	C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis. <b>2001</b> , 32, 2748-52	91
1627	C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. <b>2001</b> , 56, 375-80	154
1626	Reducing cardiovascular risk in diabetes. Which factors to modify first?. <b>2001</b> , 109, 26-30, 33-6	10
1625	Prothrombotic Changes in Hemostatic Parameters and C-reactive Protein in the Elderly with Winter Acute Respiratory Tract Infections. <b>2001</b> , 85, 245-249	35
1624	Genetics of arterial prothrombotic risk states. <b>2001</b> , 226, 409-19	44
1623	Periodontal Disease and Its Association with Systemic Disease. <b>2001</b> , 166, 85-89	42
1622	[Hyperlipoproteinemia and LDL apheresis. Clinical experiences with the H.E.L.P. system]. <b>2001</b> , 26, 531-44	3
1621	[Arteriosclerosis--an ultrachronic Chlamydia infection]. <b>2001</b> , 42, 1189-90, 1193-5	0
1620	Cardiovascular disease risk factors and atherosclerosis in children and adolescents. <b>2001</b> , 3, 479-85	51

1619	Diagnostik und Risikostratifizierung bei Patienten mit akutem Koronarsyndrom mittels Myoglobin, Troponin T und CK/CK-MB. <b>2001</b> , 38, 385-393	1
1618	[Atherothrombosis and inflammation]. <b>2001</b> , 90, 379-84	2
1617	Évaluation du réactif ultrasensible de dosage de la CRP sur le dimension RXL. <b>2001</b> , 2001, 55-59	
1616	Interleukin 6 and haemostasis. <b>2001</b> , 115, 3-12	235
1615	Interleukin-10: an anti-atherogenic cytokine?. <b>2001</b> , 31, 1-2	6
1614	Levels of alpha1 acid glycoprotein and ceruloplasmin predict future albumin levels in hemodialysis patients. <b>2001</b> , 60, 2360-6	27
1613	Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. <b>2001</b> , 60, 333-40	148
1612	End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?. <b>2001</b> , 59, 407-14	272
1611	Transcription factor-kappa B (NF-kappa B) and renal disease. <b>2001</b> , 59, 415-24	374
1610	Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. <b>2001</b> , 59, 1960-6	154
1609	Complement components as uremic toxins and their potential role as mediators of microinflammation. <b>2001</b> , 78, S271-7	24
1608	C-reactive protein: a story half told. <b>2000</b> , 13, 143-6	12
1607	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysis Patients?. <b>2001</b> , 13, 164-166	1
1606	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysis Patients?. <b>2001</b> , 13, 167-169	1
1605	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysis Patients?. <b>2001</b> , 13, 169-171	
1604	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysis Patients?. <b>2001</b> , 13, 171-173	1
1603	What Are the Causes and Consequences of the Chronic Inflammatory State in Chronic Dialysis Patients?. <b>2001</b> , 13, 174-175	3
1602	What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?. <b>2000</b> , 13, 163-75	81

1601	Atherosclerosis risk is higher in continuous ambulatory peritoneal dialysis patients than in hemodialysis patients. <b>2001</b> , 25, 448-52	13
1600	Primary stroke prevention. <b>2001</b> , 8, 1-15	23
1599	Is the observed association between periodontitis and atherosclerosis causal?. <b>2001</b> , 109, 2-7	22
1598	Atherosclerosis and plaque rupture. <b>2001</b> , 53, 56-63	13
1597	General health risk of periodontal disease. <b>2001</b> , 51, 417-27	29
1596	Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. <b>2001</b> , 44, 1170-6	50
1595	High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. <b>2001</b> , 44, 2737-2745	1035
1594	Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. <b>2001</b> , 34, 309-15	32
1593	Soluble CD40L and cardiovascular risk in women. <i>Circulation</i> , <b>2001</b> , 104, 2266-8	16.7 396
1592	Novel clinical markers of vascular wall inflammation. <b>2001</b> , 89, 763-71	592
1591	C-reactive protein is a marker for a complex culprit lesion anatomy in unstable angina. <b>2001</b> , 24, 506-10	21
1590	Assessment of subclinical atherosclerosis and cardiovascular risk. <b>2001</b> , 24, 642-50	8
1589	Interleukin-6 and acute coronary syndrome. <b>2001</b> , 24, 701-4	116
1588	Homocysteine and C-reactive protein levels in haemodialysis patients. <b>2001</b> , 33, 207-15	14
1587	Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment. <b>2001</b> , 11, 49-81	8
1586	C-reactive protein and coronary heart disease: diagnostic and therapeutic implications for primary prevention. <b>2001</b> , 1, 153-7	13
1585	Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. <b>2001</b> , 25, 1327-31	256
1584	The relation of body fat mass and distribution to markers of chronic inflammation. <b>2001</b> , 25, 1407-15	486

1583	Cardiovascular monitoring and therapy for HIV-infected patients. <b>2001</b> , 946, 236-73	14
1582	Is Serum Uric Acid Level Associated with All-Cause Mortality in High-Functioning Older Persons: MacArthur Studies of Successful Aging?. <b>2001</b> , 49, 1679-1684	27
1581	Association between C-reactive protein, anti-Chlamydia pneumoniae antibodies, and vascular function in healthy adults. <b>2001</b> , 87, 119-21, A9	16
1580	Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. <b>2001</b> , 87, 636-9, A10	139
1579	Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. <b>2001</b> , 87, 663-6, A11	79
1578	Laboratory surrogates for anti-atherosclerotic drug development. <b>2001</b> , 87, 21A-26A	49
1577	Antibodies to chlamydial lipopolysaccharides in unstable angina pectoris. <b>2001</b> , 87, 1150-3	11
1576	Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. <b>2001</b> , 87, 1361-6	98
1575	Association of C-reactive protein with markers of prevalent atherosclerotic disease. <b>2001</b> , 88, 112-7	195
1574	Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS). <b>2001</b> , 88, 214-8	21
1573	The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall. <b>2001</b> , 88, 12E-15E	36
1572	C-reactive protein and coronary heart disease in western Turkey. <b>2001</b> , 88, 601-7	43
1571	Going from immutable to mutable atherosclerotic plaques. <b>2001</b> , 88, 2F-9F	30
1570	What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?. <b>2001</b> , 88, 7J-16J	15
1569	Inflammatory pathways in atherosclerosis and acute coronary syndromes. <b>2001</b> , 88, 10K-15K	181
1568	C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. <b>2001</b> , 88, 1139-42	120
1567	Relation of the leukocyte count to recurrent cardiac events in stable patients after acute myocardial infarction. <b>2001</b> , 88, 1221-4	31
1566	[Physiopathology of unstable angina]. <b>2001</b> , 50, 359-65	1



1565	Manipulating the vascular biology of coronary atherosclerosis in diabetes: new opportunities. <b>2001</b> , 137, 82-92	1
1564	Translating basic aging research into geriatric health care. <b>2001</b> , 36, 193-203	5
1563	Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. <b>2001</b> , 38, 1271-6	27
1562	Oxidative stress and inflammation in hemodialysis patients. <b>2001</b> , 38, 1408-13	160
1561	Genetic predictors of perioperative neurological and cognitive injury and recovery. <b>2001</b> , 15, 247-276	4
1560	How can the risk of long-term consequences of rheumatoid arthritis be reduced?. <b>2001</b> , 15, 139-70	21
1559	Diagnosis and management of carotid artery disease: the role of carotid artery stenting. <b>2001</b> , 26, 499-555	0
1558	Increased acute phase reactants are associated with levels of lipoproteins and increased carotid plaque volume. <b>2001</b> , 21, 227-34	32
1557	Update on the cardiometabolic syndrome. <b>2001</b> , 4, 17-23	32
1556	Is obesity an inflammatory condition?. <b>2001</b> , 17, 953-66	594
1555	Interleukin-6 is a major effector molecule of short-term G-CSF treatment inducing bone metabolism and an acute-phase response. <b>2001</b> , 29, 812-21	25
1554	Effect of mycelial culture broth of <i>Ganoderma lucidum</i> on the growth characteristics of human cell lines. <b>2001</b> , 92, 550-555	12
1553	Candidate foods in the Asia-Pacific region for cardiovascular protection: fish, fruit and vegetables. <b>2001</b> , 10, 134-7	5
1552	False increase in serum C-reactive protein caused by monoclonal IgM-lambda: a case report. <b>2001</b> , 39, 983-7	15
1551	Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. <b>2001</b> , 285, 2481-5	909
1550	Increased common carotid intima-media thickness in UK African Caribbeans and its relation to chronic inflammation and vascular candidate gene polymorphisms. <b>2001</b> , 32, 2465-71	39
1549	Inflammatory mechanisms. <b>2001</b> , 59, 55-68	8
1548	Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. <b>2001</b> , 21, 961-7	442

1547	Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. <b>2001</b> , 286, 1187-94		171
1546	Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. <b>2001</b> , 21, 968-70		251
1545	Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. <i>Circulation</i> , <b>2001</b> , 103, 1933-5	16.7	605
1544	Markers of the acute phase response in cardiovascular disease: an update. <b>2001</b> , 39, 1054-64		10
1543	Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T. <b>2001</b> , 85, 571-5		34
1542	The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. <b>2001</b> , 50, 2384-9		473
1541	Influence of plasma fibrinogen levels on the incidence of myocardial infarction and death is modified by other inflammation-sensitive proteins: a long-term cohort study. <b>2001</b> , 21, 452-8		55
1540	Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. <i>Circulation</i> , <b>2001</b> , 103, 3062-8	16.7	80
1539	C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. <i>Circulation</i> , <b>2001</b> , 104, 63-7	16.7	161
1538	Association between myeloperoxidase levels and risk of coronary artery disease. <b>2001</b> , 286, 2136-42		663
1537	Prospects for cardiovascular research. <b>2001</b> , 285, 581-7		78
1536	Cigarette smoking and hypertension influence nitric oxide release and plasma levels of adhesion molecules. <b>2001</b> , 39, 822-6		53
1535	Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. <b>2001</b> , 21, 255-61		77
1534	Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese-American men. <b>2001</b> , 21, 1065-70		51
1533	Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. <i>Circulation</i> , <b>2001</b> , 103, 947-53	16.7	361
1532	Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. <b>2001</b> , 22, 2135-7		37
1531	C-reactive protein and chronic Chlamydia pneumoniae infection--long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. <b>2001</b> , 16, 809-15		93
1530	High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis. <b>2001</b> , 22, 349-52		46

1529	Reverse cholesterol transport substantially influences the individual risk of coronary heart disease in hypercholesterolaemic patients. <b>2001</b> , 22, 442-3		0
1528	Particulate air pollution, C-reactive protein, and cardiac risk. <b>2001</b> , 22, 1149-50		27
1527	The Treatment of Coronary Heart Disease: An Update. <b>2001</b> , 17, 18-26		27
1526	Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. <b>2001</b> , 286, 2107-13		395
1525	Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. <b>2001</b> , 19, 143-51		119
1524	The role of risk factors in the development of atherosclerosis. <b>2001</b> , 38, 401-40		21
1523	Vascular stiffness in women with systemic lupus erythematosus. <b>2001</b> , 37, 1075-82		222
1522	C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. <i>Circulation</i> , <b>2001</b> , 103, 1194-7	16.7	666
1521	C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. <i>Circulation</i> , <b>2001</b> , 104, 145-50	16.7	323
1520	Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. <i>Circulation</i> , <b>2001</b> , 103, 2531-4	16.7	684
1519	Prospective study of pathogen burden and risk of myocardial infarction or death. <i>Circulation</i> , <b>2001</b> , 103, 45-51	16.7	216
1518	Risk factors for coronary disease: the time for a paradigm shift?. <b>2001</b> , 39, 907-19		7
1517	Unstable angina: the first 48 hours and later in-hospital management. <b>2001</b> , 59, 69-87		4
1516	Candidate foods in the Asia-Pacific region for cardiovascular protection: fish, fruit and vegetables. <b>2001</b> , 10, 134-137		16
1515	C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis?. <b>2001</b> , 21, 603-10		165
1514	Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. <b>2001</b> , 153, 1094-101		85
1513	Is visceral adiposity the "enemy within"?. <b>2001</b> , 21, 881-3		62
1512	High sensitivity immunoassays for C-reactive protein: promises and pitfalls. <b>2001</b> , 39, 1171-6		42

1511	Low-grade systemic inflammation in overweight children. <b>2001</b> , 107, E13		265
1510	White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. <b>2001</b> , 154, 758-64		240
1509	Coronary risk factors: new perspectives. <b>2001</b> , 30 Suppl 1, S41-7		11
1508	Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. <i>Circulation</i> , <b>2001</b> , 103, 2236-41	16.7	82
1507	Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. <i>Circulation</i> , <b>2001</b> , 103, 1064-70	16.7	432
1506	Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. <i>Circulation</i> , <b>2001</b> , 103, 163-82	16.7	289
1505	Inflammatory markers in coronary artery disease: let prevention douse the flames. <b>2001</b> , 286, 2154-6		34
1504	Statins for stroke: the second story?. <i>Circulation</i> , <b>2001</b> , 103, 348-50	16.7	16
1503	Role of nested case-control studies in the difficult quest for new coronary risk factors. <b>2001</b> , 85, 125-6		
1502	Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. <b>2001</b> , 21, 1712-9		1066
1501	Atherosclerosis and autoimmunity. <b>2001</b> , 10, 249-52		21
1500	Insulin resistance and periodontal disease: an epidemiologic overview of research needs and future directions. <b>2001</b> , 6, 119-24		15
1499	Aspirin therapy in diabetes is underutilized. <b>2001</b> , 24, 195-6		8
1498	Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. <i>Circulation</i> , <b>2001</b> , 103, 1191-3	16.7	355
1497	Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. <b>2001</b> , 14, 727-52, table of contents		309
1496	Serological evidence for an inflammatory response in murine scrapie. <b>2001</b> , 183, 185-191		4
1495	Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. <b>2001</b> , 98, 4770-5		904
1494	C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. <b>2001</b> , 286, 327-34		2927

1493	C-reactive protein in ischemic stroke: an independent prognostic factor. <b>2001</b> , 32, 917-24		320
1492	Soluble P-selectin and the risk of future cardiovascular events. <i>Circulation</i> , <b>2001</b> , 103, 491-5	16.7	453
1491	C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. <i>Circulation</i> , <b>2001</b> , 104, 2886-91	16.7	1089
1490	C-reactive protein: linking inflammation to cardiovascular complications. <i>Circulation</i> , <b>2001</b> , 104, 974-5	16.7	157
1489	Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. <b>2001</b> , 6, 145-9		28
1488	Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. <b>2001</b> , 21, 1962-8		105
1487	The antiinflammatory effects of statins. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1209-10; author reply 1210-1	59.2	7
1486	Early statin treatment following acute myocardial infarction and 1-year survival. <b>2001</b> , 285, 430-6		380
1485	C reactive protein in patients with chronic renal diseases. <b>2001</b> , 23, 551-62		104
1484	Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. <b>2001</b> , 21, 231-40		91
1483	Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. <b>2001</b> , 153, 1183-90		185
1482	Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. <b>2001</b> , 32, 2575-9		668
1481	Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 1959-65	59.2	1298
1480	The role of endothelial cell dysfunction in the cardiovascular mortality of RA. <b>2002</b> , 21, 1-17		49
1479	Hemostatic and inflammatory markers as risk factors for coronary disease in the elderly. <b>2002</b> , 11, 93-100, 107		16
1478	Prospective analysis of the association of infection with CagA bearing strains of <i>Helicobacter pylori</i> and coronary heart disease. <b>2002</b> , 88, 43-6		42
1477	Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. <i>Circulation</i> , <b>2002</b> , 106, 1447-52	16.7	301
1476	A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. <b>2002</b> , 25, 1737-43		180

1475	Association between influenza vaccination and reduced risk of brain infarction. <b>2002</b> , 33, 513-8		160
1474	Relationships among clinical measures of periodontal disease and their associations with systemic markers. <b>2002</b> , 7, 79-89		92
1473	Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 1557-65	59.2	2812
1472	High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment. <b>2002</b> , 39, 459-97		44
1471	Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response. <b>2002</b> , 99, 12515-7		36
1470	Postischemic microcirculatory blood flow correlates negatively and independently with plasma C-reactive protein in longstanding type 1 diabetes. <b>2002</b> , 25, 802-3		4
1469	Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. <b>2002</b> , 33, 862-75		166
1468	Prospective study of effect of androgens on serum inflammatory markers in men. <b>2002</b> , 22, 1136-41		61
1467	High doses of vitamin C reverse Escherichia coli endotoxin-induced hyporeactivity to acetylcholine in the human forearm. <i>Circulation</i> , <b>2002</b> , 106, 1460-4	16.7	74
1466	Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. <i>Circulation</i> , <b>2002</b> , 105, 457-61	16.7	57
1465	Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. <b>2002</b> , 22, 1662-7		193
1464	Course of platelet activation markers after ischemic stroke. <b>2002</b> , 33, 2570-4		130
1463	Effect of ciprofibrate on C-reactive protein and fibrinogen levels. <b>2002</b> , 53, 273-7		45
1462	What is C-reactive protein telling us about coronary artery disease?. <b>2002</b> , 162, 389-92		19
1461	Inflammation in acute coronary syndromes. <b>2002</b> , 4, B8-B13		7
1460	Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease. <b>2002</b> , 11, 744-52		23
1459	Evaluation of Denka-Seiken turbidimetric high-sensitivity C-reactive protein assay. <b>2002</b> , 40, 840-5		8
1458	The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. <b>2002</b> , 162, 2033-6		20

1457	Inflammatory response to coronary stent implantation in patients with unstable angina. <b>2002</b> , 40, 769-74	12
1456	Relationship between the sialic acid content of low-density lipoprotein (LDL) and autoantibodies to oxidized LDL in the plasma of healthy subjects and patients with atherosclerosis. <b>2002</b> , 40, 15-20	6
1455	Need to test the arterial inflammation hypothesis. <i>Circulation</i> , <b>2002</b> , 106, 136-40	16.7 106
1454	Gender differences in C-reactive protein concentrations-confirmation with two sensitive methods. <b>2002</b> , 40, 56-9	49
1453	Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. <b>2002</b> , 22, 1042-5	33
1452	Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. <i>Circulation</i> , <b>2002</b> , 106, 1925-9	16.7 253
1451	Critical review of unstable angina and non-ST elevation myocardial infarction. <b>2002</b> , 78, 717-26	15
1450	Short-term effects of atorvastatin on C-reactive protein. <b>2002</b> , 23, 794-9	60
1449	VII.5 Microinflammatory state. <b>2002</b> , 17, 100-109	
1448	Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques. <b>2002</b> , 23, 1664-9	55
1447	Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESDR patients. <b>2002</b> , 17 Suppl 3, 24-9	25
1446	Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes. <b>2002</b> , 17, 497-502	18
1445	Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. <b>2002</b> , 17, 2178-83	18
1444	Intermittent claudication and endothelial dysfunction. <b>2002</b> , 4, B35-B40	3
1443	Influencing the inflammatory response of haemodialysis patients by cytokine elimination using large-pore membranes. <b>2002</b> , 17, 17-9	19
1442	C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. <b>2002</b> , 91, 594-600	95
1441	Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. <b>2002</b> , 9, 1831-50	49
1440	Use of statins and aspirin to reduce risks of cardiovascular disease. <b>2002</b> , 7, 77-80	15

1439	Systemic inflammation, endothelial dysfunction, dietary fatty acids and micronutrients as risk factors for stroke: a selective review. <b>2002</b> , 13, 219-24		15
1438	Clinical practice. Aspirin for primary prevention of coronary events. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 1468-74	59.2	123
1437	Diabetes and atherothrombotic disease: linked through inflammation?. <b>2002</b> , 2, 67-73		4
1436	Inflammation and cholesterol. <b>2002</b> , 4, A18-A25		1
1435	Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. <b>2002</b> , 87, 1692-9		82
1434	[Does chronic periodontitis play a role in the pathogenesis of cardiovascular and cerebrovascular diseases?]. <b>2002</b> , 64, 89-98		3
1433	The need for risk factor assessment in atherothrombotic vascular disease. <b>2002</b> , 2, 231-2		2
1432	Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. <b>2002</b> , 26, 659-62		140
1431	Importance of periodontal disease in the kidney patient. <b>2002</b> , 20, 113-9		41
1430	Limited clinical utility of high-sensitivity plasma C-reactive protein assays. <b>2002</b> , 39, 85-8		45
1429	Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. <b>2002</b> , 22, 1631-6		291
1428	The Role of Inflammation in Atherosclerosis. <b>2002</b> , 13, 203-216		1
1427	Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. <b>2002</b> , 22, 838-42		133
1426	C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. <b>2002</b> , 22, 1512-3		38
1425	Vascular inflammation and the renin-angiotensin system. <b>2002</b> , 22, 1257-66		493
1424	Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. <i>Circulation</i> , <b>2002</b> , 106, 2555-60	16.7	205
1423	C-reactive protein and carotid intimal medial thickness in a community population. <b>2002</b> , 9, 97-103		43
1422	Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. <b>2002</b> , 90, 770-6		310



1421	Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. <b>2002</b> , 288, 2724-31		199
1420	Inflammation in end-stage renal failure: could it be treated?. <b>2002</b> , 17 Suppl 8, 33-8; discussion 40		109
1419	Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. <b>2002</b> , 39, 777-80		158
1418	Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. <i>Circulation</i> , <b>2002</b> , 105, 800-3	16.7	111
1417	Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. <i>Circulation</i> , <b>2002</b> , 105, 2632-7	16.7	157
1416	Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. <b>2002</b> , 15, 1-20		150
1415	Polycyclic aromatic hydrocarbons present in cigarette smoke cause endothelial cell apoptosis by a phospholipase A2-dependent mechanism. <b>2002</b> , 16, 1463-4		58
1414	Plaque vulnerability, plaque rupture, and acute coronary syndromes: (multi)-focal manifestation of a systemic disease process. <i>Circulation</i> , <b>2002</b> , 106, 760-2	16.7	68
1413	Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. <i>Circulation</i> , <b>2002</b> , 105, 1531-3	16.7	69
1412	Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. <i>Circulation</i> , <b>2002</b> , 105, 2019-23	16.7	306
1411	A new paradigm for plaque stabilization. <i>Circulation</i> , <b>2002</b> , 105, 2000-4	16.7	58
1410	Weight loss reduces C-reactive protein levels in obese postmenopausal women. <i>Circulation</i> , <b>2002</b> , 105, 564-9	16.7	422
1409	Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. <i>Circulation</i> , <b>2002</b> , 106, 1690-5	16.7	156
1408	C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. <b>2002</b> , 25, 1813-7		51
1407	Evidence-based risk stratification to target therapies in acute coronary syndromes. <i>Circulation</i> , <b>2002</b> , 106, 1588-91	16.7	44
1406	Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. <i>Circulation</i> , <b>2002</b> , 105, 2583-5	16.7	47
1405	Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. <b>2002</b> , 288, 980-7		487
1404	C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. <b>2002</b> , 33, 2750-5		159

1403	Role of inflammation and its treatment in ESRD patients. <b>2002</b> , 20, 70-80	36
1402	Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. <b>2002</b> , 53, 54-8	28
1401	Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. <b>2002</b> , 26, 469-74	51
1400	C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. <b>2002</b> , 22, 593-8	96
1399	Inflammation, CRP, calcium overload and a high calcium-phosphate product: a "liaison dangereuse". <b>2002</b> , 17, 201-3	41
1398	C-reactive protein and prognosis after percutaneous coronary intervention. <b>2002</b> , 23, 923-5	13
1397	. <b>2002</b> , 9, 1-6	14
1396	Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. <b>2002</b> , 20, 1407-12	44
1395	Ethical considerations in image-based screening for coronary artery disease. <b>2002</b> , 13, 95-106	1
1394	Relationship of C-reactive protein to presence and severity of coronary atherosclerosis in patients with stable angina pectoris or a pathological exercise test. <b>2002</b> , 13, 151-4	26
1393	High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. <b>2002</b> , 17, 325-31	36
1392	Coagulation indicators in chronic stable effort angina and unstable angina: relationship with acute phase reactants and clinical outcome. <b>2002</b> , 13, 247-55	10
1391	Aspirin in the prophylaxis of coronary artery disease. <b>2002</b> , 17, 552-8	32
1390	Cyclooxygenase-2 and atherosclerosis. <b>2002</b> , 13, 497-504	35
1389	. <b>2002</b> , 9, 97-103	80
1388	Psychoneuroimmunology and psychosomatic medicine: back to the future. <b>2002</b> , 64, 15-28	205
1387	Coronary artery disease and rheumatoid arthritis. <b>2002</b> , 14, 115-20	98
1386	Low-density lipoprotein modification by normal, myeloperoxidase-deficient and NADPH oxidase-deficient granulocytes and the impact of redox active transition metal ions. <b>2002</b> , 7, 111-9	4

1385	Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial. <b>2002</b> , 17, 2748-53	18
1384	C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. <b>2002</b> , 17 Suppl 8, 29-32; discussion 39-40	93
1383	Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. <b>2002</b> , 33, 2459-64	177
1382	Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. <b>2002</b> , 75, 492-8	445
1381	Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. <b>2002</b> , 33, 2744-9	74
1380	Diagnostic value of CRP and Lp(a) in coronary heart disease. <b>2002</b> , 57, 197-204	36
1379	Cardiovascular disease in patients with chronic kidney disease. <b>2002</b> , 22, 459-73	23
1378	Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels*1. <b>2002</b> , 35, 137-145	2
1377	Is metabolic syndrome X an inflammatory condition?. <b>2002</b> , 227, 989-97	106
1376	Triad of malnutrition, inflammation, and atherosclerosis in hemodialysis patients. <b>2002</b> , 91, 456-62	21
1375	Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. <b>2002</b> , 162, 1286-92	327
1374	Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology?. <b>2002</b> , 33, 2141-3	34
1373	Understanding the pathophysiology of the arterial wall: which method should we choose?. <b>2002</b> , 4, F24-F28	0
1372	Resolution of crevicular fluid leukocyte activity in patients treated for aggressive periodontal disease. <b>2002</b> , 73, 995-1002	14
1371	Immunological basis of inflammation in dialysis. <b>2002</b> , 17 Suppl 8, 16-24	68
1370	Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. <b>2002</b> , 23, 831-4	149
1369	Diabetes and cardiovascular disease. <b>2002</b> , 53, 245-67	111
1368	Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. <b>2002</b> , 112, 269-74	64

1367	Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. <b>2002</b> , 112, 275-80	135
1366	Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. <b>2002</b> , 113, 188-93	141
1365	Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. <b>2002</b> , 113, 331-4	28
1364	Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). <b>2002</b> , 113, 636-42	294
1363	C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. <b>2002</b> , 5, 42-6	13
1362	Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. <b>2002</b> , 39, 231-7	47
1361	High coronary artery calcium scores pose an extremely elevated risk for hard events. <b>2002</b> , 39, 225-30	249
1360	C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. <b>2002</b> , 39, 632-7	179
1359	Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. <b>2002</b> , 39, 1133-8	75
1358	Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. <b>2002</b> , 40, 49-55	35
1357	Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. <b>2002</b> , 40, 1761-8	204
1356	Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. <b>2002</b> , 160, 49-58	104
1355	The role of chemokines in human cardiovascular pathology: enhanced biological insights. <b>2002</b> , 160, 91-102	161
1354	C-reactive protein predicts death in patients with previous premature myocardial infarction--a 10 year follow-up study. <b>2002</b> , 160, 433-40	70
1353	Parameters of inflammation and infection in a community based case-control study of coronary heart disease. <b>2002</b> , 160, 457-63	34
1352	Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. <b>2002</b> , 160, 471-6	49
1351	Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. <b>2002</b> , 161, 233-42	179
1350	Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. <b>2002</b> , 162, 187-91	28

1349	Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. <b>2002</b> , 162, 217-9	182
1348	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. <b>2002</b> , 162, 245-51	37
1347	Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women. <b>2002</b> , 163, 149-56	28
1346	Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. <b>2002</b> , 163, 349-54	45
1345	Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease. <b>2002</b> , 164, 153-60	23
1344	Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients. <b>2002</b> , 165, 159-66	19
1343	The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. <b>2002</b> , 165, 301-7	85
1342	Toll-like receptor 4 polymorphisms and atherogenesis. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 185-93.2	912
1341	Orosomucoid: a mortality risk factor in elderly people living in the community?. <b>2002</b> , 21, 45-50	13
1340	Atorvastatin Reduces Expression of the CCR2 and MAC-1 Receptors on Monocytes, and Plasma Levels of Monocyte Chemoattractant Protein-1 and C-Reactive Protein, in Patients with Coronary Heart Disease. <b>2002</b> , 22, 1-8	2
1339	Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. <b>2002</b> , 25, 1432-8	102
1338	Oxidative Stress and Inflammation in Hemodialysis Patients. <b>2002</b> , 45-52	1
1337	Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. <b>2002</b> , 35, 137-145	112
1336	The search for the ideal SERM. <b>2002</b> , 3, 681-91	27
1335	Hypolipemic agents for stroke prevention. <b>2002</b> , 24, 573-94	5
1334	How do HMG-CoA reductase inhibitors prevent stroke?. <b>2002</b> , 2, 7-14	8
1333	Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?. <b>2002</b> , 1, 45-52	9
1332	Factors associated with oxidative stress in human populations. <b>2002</b> , 156, 274-85	326

1331	Markers of inflammation and hypercoagulability in diabetic and nondiabetic patients with lower extremity ischemia. <b>2002</b> , 105, 379-83	18
1330	Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. <b>2002</b> , 359, 2159-63	198
1329	C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. <b>2002</b> , 360, 1462-7	99
1328	C-reactive protein and progressive atherosclerosis. <b>2002</b> , 360, 1436-7	9
1327	Alterations of serum selenium concentrations in the acute phase of pathological conditions. <b>2002</b> , 316, 137-46	117
1326	C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. <b>2002</b> , 317, 1-15	115
1325	Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range. <b>2002</b> , 322, 163-8	75
1324	Stress, inflammation and cardiovascular disease. <b>2002</b> , 52, 1-23	533
1323	Depression and immune function: central pathways to morbidity and mortality. <b>2002</b> , 53, 873-6	412
1322	Autoimmunity, oxidized LDL and cardiovascular disease. <b>2002</b> , 1, 233-7	78
1321	Immune-mediated inflammatory disorders. <b>2002</b> , 30, 1-3	
1320	C-reactive protein and insulin resistance in non-obese Japanese type 2 diabetic patients. <b>2002</b> , 51, 1578-81	36
1319	Fibrinogen: associations with cardiovascular events in an outpatient clinic. <b>2002</b> , 143, 277-82	21
1318	CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. <b>2002</b> , 143, 971-6	37
1317	C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. <b>2002</b> , 144, 233-8	173
1316	High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. <b>2002</b> , 144, 449-55	52
1315	Exercise testing for assessment of autonomic function. <b>2002</b> , 144, 580-2	1
1314	Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention. <b>2002</b> , 144, 491-500	25

1313	Stress and the inflammatory response: a review of neurogenic inflammation. <b>2002</b> , 16, 622-53	692
1312	C-reactive protein and myocardial infarction. <b>2002</b> , 55, 445-51	136
1311	C-reactive protein: history and revival. <b>2002</b> , 13, 412	112
1310	Different associations of C-reactive protein, fibrinogen and C3 with traditional risk factors in middle-aged men. <b>2002</b> , 83, 63-71	22
1309	Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death. <b>2002</b> , 85, 277-83	17
1308	Inflammation in atherosclerosis and acute coronary syndromes. <b>2002</b> , 1229, 95-102	1
1307	Inflammation and atherosclerosis. <i>Circulation</i> , <b>2002</b> , 105, 1135-43	16.7 5212
1306	Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). <b>2002</b> , 22, 599-604	145
1305	Exercise testing for assessment of autonomic function. <b>2002</b> , 144, 580-582	6
1304	[Interleukin-10 and coronary disease]. <b>2002</b> , 55, 738-50	30
1303	Aterosclerosis e inflamaci3n: papel central del factor de transcripci3n NF-B. <b>2002</b> , 14, 77-84	2
1302	[Systemic lupus erythematosus and cardiovascular disease]. <b>2002</b> , 119, 699-706	2
1301	Clinical carotid atherosclerosis. <b>2002</b> , 12, 403-19	9
1300	[Eptifibatide blocks the increase in C-reactive protein concentration after coronary angioplasty]. <b>2002</b> , 55, 186-9	6
1299	Inflammatory response in the acute phase of deep vein thrombosis. <b>2002</b> , 35, 701-6	121
1298	Tratamientos que reducen la inflamaci3n vascular. <b>2002</b> , 14, 114-115	
1297	Gender and asthma. <b>2002</b> , 22, 753-789	15
1296	Inflamaci3n, hemostasia y enfermedad coronaria. La prote3na C reactiva y el d3mero D como marcadores del proceso de la arteriosclerosis. <b>2002</b> , 14, 242-257	

1295	[Reproducibility of C-reactive protein analyses]. <b>2002</b> , 55, 1101-4	2
1294	Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. <b>2002</b> , 165, 361-6	102
1293	Management of intermittent claudication. <b>2002</b> , 20, 521-34	5
1292	Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. <i>Circulation</i> , <b>2002</b> , 105, 2595-9	16.7 418
1291	Inflammation in acute coronary syndromes. <b>2002</b> , 87, 201-4	94
1290	Effect of <i>Helicobacter pylori</i> infection on fibrinogen level in elderly patients with ischaemic heart disease. <b>2002</b> , 57, 317-22	9
1289	Ultrarapid, Ultrasensitive One-Step Kinetic Immunoassay for C-Reactive Protein (CRP) in Whole Blood Samples: Measurement of the Entire CRP Concentration Range with a Single Sample Dilution. <b>2002</b> , 48, 269-277	43
1288	Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity. <b>2002</b> , 48, 877-883	118
1287	Serum Vitamin E and Lipid-adjusted Vitamin E Assessment in Friedreich Ataxia Phenotype Patients and Unaffected Family Members. <b>2002</b> , 48, 577-579	6
1286	C-Reactive Protein Kinetics in Newborns: Application of a High-Sensitivity Analytic Method in Its Determination. <b>2002</b> , 48, 1103-1106	34
1285	Lack of Seasonal Variation in C-Reactive Protein. <b>2002</b> , 48, 575-577	35
1284	Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort. <b>2002</b> , 33, 2182-6	60
1283	Vascular calcifications as a footprint of increased calcium load and chronic inflammation in uremic patients: a need for a neutral calcium balance during hemodialysis?. <b>2002</b> , 25, 18-26	10
1282	Elevated C-reactive protein is associated with an increased intima to media thickness of the common carotid artery. <b>2002</b> , 13, 57-63	45
1281	Inflammation, blood pressure, and stroke: an opportunity to target primary prevention?. <b>2002</b> , 33, 2732-3	5
1280	Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. <b>2002</b> , 33, 31-7	108
1279	Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. <b>2002</b> , 33, 1763-71	160
1278	Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. <b>2002</b> , 121, 906-20	38



1277	New tools for coronary risk assessment: what are their advantages and limitations?. <i>Circulation</i> , <b>2002</b> , 105, 886-92	16.7	155
1276	Predictive Value of C-Reactive Protein for Cardiac Events after Coronary Stenting. <b>2002</b> , 32, 766		
1275	Prediction of cardiovascular risk using soluble cell adhesion molecules. <b>2002</b> , 23, 1569-74		66
1274	On Evolutionary Biology, Inflammation, Infection, and the Causes of Atherosclerosis. <i>Circulation</i> , <b>2002</b> , 105, 2-4	16.7	112
1273	Similarities in mortality patterns from influenza in the first half of the 20th century and the rise and fall of ischemic heart disease in the United States: a new hypothesis concerning the coronary heart disease epidemic. <b>2002</b> , 18, 557-66; discussion 567-77		25
1272	Atherosclerosis or atheroscleritis: what's in a name?. <b>2002</b> , 98, 111-2		2
1271	C-reactive protein and coronary artery disease. <b>2002</b> , 43, 607-19		42
1270	A Prospective Evaluation of the Heat Shock Protein 70 Gene Polymorphisms and the Risk of Stroke. <b>2002</b> , 87, 622-625		9
1269	Is C-reactive protein specific for vascular disease in women?. <b>2002</b> , 136, 529-33		59
1268	Effects of Transdermal and Oral Oestrogen Replacement Therapy on C-Reactive Protein Levels in Postmenopausal Women: A Randomised, Placebo-Controlled Trial. <b>2002</b> , 88, 605-610		41
1267	Diagnostic strategies for C-reactive protein. <b>2002</b> , 2, 9		12
1266	Multifocal coronary plaque instability. <b>2002</b> , 44, 449-54		15
1265	Dyslipidemia and the vulnerable plaque. <b>2002</b> , 44, 415-28		25
1264	Systemic and local inflammation in patients with unstable atherosclerotic plaques. <b>2002</b> , 44, 469-78		49
1263	Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice. <b>2002</b> , 17, 174-85		15
1262	Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. <b>2002</b> , 89, 145-9		144
1261	Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. <b>2002</b> , 89, 216-21		45
1260	Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. <b>2002</b> , 89, 672-8		201

1259	Relative risk of cardiovascular events in patients with rheumatoid arthritis. <b>2002</b> , 89, 33D-38D	72
1258	Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. <b>2002</b> , 89, 901-8	114
1257	Association of systemic inflammatory state with troponin I elevation after elective uncomplicated percutaneous coronary intervention. <b>2002</b> , 89, 981-3	37
1256	Relation between markers of systemic vascular inflammation and smoking in women. <b>2002</b> , 89, 1117-9	291
1255	Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen. <b>2002</b> , 89, 1133-5	51
1254	Aspirin beyond platelet inhibition. <b>2002</b> , 90, 39-41	12
1253	Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. <b>2002</b> , 90, 7F-10F	36
1252	Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. <b>2002</b> , 90, 942-6	31
1251	Clinical depression and inflammatory risk markers for coronary heart disease. <b>2002</b> , 90, 1279-83	345
1250	The biological functions of C-reactive protein. <b>2002</b> , 39, 105-7	42
1249	Yellow fever vaccination as a model to study the response to stimulation of the inflammation system. <b>2002</b> , 39, 117-21	26
1248	Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. <b>2002</b> , 39, 149-54	54
1247	Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. <b>2002</b> , 39, 1096-101	37
1246	Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. <b>2002</b> , 40, 307-14	112
1245	ACE inhibitors in hemodialysis patients: does survival improve?. <b>2002</b> , 40, 1100-2	4
1244	Exercise training reduces the acute inflammatory response associated with claudication. <b>2002</b> , 23, 309-16	49
1243	C-reactive protein is elevated in symptomatic compared with asymptomatic patients with carotid artery disease. <b>2002</b> , 23, 505-9	21
1242	Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. <b>2002</b> , 16, 201-8	62

1241	Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules. <b>2002</b> , 16, 321-6	25
1240	The role of inflammation and infection in coronary artery disease: a clinical perspective. <b>2002</b> , 11, 32-34	9
1239	Clinical and angiographic determinants of adverse cardiac events in patients with stent restenosis. <b>2002</b> , 55, 331-7	4
1238	Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. <b>2002</b> , 46, 862-73	493
1237	Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. <b>2002</b> , 46, 2010-9	295
1236	Reference distributions for serum iron and transferrin saturation: a practical, simple, and clinically relevant approach in a large cohort. <b>2002</b> , 16, 237-45	34
1235	Management After Myocardial Infarction. <b>2002</b> , 4, 41-54	
1234	Genetic determinants of diabetes and atherosclerosis. <b>2002</b> , 4, 193-8	8
1233	Vascular inflammation as a therapeutic target for prevention of cardiovascular disease. <b>2002</b> , 4, 77-81	7
1232	Statins and inflammatory markers. <b>2002</b> , 4, 42-7	17
1231	The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease. <b>2002</b> , 4, 278-88	37
1230	Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. <b>2002</b> , 4, 514-21	27
1229	Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease. <b>2002</b> , 4, 93-5	2
1228	The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. <b>2002</b> , 80, 507-13	103
1227	[Acute coronary syndrome--better risk stratification by determination of inflammatory parameters?]. <b>2002</b> , 97, 63-9	
1226	[Manifestations of atherosclerosis in various vascular regions. Similarities and differences regarding epidemiology, etiology and prognosis]. <b>2002</b> , 97, 221-8	23
1225	C-reactive protein and mortality in patients with acute aortic disease. <b>2002</b> , 28, 740-5	92
1224	The promoter polymorphism of the IL-6 gene is associated with levels of antibodies to 60-kDa heat-shock proteins. <b>2002</b> , 53, 851-6	30

1223	The role of platelets in peripheral arterial disease: therapeutic implications. <b>2002</b> , 16, 246-58	37
1222	[C-reactive protein in coronary plaques -- prevalence with acute coronary syndrome]. <b>2002</b> , 91, 913-20	2
1221	Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. <b>2001</b> , 88, 787-800	125
1220	Differences in the detection of cyclo-oxygenase 1 and 2 proteins in symptomatic and asymptomatic carotid plaques. <b>2001</b> , 88, 951-7	4
1219	Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and Chlamydia pneumoniae IgA antibodies. <b>2002</b> , 251, 61-8	18
1218	Effects of simvastatin and atorvastatin on inflammation markers in plasma. <b>2002</b> , 251, 338-47	91
1217	Inflammatory bio-markers and cardiovascular risk prediction. <b>2002</b> , 252, 283-94	498
1216	Relevance of C-reactive protein levels in peritoneal dialysis patients. <b>2002</b> , 61, 615-20	39
1215	Advanced glycation end products and mortality in hemodialysis patients. <b>2002</b> , 62, 301-10	157
1214	Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. <b>2002</b> , 62, 949-55	107
1213	Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?. <b>2002</b> , 62, 1791-8	137
1212	Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. <b>2002</b> , 62, 2208-15	62
1211	Inflammation and cardiovascular risk in dialysis patients. <b>2002</b> , 99-102	153
1210	Inflammation in end-stage renal disease: sources, consequences, and therapy. <b>2002</b> , 15, 329-37	286
1209	Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. <b>2002</b> , 17, 895-904	102
1208	Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atherosclerosis. <b>2002</b> , 1, 3	70
1207	Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. <b>2002</b> , 54, 327-32	51
1206	Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. <b>2002</b> , 118, 893-8	95

1205	C-reactive protein in the diagnosis of deep vein thrombosis. <b>2002</b> , 119, 385-9	38
1204	Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia. <b>2002</b> , 119, 1011-6	31
1203	Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. <b>2002</b> , 32, 895-900	9
1202	Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. <b>2002</b> , 32 Suppl 1, 84-90	39
1201	Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes. <b>2002</b> , 19, 847-52	56
1200	Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. <b>2002</b> , 56, 1130-6	173
1199	Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. <b>2002</b> , 3, 14-9	122
1198	The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome--an analysis by structural equation modelling. <b>2002</b> , 26, 994-1008	93
1197	Inflammation and infection in clinical stroke. <b>2002</b> , 22, 1399-419	212
1196	C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss. <b>2002</b> , 13, 316-321	61
1195	C-reactive protein and cardiovascular disease in peritoneal dialysis patients. <b>2002</b> , 62, 1417-22	105
1194	Elevated serum C-reactive protein levels and early arterial changes in healthy children. <b>2002</b> , 22, 1323-8	255
1193	Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital. <b>2002</b> , 25, 16-8	9
1192	C-reactive protein as a marker for active coronary artery disease in patients with chest pain in the emergency room. <b>2002</b> , 25, 456-60	12
1191	Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study. <b>2002</b> , 25, 461-6	28
1190	Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. <b>2002</b> , 14, 139-43	29
1189	Cardiology and emergency medicine: united we stand, divided we fall. <b>2002</b> , 39, 164-7	5
1188	Antiinflammatory and immunomodulatory properties of statins. <b>2002</b> , 25, 271-85	54

1187	Varied biologic functions of C-reactive protein: lessons learned from transgenic mice. <b>2002</b> , 26, 279-87	63
1186	Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. <b>2002</b> , 53, 83-107	756
1185	Hormone therapies and vascular outcomes: who is at risk?. <b>2003</b> , 16, 87-90	5
1184	PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. <b>2003</b> , 17, 83-91	20
1183	Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. <b>2003</b> , 249, 67-73	8
1182	Relationship between minor myocardial damage and inflammatory acute-phase reaction in acute coronary syndromes. <b>2003</b> , 15, 33-9	9
1181	The incidence of infectious diseases and changes in the mortality of atherosclerosis-related complications in the Czech population over the past two decades. <b>2004</b> , 19, 707-10	3
1180	Relationships of differential leukocyte and lymphocyte subpopulations with carotid atherosclerosis in elderly men. <b>2003</b> , 23, 469-76	26
1179	Treatment options for intracranial arterial stenosis and progress of ongoing clinical trials. <b>2003</b> , 3, 31-37	
1178	Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. <b>2003</b> , 8, 71-86	112
1177	Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. <b>2003</b> , 26, 472-6	46
1176	Connecting the role of C-reactive protein and statins in cardiovascular disease. <b>2003</b> , 26, III39-44	39
1175	An antiinflammatory galactolipid from rose hip ( <i>Rosa canina</i> ) that inhibits chemotaxis of human peripheral blood neutrophils in vitro. <b>2003</b> , 66, 994-5	135
1174	Inflammation and infections as risk factors for ischemic stroke. <b>2003</b> , 34, 2518-32	379
1173	Relationship between levels of serum C-reactive protein, leucocyte count and carotid plaque in patients with ischemic stroke. <b>2003</b> , 23, 263-5	1
1172	Deep vein thrombosis and systemic inflammatory response: a pilot trial. <b>2003</b> , 115, 111-4	23
1171	Hypercholesterolemia and Dyslipidemia: Issues for the Clinician. <b>2003</b> , 5, 35-50	5
1170	C-reactive protein and risk of cardiovascular disease: evidence and clinical application. <b>2003</b> , 5, 341-9	80

1169	C-reactive protein: the pawn has been promoted to queen. <b>2003</b> , 5, 101-5	25
1168	Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. <b>2003</b> , 3, 248-54	45
1167	C-reactive protein-induced production of interleukin-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndrome. <b>2003</b> , 18, 183-7	33
1166	The C(-260)>T gene polymorphism in the promoter of the CD14 monocyte receptor gene is not associated with acute myocardial infarction. <b>2003</b> , 3, 161-5	21
1165	Amino acid and protein oxidation in cardiovascular disease. <b>2003</b> , 25, 365-74	50
1164	Helicobacter pylori infection is not related to restenosis following angioplasty. <b>2003</b> , 12, 111-113	
1163	C-Reactive Protein and Cardiovascular Diseases. <b>2003</b> , 12, 1-12	17
1162	The mechanisms of inhibitory actions of gliclazide on neutrophils-endothelial cells adhesion and surface expression of endothelial adhesion molecules mediated by a high glucose concentration. <b>2003</b> , 17, 22-6	25
1161	Atherosclerosis as an inflammatory arterial disease. <b>2003</b> , 12, 23-25	1
1160	Co-morbidity in rheumatoid arthritis. <b>2003</b> , 17, 729-52	68
1159	C-reaktives Protein in der Risikovorhersage und Intervention bei kardiovaskulären Erkrankungen. <b>2003</b> , 27, 100-112	
1158	A comparison of acute phase proteins and traditional risk factors as markers of combined plaque and intima-media thickness and plaque density in carotid and femoral arteries. <b>2003</b> , 26, 81-7	10
1157	Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1. <b>2003</b> , 26, 387-91	13
1156	Associations between circulating inflammatory markers and residual renal function in CRF patients. <b>2003</b> , 41, 1212-8	319
1155	Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. <b>2003</b> , 42, 256-63	50
1154	C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. <b>2003</b> , 42, 355-61	36
1153	C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. <b>2003</b> , 126, 1886-91	73
1152	Role of C-reactive protein in the assessment of cardiovascular risk. <b>2003</b> , 91, 200-2	37

1151	Effects of statins on inflammation in patients with acute and chronic coronary syndromes. <b>2003</b> , 91, 9B-13B	44
1150	Relation of admission white blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (The Stent PAMI Trial). <b>2003</b> , 91, 729-31	44
1149	Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. <b>2003</b> , 91, 12H-18H	227
1148	Relation of C-reactive protein and fibrinogen to coronary artery calcium in subjects with systemic hypertension. <b>2003</b> , 92, 56-8	10
1147	Utility of inflammatory markers in the management of coronary artery disease. <b>2003</b> , 92, 10i-8i	64
1146	A practical approach to risk assessment to prevent coronary artery disease and its complications. <b>2003</b> , 92, 19i-26i	62
1145	Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. <b>2003</b> , 92, 136-40	32
1144	Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. <b>2003</b> , 92, 236-9	29
1143	Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). <b>2003</b> , 92, 522-8	228
1142	High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. <b>2003</b> , 92, 17K-22K	174
1141	C-reactive protein and depressed mood in a sub-group of smokers during nicotine abstinence. <b>2003</b> , 18, 329-37	9
1140	Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. <b>2003</b> , 15, 91-100	37
1139	Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. <b>2003</b> , 48, 72-80	120
1138	Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. <b>2003</b> , 48, 81-9	164
1137	Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. <b>2003</b> , 48, 1833-40	250
1136	Radiation-associated cardiovascular disease. <b>2003</b> , 45, 55-75	393
1135	Effect of treatment of chronic periodontitis on levels of serum markers of acute-phase inflammatory and vascular responses. <b>2003</b> , 30, 334-40	141
1134	Cardiovascular diseases and periodontology. <b>2003</b> , 30, 279-92	22



1133	Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers. <b>2003</b> , 16, 231-42	30
1132	Does inflammation or undernutrition explain the low cholesterol-mortality association in high-functioning older persons? MacArthur studies of successful aging. <b>2003</b> , 51, 80-4	43
1131	Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. <b>2003</b> , 253, 153-60	45
1130	Plasma oxidized LDL: a predictor for acute myocardial infarction?. <b>2003</b> , 253, 425-9	52
1129	Prognostic value of plasma C-reactive protein and fibrinogen determinations in patients with acute myocardial infarction treated with thrombolysis. <b>2003</b> , 254, 244-50	10
1128	Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. <b>2003</b> , 63, 315-22	22
1127	Anti-inflammatory and immunomodulatory effects of statins. <b>2003</b> , 63, 12-23	229
1126	C-reactive protein is associated with renal function abnormalities in a non-diabetic population. <b>2003</b> , 63, 654-61	165
1125	Endothelial dysfunction and inflammation in asymptomatic proteinuria. <b>2003</b> , 63, 624-33	65
1124	Endothelial dysfunction and inflammation: what is the link?. <b>2003</b> , S45-9	50
1123	Uremia-associated immune defect: the IL-10-CRP axis. <b>2003</b> , S76-9	28
1122	Traditional and emerging cardiovascular risk factors in end-stage renal disease. <b>2003</b> , S105-10	132
1121	Uremia-related metabolic cardiac risk factors in chronic kidney disease. <b>2003</b> , 16, 148-56	30
1120	Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. <b>2003</b> , 7, 431-4	29
1119	TxA2-mediated myocardial ischemia as a consequence of an acute lung inflammatory reaction in the rabbit. <b>2003</b> , 1, 314-9	4
1118	Integration of vascular biology and magnetic resonance imaging in the understanding of atherothrombosis and acute coronary syndromes. <b>2003</b> , 1, 1410-21	32
1117	Atherosclerotic plaques: how vulnerable is the definition of "the vulnerable plaque"?. <b>2003</b> , 16, 115-22	9
1116	[Prevention of stroke]. <b>2003</b> , 153, 6-13	1

1115	C-reactive protein as a cardiovascular risk factor and its therapeutic implications in end-stage renal disease patients. <b>2003</b> , 8 Suppl, S40-4	9
1114	Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis. <b>2003</b> , 33, 380-6	59
1113	Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. <b>2003</b> , 33, 450-62	66
1112	Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial. <b>2003</b> , 33, 209-15	22
1111	Acute-phase response of human hepatocytes after infection with Chlamydia pneumoniae and cytomegalovirus. <b>2003</b> , 33, 720-5	9
1110	C-reactive protein concentration and concentrations of blood vitamins, carotenoids, and selenium among United States adults. <b>2003</b> , 57, 1157-63	111
1109	Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding. <b>2003</b> , 27, 355-61	44
1108	The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. <b>2003</b> , 27, 443-9	158
1107	Long-term body weight variability is associated with elevated C-reactive protein independent of current body mass index among Japanese men. <b>2003</b> , 27, 1059-65	29
1106	Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. <b>2003</b> , 17, 223-30	144
1105	Scientific and therapeutic advances in antiplatelet therapy. <b>2003</b> , 2, 15-28	288
1104	Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. <b>2003</b> , 14, 513-21	108
1103	C-reactive protein, inflammation, and coronary risk. <b>2003</b> , 21, 315-25	141
1102	Insulin sensitizers. <b>2003</b> , 78, 471-9	26
1101	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. <b>2003</b> , 15, 171-173	
1100	Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. <b>2003</b> , 23, 2063-9	242
1099	Clinical relevance of peripheral vascular occlusive disease in patients with rheumatoid arthritis and systemic lupus erythematosus. <b>2003</b> , 38, 111-5	12
1098	Chronic infection and coronary artery disease. <b>2003</b> , 21, 333-62	52

1097	Infección, Chlamydia y arteriosclerosis. <b>2003</b> , 15, 24-28	1
1096	Aspirin for the prevention of cardiovascular events in the elderly. <b>2003</b> , 20, 999-1010	16
1095	Relationship of destructive periodontal disease to the acute-phase response. <b>2003</b> , 74, 1007-16	171
1094	Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. <b>2003</b> , 42, 1747-53	47
1093	Angiotensin-converting enzyme inhibitors: ischemia is not the correct measure of benefit. <b>2003</b> , 42, 2060-2	1
1092	Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. <b>2003</b> , 54, 566-72	423
1091	PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. <b>2003</b> , 166, 195-6	6
1090	Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. <b>2003</b> , 166, 379-86	176
1089	Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. <b>2003</b> , 167, 73-9	186
1088	Circulating markers of inflammation and atherosclerosis. <b>2003</b> , 169, 203-14	314
1087	Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. <b>2003</b> , 169, 155-8	73
1086	Carotid artery lesions and atherosclerotic risk factors in Japanese hemodialysis patients. <b>2003</b> , 169, 183-92	27
1085	Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. <b>2003</b> , 169, 317-21	50
1084	Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. <b>2003</b> , 170, 261-7	55
1083	Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men. <b>2003</b> , 41, 333-9	13
1082	Combined role of the Lewis antigenic system, Chlamydia pneumoniae, and C-reactive protein in unstable angina. <b>2003</b> , 41, 546-50	6
1081	C-reactive protein and other inflammatory risk markers in acute coronary syndromes. <b>2003</b> , 41, 375-425	255
1080	Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. <b>2003</b> , 41, 916-24	187

1079	Atherothrombosis, inflammation, and diabetes. <b>2003</b> , 41, 1071-7	190
1078	34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap?. <b>2003</b> , 41, 1863-74	147
1077	C-Reactive protein and cardiac allograft vasculopathy. is inflammation the critical link?. <b>2003</b> , 42, 483-5	19
1076	Acute coronary syndromes, plaque vulnerability, and carotid artery disease: the changing role of atherosclerosis imaging. <b>2003</b> , 42, 1033-6	18
1075	Physical fitness and C-reactive protein level in children and young adults: the Columbia University BioMarkers Study. <b>2003</b> , 111, 332-8	93
1074	Chlamydia pneumoniae and coronary artery disease: the antibiotic trials. <b>2003</b> , 78, 321-32	24
1073	C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. <b>2003</b> , 23, 1255-61	296
1072	Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. <b>2003</b> , 41, 1183-90	933
1071	Association between alveolar bone loss and elevated serum C-reactive protein in Japanese men. <b>2003</b> , 74, 1741-6	73
1070	Associations of periodontal status with general health conditions and serum antibody titers for Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans. <b>2003</b> , 74, 1491-7	24
1069	Elevated concentrations of C-reactive protein in subjects with type 2 diabetes mellitus are moderately influenced by glycemic control. <b>2003</b> , 26, 216-21	17
1068	Relation of inflammation and benefit of statins after percutaneous coronary interventions. <i>Circulation</i> , <b>2003</b> , 107, 1750-6	16.7 166
1067	Acute inflammatory events and ischemic stroke subtypes. <b>2003</b> , 15, 215-21	32
1066	C-reactive protein and glycemic control in adults with diabetes. <b>2003</b> , 26, 1535-9	193
1065	Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. <b>2003</b> , 115, 695-701	88
1064	The prognostic value of markers of inflammation in patients with troponin T-negative chest pain before discharge from the emergency department. <b>2003</b> , 115, 521-8	16
1063	Neopterin levels in patients with coronary artery disease are independent of Chlamydia pneumoniae seropositivity. <b>2003</b> , 146, 69-74	10
1062	Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. <b>2003</b> , 146, 62-8	147

1061	Prediction of Recurrent Events by D-Dimer and Inflammatory Markers in Patients with Normal Cardiac Troponin I (PREDICT) Study. <b>2003</b> , 145, 986-92	39
1060	Markers of inflammation and thrombosis: clues to plaque instability?. <b>2003</b> , 145, 941-2	5
1059	Inflammation in atherosclerosis: causal or casual? The need for randomized trials. <b>2003</b> , 146, 199-202	2
1058	Effect of transdermal nitroglycerin on inflammatory mediators in patients with peripheral atherosclerotic vascular disease. <b>2003</b> , 146, E14	12
1057	Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. <b>2003</b> , 146, 591-604	100
1056	C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy. <b>2003</b> , 146, 1099-104	23
1055	The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. <b>2003</b> , 114, 199-205	73
1054	C-reactive protein and the risk of cardiovascular mortality. <b>2003</b> , 114, 241-2	
1053	Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. <b>2003</b> , 114, 485-94	40
1052	Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. <b>2003</b> , 114, 715-22	75
1051	C-reactive protein activates complement in infarcted human myocardium. <b>2003</b> , 163, 269-75	81
1050	Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. <i>Circulation</i> , <b>2003</b> , 108, 2317-22	16.7 742
1049	Clinical application of C-reactive protein for cardiovascular disease detection and prevention. <i>Circulation</i> , <b>2003</b> , 107, 363-9	16.7 1772
1048	C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. <i>Circulation</i> , <b>2003</b> , 107, 391-7	16.7 1881
1047	Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. <i>Circulation</i> , <b>2003</b> , 107, 499-511	16.7 4541
1046	Preoperative white blood cell count and mortality and morbidity after coronary artery bypass grafting. <b>2003</b> , 76, 760-4	37
1045	C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. <b>2003</b> , 52, 1113-6	96
1044	The evaluation of C-reactive protein, homocysteine and vitamin B6 concentrations in Behçet and rheumatoid arthritis disease. <b>2003</b> , 329, 143-5	8

1043	Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood. <b>2003</b> , 332, 51-9	77
1042	Evaluation of a modified hsCRP method for point-of-service testing. <b>2003</b> , 334, 249-52	2
1041	Depression and cardiovascular disease: mechanisms of interaction. <b>2003</b> , 54, 248-61	354
1040	Influence of Chlamydia pneumoniae infection on aortic stiffness in healthy young men. <b>2003</b> , 171, 117-22	14
1039	Pre-diabetes, insulin resistance, inflammation and CVD risk. <b>2003</b> , 61 Suppl 1, S9-S18	101
1038	New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione. <b>2003</b> , 25, 1895-917	13
1037	Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. <b>2003</b> , 25 Suppl B, B47-63	39
1036	The athero-thrombotic and inflammatory profile of visceral obesity. <b>2003</b> , 1253, 27-34	1
1035	Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. <b>2003</b> , 60, 634-9	12
1034	C-reactive protein on admission and the success of thrombolytic therapy with streptokinase: is there any relation?. <b>2003</b> , 92, 27-33	7
1033	C-reactive protein in ischemic stroke and its etiologic subtypes. <b>2003</b> , 12, 74-81	31
1032	Porphyromonas gingivalis infection is associated with carotid atherosclerosis in non-obese Japanese type 2 diabetic patients. <b>2003</b> , 52, 142-5	41
1031	Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. <b>2003</b> , 145, 248-53	67
1030	Increase of inflammatory state in overweight adults with combined hyperlipidemia. <b>2003</b> , 13, 227-31	7
1029	The prognostic value of high-sensitive C-reactive protein and cardiac troponin T in young and middle-aged patients with chest pain without ECG changes. <b>2003</b> , 14, 310-314	5
1028	Coronary artery disease: new insights into the pathophysiology, prevalence and early detection of a monster menace. <b>2003</b> , 24, 114-22	3
1027	C-reactive protein, Helicobacter pylori, Chlamydia pneumoniae, cytomegalovirus and risk for myocardial infarction. <b>2003</b> , 13, 170-7	30
1026	Growth hormone and cardiovascular risk markers. <b>2003</b> , 13 Suppl A, S109-15	12

1025	Inflammation, infection, and atherosclerosis. <b>2003</b> , 17, 238-44		22
1024	Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. <b>2003</b> , 17, 276-85		198
1023	Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. <b>2003</b> , 29, 65-71		27
1022	Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. <b>2003</b> , 29, 133-8		51
1021	[Role of anti-inflammatory drugs in the treatment of acute coronary syndromes. From athero-inflammation to athero-thrombosis]. <b>2003</b> , 56, 9-15		4
1020	Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. <i>Circulation</i> , <b>2003</b> , 108, 2292-7	16.7	355
1019	Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 2399-406	59.2	1084
1018	Minireview: adiposity, inflammation, and atherogenesis. <b>2003</b> , 144, 2195-200		610
1017	La proteína C reactiva como marcador del riesgo cardiovascular. <b>2003</b> , 20, 74-81		
1016	High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. <b>2003</b> , 38, 1018-24		89
1015	Antimicrobial periodontal treatment decreases serum C-reactive protein, tumor necrosis factor-alpha, but not adiponectin levels in patients with chronic periodontitis. <b>2003</b> , 74, 1231-6		129
1014	Statin therapy in the elderly: does it make good clinical and economic sense?. <b>2003</b> , 20, 263-75		15
1013	Inflammation Protocols. <b>2003</b> ,		22
1012	Markers of inflammation in women on different hormone replacement therapies. <b>2003</b> , 35, 353-61		22
1011	Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. <b>2003</b> , 24, 1128-33		27
1010	Coming of age of C-reactive protein: using inflammation markers in cardiology. <i>Circulation</i> , <b>2003</b> , 107, 370-1	16.7	309
1009	Carvedilol modulates in-vitro granulocyte-macrophage colony-stimulating factor-induced interleukin-10 production in U937 cells and human monocytes. <b>2003</b> , 32, 43-58		5
1008	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. <i>Circulation</i> , <b>2003</b> , 108, 1772-8	16.7	886

1007	Potential cardiovascular effects of COX-2 selective nonsteroidal antiinflammatory drugs. <b>2003</b> , 17, 27-50		3
1006	Chronic stress and age-related increases in the proinflammatory cytokine IL-6. <b>2003</b> , 100, 9090-5		872
1005	Primary prevention of cardiovascular diseases. <b>2003</b> , 21, 68-74		8
1004	Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. <b>2003</b> , 19, 187-91		9
1003	Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. <i>Circulation</i> , <b>2003</b> , 107, 1103-5	16.7	153
1002	Major risk factors for cardiovascular disease: debunking the "only 50%" myth. <b>2003</b> , 290, 947-9		82
1001	Diagnostic implications of C-reactive protein. <b>2003</b> , 138, 220-4		62
1000	Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. <i>Circulation</i> , <b>2003</b> , 107, 1729-32	16.7	45
999	Alcohol consumption and plasma concentration of C-reactive protein. <i>Circulation</i> , <b>2003</b> , 107, 443-7	16.7	264
998	C reactive protein for risk stratification in acute coronary syndromes? Verdict: unproven. <b>2003</b> , 89, 1288-90		8
997	Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. <b>2003</b> , 163, 1145-53		61
996	Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. <b>2003</b> , 49, 666-9		149
995	Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. <b>2003</b> , 52, 442-7		116
994	Blood pressure, C-reactive protein, and risk of future cardiovascular events. <i>Circulation</i> , <b>2003</b> , 108, 2993-6.7	16.7	259
993	Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. <b>2003</b> , 158, 844-51		78
992	High-sensitivity analysis of serum C-reactive protein in young patients with lumbar disc herniation. <b>2003</b> , 85, 1151-4		22
991	Review: The management of stable angina in diabetes. <b>2003</b> , 3, 18-25		2
990	The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. <b>2003</b> , 54, 391-9		29



989	C-reactive protein and the risk of developing hypertension. <b>2003</b> , 290, 2945-51		683
988	Communtability of the CRM 470 C-reactive protein value in the Dade Behring N High Sensitivity CRP assay. <b>2003</b> , 41, 177-82		7
987	White cell telomere length and risk of premature myocardial infarction. <b>2003</b> , 23, 842-6		469
986	C-reactive protein and lesion morphology in patients with acute myocardial infarction. <i>Circulation</i> , <b>2003</b> , 108, 282-5	16.7	117
985	Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. <b>2003</b> , 26, 2754-7		118
984	C-reactive protein and the future risk of thromboembolic stroke in healthy men. <i>Circulation</i> , <b>2003</b> , 107, 2016-20	16.7	151
983	Cardiovascular risk factors and atherosclerosis in young males: ARMY study (Atherosclerosis Risk-Factors in Male Youngsters). <i>Circulation</i> , <b>2003</b> , 108, 1064-9	16.7	155
982	Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. <i>Circulation</i> , <b>2003</b> , 108, 2473-8	16.7	196
981	Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. <i>Circulation</i> , <b>2003</b> , 107, 2416-21	16.7	198
980	Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. <i>Circulation</i> , <b>2003</b> , 108, 2323-8	16.7	77
979	Unusual morphologic changes in apical hypertrophic cardiomyopathy. <b>2003</b> , 89, 1290		2
978	Dietary salicylates. <b>2003</b> , 56, 649-50		22
977	HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease. <b>2003</b> , 41, 1314-9		21
976	Problems with high-sensitivity C-reactive protein. <b>2003</b> , 49, 201; author reply 201-2		7
975	The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: a dose-response study. <b>2003</b> , 89, 517-22		93
974	Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy. <b>2003</b> , 42, 1055-61		20
973	Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. <i>Circulation</i> , <b>2003</b> , 108, 161-5	16.7	207
972	Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. <i>Circulation</i> , <b>2003</b> , 108, 512-5	16.7	245

971	Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. <b>2003</b> , 24, 2006-11	58
970	A dietary supplement attenuates IL-6 and CRP after eccentric exercise in untrained males. <b>2003</b> , 35, 2032-7	111
969	Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. <b>2003</b> , 23, 1444-8	128
968	Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. <b>2003</b> , 62, 414-8	121
967	Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients?. <b>2003</b> , 14, 1871-9	147
966	Risk of myocardial infarction in relation to plasma levels of homocysteine and inflammation-sensitive proteins: a long-term nested case-control study. <b>2003</b> , 54, 401-10	5
965	Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. <i>Circulation</i> , <b>2003</b> , 108, III22-7	16.7 30
964	Increased long-term mortality after an episode of community-acquired pneumonia--time to move beyond descriptive studies. <b>2003</b> , 37, 1625-8	9
963	C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. <i>Circulation</i> , <b>2003</b> , 108, 166-70	16.7 267
962	Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. <b>2003</b> , 289, 2673-84	818
961	C-reactive protein and coronary artery calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). <b>2003</b> , 23, 1851-6	84
960	Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. <b>2003</b> , 10, 652-7	82
959	Pretransplantation soluble adhesion molecule expression predicts outcome after living donor renal transplantation. <b>2003</b> , 138, 1113-9; discussion 1119-20	6
958	C-reactive proteins and chronic disease: what role does nutrition play?. <b>2003</b> , 18, 227-33	10
957	High sensitivity C-reactive protein in clinical practice. <b>2003</b> , 1, 207-11	23
956	Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. <i>Circulation</i> , <b>2003</b> , 107, 1303-7	16.7 946
955	Overweight and obesity in women: health risks and consequences. <b>2003</b> , 12, 163-72	123
954	Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. <i>Circulation</i> , <b>2003</b> , 108, 150-4	16.7 91

953	First-trimester C-reactive protein and subsequent gestational diabetes. <b>2003</b> , 26, 819-24		178
952	Association between blood pressure and C-reactive protein levels in acute ischemic stroke. <b>2003</b> , 42, 1117-23		31
951	Inflammatory and thrombotic mechanisms in coronary atherosclerosis. <b>2003</b> , 89, 993-7		101
950	CD14 promoter polymorphism is associated with acute myocardial infarction resulting from insignificant coronary artery stenosis. <b>2003</b> , 89, 931-2		12
949	C-reactive protein, antiinflammatory drugs, and quality of life in diabetes. <b>2003</b> , 37, 1593-7		13
948	Determination of C-reactive protein: comparison of three high-sensitivity immunoassays. <b>2003</b> , 49, 1691-5		28
947	Sophisticated tests for susceptibility to atherosclerosis: an added value for heart hospitals. <b>2003</b> , 1, 135-40		
946	Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. <b>2003</b> , 49, 611-6		59
945	Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. <b>2003</b> , 49, 1258-71		165
944	Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. <b>2003</b> , 26, 2764-9		73
943	Evaluation of two new high-sensitivity methods for C-reactive protein. <b>2003</b> , 40, 398-405		17
942	C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study. <i>Circulation</i> , <b>2003</b> , 107, 245-50	16.7	57
941	Serum amyloid a in obstructive sleep apnea. <i>Circulation</i> , <b>2003</b> , 108, 1451-4	16.7	71
940	Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999-2000. <b>2003</b> , 49, 686-90		68
939	C-reaktives Protein in der Risikovorhersage und Intervention bei kardiovaskulären Erkrankungen/C-Reactive Protein for Risk Prediction and Intervention in Cardiovascular Disease. <b>2003</b> , 27, 100-112		
938	Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation. <b>2003</b> , 23, 1245-9		267
937	New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding. <b>2003</b> , 18, 252-7		73
936	Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. <b>2003</b> , 23, 1042-7		307

935	C-reactive protein and cardiovascular disease: new insights from an old molecule. <b>2003</b> , 96, 793-807	173
934	Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. <b>2003</b> , 18, 106-12	77
933	Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease. <b>2003</b> , 24, 86-93	25
932	Cardiac Involvement in Systemic Lupus Erythematosus. <b>2003</b> , 1, 145-161	1
931	Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. <b>2003</b> , 24, 1824-32	53
930	Relationship between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study. <b>2003</b> , 163, 1172-9	231
929	Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk. <b>2003</b> , 18, 1976-9	32
928	Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. <b>2003</b> , 34, 2922-9	96
927	Pathophysiology of atherosclerotic plaque development and rupture: an overview. <b>2003</b> , 3, 347-54	14
926	Novel Biomedical Risk Markers for Cardiovascular Disease. <b>2003</b> , 10, 41-55	2
925	Angioplasty, C-reactive protein, and the patient at risk. <b>2003</b> , 227, 314-5	0
924	Antiplatelet agents in acute coronary syndromes. <b>2003</b> , 3, 403-14	4
923	Inflammatory cytokines and cardiovascular disease. <b>2003</b> , 2, 257-65	112
922	[Moderate alcohol consumption and plasma concentration of sensitive markers of inflammation. Comment on an atheroprotective relationship]. <b>2003</b> , 128, 2237-41	10
921	Laboratory assessment of the acute phase response: using CRP as a model. <b>2003</b> , 225, 343-52	2
920	Platelet activation, inflammatory mediators and hypercholesterolemia. <b>2003</b> , 1, 157-69	57
919	Testosterone for secondary prevention in men with ischaemic heart disease?. <b>2003</b> , 96, 521-9	38
918	Role of platelets in the pathophysiology of acute coronary syndrome. <b>2003</b> , 3, 147-62	77

917	Advances in antiplatelet therapy. <b>2003</b> , 8, 349-63	17
916	Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: the Copenhagen City Heart Study. <b>2003</b> , 24, 567-76	52
915	Risk assessment in cardiovascular disease: from traditional risk factors to genomics. <b>2003</b> , 5, F48-F55	0
914	Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. <b>2003</b> , 60, 1009-14	177
913	C-reactive protein: a novel marker of cardiovascular risk. <b>2003</b> , 11, 169-79	43
912	When the endothelium cannot say 'NO' anymore. ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular disease. <b>2003</b> , 24, 1901-2	19
911	Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. <b>2003</b> , 22, 106-17	100
910	The Properties of Enterococcus faecium and the Fermented Milk Product Gaio□□□ <b>2003</b> , 59-75	3
909	Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. <b>2003</b> , 21, 1841-6	106
908	Statins, inflammation, and sepsis: hypothesis. <b>2003</b> , 124, 740-3	92
907	Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. <b>2003</b> , 18, 2300-7	48
906	Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. <b>2003</b> , 24, 77-85	37
905	. <b>2003</b> , 14, 329-334	8
904	Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. <b>2003</b> , 163, 33-40	114
903	The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers. <b>2003</b> , 18, 295-300	15
902	Update on vascular disease in systemic lupus erythematosus. <b>2003</b> , 15, 519-27	59
901	Soluble CD14 and aortic stiffness in a population-based study. <b>2003</b> , 21, 1869-77	44
900	Obesity and heart failure. <b>2003</b> , 18, 360-6; quiz 367-8	19

899	Statins as potential therapeutic agents in neuroinflammatory disorders. <b>2003</b> , 16, 393-401	86
898	. <b>2003</b> , 10, 41-55	10
897	Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. <b>2003</b> , 18, 471-8	68
896	. <b>2003</b> , 14, 323-327	12
895	Inflammatory biomarkers of the patient with myocardial insufficiency. <b>2003</b> , 9, 369-74	8
894	Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. <b>2003</b> , 17 Suppl 1, S96-122	25
893	Toll-like receptor 4 and atherogenesis. <b>2003</b> , 35, 164-71	40
892	C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?. <b>2003</b> , 21, 1787-803	133
891	Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. <b>2003</b> , 14, 329-34	50
890	Novel Serum Cardiac Risk Biomarkers: Risk Assessment for Primary Prevention. <b>2003</b> , 6, 121-128	
889	Body mass index, but not physical activity, is associated with C-reactive protein. <b>2003</b> , 35, 1160-6	91
888	Inflammation-sensitive plasma proteins and incidence of myocardial infarction in men with low cardiovascular risk. <b>2003</b> , 23, 2247-51	34
887	Statins and stroke. <b>2003</b> , 58, 49-58	2
886	Cardiac Involvement in Rheumatoid Arthritis. <b>2003</b> , 121-143	
885	Association between depression and elevated C-reactive protein. <b>2003</b> , 65, 347-56	245
884	Handbook of Fermented Functional Foods. <b>2003</b> ,	50
883	C-reactive protein is independently associated with fasting insulin in nondiabetic women. <b>2003</b> , 23, 650-5	161
882	Inflammation in uremic patients: what is the link?. <b>2003</b> , 26, 65-75	11

881	Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. <b>2003</b> , 124, 49S-57S	80
880	Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia. <b>2003</b> , 104, 627-32	34
879	Statins and their role in vascular protection. <b>2003</b> , 105, 251-66	87
878	C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. <b>2003</b> , 163, 93-9	242
877	Physical activity, coronary heart disease, and inflammatory response. <b>2003</b> , 163, 1200-5	71
876	Nanotechnology in dentistry: reduction to practice. <b>2003</b> , 30, 10-5	35
875	C-reactive protein as a novel biomarker. Reactant can flag atherosclerosis and help predict cardiac events. <b>2003</b> , 114, 39-44; quiz 16	16
874	Aspirin for cardiovascular disease prevention. <b>2003</b> , 179, 147-152	37
873	Inflammation and vascular endothelial activation in an Aboriginal population: relationships to coronary disease risk factors and nutritional markers. <b>2003</b> , 178, 495-500	64
872	Statins as potential therapeutic agents in neuroinflammatory disorders. <b>2003</b> , 16, 393-401	59
871	Nutritional Problems of Asian Peritoneal Dialysis Patients. <b>2003</b> , 23, 58-64	7
870	Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. <b>2003</b> , 89, 1058-1063	52
869	Imaging of high-risk plaque. <b>2003</b> , 100, 160-75	16
868	The Prognostic Significance of Statin Therapy According to the Level of C-Reactive Protein in Acute Myocardial Infarction Patients who Underwent Percutaneous Coronary Intervention. <b>2003</b> , 33, 891	7
867	Inflammation and coronary artery disease. <b>2003</b> , 1, 65-70	55
866	C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?. <b>2003</b> , 285, R1250-2	29
865	[Treatment of obesity: the need to target attention on high-risk patients characterized by abdominal obesity]. <b>2003</b> , 19 Suppl 1, S7-19	10
864	Plasma concentrations of interleukin-2 soluble receptor in mild ischaemic left ventricular dysfunction. <b>2003</b> , 5, 23-5	10

863	Plasma levels of soluble thrombomodulin, C-reactive protein, and serum amyloid A protein in the atherosclerotic coronary circulation. <b>2003</b> , 44, 601-12	24
862	Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. <b>2003</b> , 26, 691-7	87
861	Chronic inflammation in PD patients. <b>2003</b> , 140, 104-11	7
860	Elevation of serum C-reactive protein levels is associated with obesity in boys. <b>2003</b> , 26, 541-6	48
859	The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. <b>2003</b> , 8, s750-68	50
858	Correlation between turbidimetric and nephelometric methods of measuring C-reactive protein in patients with unstable angina or non-ST elevation acute myocardial infarction. <b>2003</b> , 81, 133-6, 129-32	8
857	Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. <b>2003</b> , 90, 124-131	76
856	Investigation and Treatment of Subclinical Coronary Atherosclerosis. <b>2003</b> , 3, 97-106	
855	The role of chronic inflammation in cardiovascular mortality of uremic patients. <b>2003</b> , 26, 12-8	
854	The role of microvascular thrombosis in sepsis. <b>2004</b> , 32, 619-29	45
853	Statins in the Primary Prevention of Atherosclerosis-Related Events. <b>2004</b> , 53-92	
852	Statins, Inflammation, and C-Reactive Protein. <b>2004</b> , 219-232	
851	Atherosclerosis and biochemical markers.. <b>2004</b> , 48, 143-146	
850	Perspectives and Clinical Significance of Eicosanoids in Immunology, Endocrinology and Metabolic Regulation. 227-236	1
849	C-Reactive Protein as a Marker for Cardiovascular Disease. <b>2004</b> , 39, 735-744	1
848	C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study. <b>2004</b> , 164, 1781-7	21
847	The Effect of Systemic Inflammation on the Elevation of Troponin I after Percutaneous Transluminal Coronary Angioplasty with Stent in Patients with Stable Angina. <b>2004</b> , 34, 265	1
846	[Markers of inflammation in type 1 diabetic patients]. <b>2004</b> , 48, 253-60	5



845	Periodontal disease, but not edentulism, is independently associated with increased plasma fibrinogen levels. Results from a population-based study. <b>2004</b> , 92, 244-52	40
844	Chronic Inflammation in Peritoneal Dialysis: The Search for the Holy Grail?. <b>2004</b> , 24, 327-339	76
843	Plasma C-reactive protein and homocysteine concentrations are related to frequent fruit and vegetable intake in Hispanic and non-Hispanic white elders. <b>2004</b> , 134, 913-8	115
842	Serum albumin predicts cardiac adverse events in patients with advanced atherosclerosis - interrelation with traditional cardiovascular risk factors. <b>2004</b> , 91, 610-8	25
841	[Vascular risk factors and renal failure]. <b>2004</b> , 20, 1100-3	3
840	Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers. <b>2004</b> , 6, C21-C27	5
839	Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. <b>2004</b> , 35, 1625-30	44
838	Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. <b>2004</b> , 101, 15178-83	216
837	Relation between C reactive protein concentrations and coronary microvascular endothelial function. <b>2004</b> , 90, 750-4	63
836	Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. <b>2004</b> , 164, 1010-4	375
835	The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol. <b>2004</b> , 4, 187-95	26
834	Evaluation of high sensitive C-reactive protein and 5-10 methylenetetrahydrofolate reductase genotype in japanese young adults. <b>2004</b> , 9, 291-7	2
833	Nontraditional risk factors for cardiovascular disease in diabetes. <b>2004</b> , 25, 153-75	126
832	Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. <b>2004</b> , 35, 163-8	141
831	Diabetes and cardiovascular risk evaluation and management in primary care: progress and unresolved issues - rationale for a nationwide primary care project in Germany. <b>2004</b> , 112, 157-70	10
830	Prevalence of periodontal bacterial infection in non-obese Japanese type 2 diabetic patients: relationship with C-reactive protein and albuminuria. <b>2004</b> , 36, 116-8	15
829	Estrogen regulation of growth hormone action. <b>2004</b> , 25, 693-721	354
828	C-reactive protein, cardiovascular disease and stroke: new roles for an old biomarker. <b>2004</b> , 4, 507-18	7

827	Inflammation as a cardiovascular risk factor. <i>Circulation</i> , <b>2004</b> , 109, 112-10	16.7	670
826	Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. <b>2004</b> , 63, 31-5		191
825	The role of aspirin in cardiovascular diseases--forgotten benefits?. <b>2004</b> , 5, 109-15		16
824	Fatality of future coronary events is related to inflammation-sensitive plasma proteins: a population-based prospective cohort study. <i>Circulation</i> , <b>2004</b> , 110, 27-31	16.7	131
823	Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. <i>Circulation</i> , <b>2004</b> , 109, 1089-94	16.7	463
822	Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. <b>2004</b> , 15, 2186-94		194
821	CRP as a mediator of disease. <i>Circulation</i> , <b>2004</b> , 109, 1111-4	16.7	96
820	Role of C-reactive protein in cardiovascular disease. <b>2004</b> , 38, 110-8		50
819	Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. <i>Circulation</i> , <b>2004</b> , 110, 1678-85	16.7	137
818	Aspirin and coronary artery disease. <b>2004</b> , 92, 1175-81		47
817	Homozygous familial hyperlipidaemia presenting as severe aortic stenosis and unstable angina. <b>2004</b> , 90, 1285		2
816	Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. <i>Circulation</i> , <b>2004</b> , 110, 2349-54	16.7	358
815	Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. <i>Circulation</i> , <b>2004</b> , 110, 2713-20	16.7	88
814	Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins. <b>2004</b> , 24, 577-82		36
813	Inflammation in atherosclerosis and implications for therapy. <i>Circulation</i> , <b>2004</b> , 109, 1120-6	16.7	214
812	Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. <i>Circulation</i> , <b>2004</b> , 109, 2818-25	16.7	508
811	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. <i>Circulation</i> , <b>2004</b> , 110, e568-71	16.7	42
810	Septicemia in the United States dialysis population, 1991 to 1999. <b>2004</b> , 15, 1038-45		125

809	Monocyte cytokine production, systemic inflammation and cardiovascular disease in very elderly men and women: the Framingham Heart Study. <b>2004</b> , 11, 214-5		3
808	Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. <b>2004</b> , 164, 40-4		70
807	Chapter 2 Primary Prevention of Stroke by Modification of Selected Risk Factors. <b>2004</b> , 29, 5-54		
806	Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. <i>Circulation</i> , <b>2004</b> , 109, 1729-34	16.7	176
805	Poor predictive value of high-sensitivity C-reactive protein indicates need for reassessment. <b>2004</b> , 50, 1733-5		22
804	Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. <b>2004</b> , 90, 389-93		13
803	Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. <b>2004</b> , 15, 2494-501		179
802	Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. <b>2004</b> , 94, 1466-73		60
801	White blood cell count and C-reactive protein predict short-term prognosis in acute myocardial infarction. <b>2004</b> , 32, 646-54		7
800	Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). <i>Circulation</i> , <b>2004</b> , 109, 726-32	16.7	319
799	Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. <b>2004</b> , 43, 731-6		33
798	Triggers of perioperative myocardial ischaemia and infarction. <b>2004</b> , 93, 9-20		89
797	Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. <b>2004</b> , 43, 297-305		124
796	CagA-positive <i>Helicobacter pylori</i> strains may influence the natural history of atherosclerotic stroke. <b>2004</b> , 63, 800-4		39
795	C-reactive protein is associated with arterial stiffness in apparently healthy individuals. <b>2004</b> , 24, 969-74		309
794	Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. <b>2004</b> , 9, 27-33		54
793	Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. <b>2004</b> , 59, 892-6		97
792	Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index. <b>2004</b> , 9, 171-6		25

791	Human polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging and inflammation. <b>2004</b> , 64, 7473-8		54
790	High prevalence of aortic valve alterations in haemodialysis patients is associated with signs of chronic inflammation. <b>2004</b> , 96, c48-55		15
789	Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. <i>Circulation</i> , <b>2004</b> , 109, 1718-23	16.7	146
788	C-reactive protein: structure affects function. <i>Circulation</i> , <b>2004</b> , 109, 1914-7	16.7	85
787	Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors. <i>Circulation</i> , <b>2004</b> , 110, 1069-75	16.7	70
786	Endothelium-dependent flow-mediated vasodilation of systemic arteries is impaired in patients with myocardial virus persistence. <i>Circulation</i> , <b>2004</b> , 110, 2938-45	16.7	34
785	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the population science discussion group. <i>Circulation</i> , <b>2004</b> , 110, e554-9	16.7	54
784	C-reactive protein modifies the relationship between blood pressure and microalbuminuria. <b>2004</b> , 43, 791-6		74
783	Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. <b>2004</b> , 292, 1845-52		327
782	Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction. <b>2004</b> , 55-70		
781	COX-2 and the cardiovascular system. <b>2004</b> , 161-178		
780	CRP and risk of coronary heart disease: can exercise training cool down the flames?. <b>2004</b> , 24, 1743-5		7
779	Pathophysiology underlying accelerated atherogenesis in renal disease: closing in on the target. <b>2004</b> , 15, 1664-6		18
778	Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. <i>Circulation</i> , <b>2004</b> , 109, 588-8	16.7	144
777	Association between serum C-reactive protein elevation and left ventricular thrombus formation after first anterior myocardial infarction. <b>2004</b> , 125, 384-9		40
776	Cerebral ischemia: new risk factors. <b>2004</b> , 17 Suppl 1, 43-50		27
775	Different C-reactive protein kinetics in post-operative hip-fractured geriatric patients with and without complications. <b>2004</b> , 50, 216-22		65
774	Effect of withdrawal of statin on C-reactive protein. <b>2004</b> , 102, 166-70		28

773	Ultrasound and arterial wall disease. <b>2004</b> , 17 Suppl 1, 19-33		48
772	What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?. <b>2004</b> , 17, 296-302		18
771	Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. <i>Circulation</i> , <b>2004</b> , 109, 1955-9	16.7	378
770	Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. <i>Circulation</i> , <b>2004</b> , 110, 1747-53	16.7	200
769	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. <i>Circulation</i> , <b>2004</b> , 110, e550-3	16.7	86
768	Leukocyte count as an independent predictor of recurrent ischemic events. <b>2004</b> , 35, 1147-52		221
767	Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. <b>2004</b> , 35, 1619-24		165
766	The Role of Neutrophils and Neutrophil Extracellular Traps in Vascular Damage in Systemic Lupus Erythematosus. <b>2019</b> , 8,		20
765	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <b>2019</b> , 290, 140-205		259
764	The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. <b>2019</b> , 14, 50-59		275
763	Cardiac imaging and circulating biomarkers for primary prevention in the era of precision medicine. <b>2019</b> , 4, 299-308		
762	The Impending Epidemic of Cardiovascular Diseases in Patients With Cancer in Japan. <b>2019</b> , 83, 2191-2202		5
761	From Focal Lipid Storage to Systemic Inflammation: JACC Review Topic of the Week. <b>2019</b> , 74, 1594-1607		65
760	A Novel Anti-Inflammatory Role of Omega-3 PUFAs in Prevention and Treatment of Atherosclerosis and Vascular Cognitive Impairment and Dementia. <b>2019</b> , 11,		47
759	Racial Disparities in Limb Amputations After Traumatic Vascular Injury. <b>2019</b> , 10, S100-S105		1
758	Is atopic sensitization associated with indicators of early vascular ageing in adolescents?. <b>2019</b> , 14, e0220198		1
757	Optical coherence tomography and C-reactive protein in risk stratification of acute coronary syndromes. <b>2019</b> , 286, 7-12		10
756	Prescription of Aspirin and Statins in Primary Prevention. <b>2019</b> , 46, 13-25		2

755	Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. <b>2019</b> , 124, 437-450	104
754	How the association between obesity and inflammation may lead to insulin resistance and cancer. <b>2019</b> , 13, 1213-1224	39
753	Healthy lifestyles reduce suPAR and mortality in a Danish general population study. <b>2019</b> , 16, 1	32
752	Nuclear Imaging: Focus on Vascular Probes. <b>2019</b> , 39, 1369-1378	6
751	Association between the CD14-260C>T gene polymorphism and susceptibility to myocardial infarction: Evidence from case-control studies. <b>2019</b> , 46, 419-426	0
750	High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. <b>2019</b> , 42, 1783-1793	5
749	Is Active Transport and Leisure-Time Physical Activity Associated With Inflammatory Markers in US Adults? A Cross-Sectional Analyses From NHANES. <b>2019</b> , 16, 540-546	2
748	Predictive value of preprocedural procalcitonin for short- and long-term mortality after transfemoral transcatheter aortic valve implantation. <b>2019</b> , 34, 1993-2001	2
747	Inflammation and Peripheral Arterial Disease. <b>2019</b> , 2, 142-151	0
746	hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare-Based Study. <b>2019</b> , 8, e012638	35
745	The effect of pre-heart transplant body mass index on posttransplant outcomes: An analysis of the ISHLT Registry Data. <b>2019</b> , 33, e13621	13
744	Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. <b>2019</b> , 34, 1961-1968	23
743	Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort. <b>2019</b> , 21, 1935-1943	10
742	Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. <b>2019</b> , 365, 11628	31
741	The difference of risk factors predicting cardiac events in patients with chronic kidney disease between with and without diabetes. <b>2019</b> , 33, 532-540	2
740	Evaluation and Management of the Vulnerable Plaque. <b>2019</b> , 13, 1	1
739	Associations among circulating levels of follistatin-like 1, clinical parameters, and cardiovascular events in patients undergoing elective percutaneous coronary intervention with drug-eluting stents. <b>2019</b> , 14, e0216297	1
738	Cardiovascular disease risk factors are elevated among a cohort of young sexual and gender minorities in Chicago. <b>2019</b> , 42, 1073-1081	9

737	A redox sensitivity-based method to quantify both pentameric and monomeric C-reactive protein in a single assay. <b>2019</b> , 470, 40-45	5
736	Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target. <b>2019</b> , 115, 1178-1188	42
735	Statins: Rationale, Mode of Action, and Side Effects. <b>2019</b> , 171-200	3
734	Prognostic efficacy of C-reactive protein/albumin ratio in ST elevation myocardial infarction. <b>2019</b> , 53, 83-90	38
733	The immunometabolic role of indoleamine 2,3-dioxygenase in atherosclerotic cardiovascular disease: immune homeostatic mechanisms in the artery wall. <b>2019</b> , 115, 1408-1415	13
732	C-reactive protein and incident hypertension in a worksite population of Japanese men. <b>2019</b> , 21, 524-532	3
731	High-Sensitivity C-Reactive Protein: Retrospective Study of Potential Blood Biomarker of Inflammation in Acute Mild Traumatic Brain Injury. <b>2019</b> , 34, E28-E36	9
730	Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. <b>2019</b> , 6, 16	60
729	Novel findings in neutrophil biology and their impact on cardiovascular disease. <b>2019</b> , 115, 1266-1285	67
728	Artemisinin-indole and artemisinin-imidazole hybrids: Synthesis, cytotoxic evaluation and reversal effects on multidrug resistance in MCF-7/ADR cells. <b>2019</b> , 29, 1138-1142	11
727	Cardiac Biomarkers Predicting MACE in Patients Undergoing Noncardiac Surgery: A Meta-Analysis. <i>Frontiers in Physiology</i> , <b>2018</b> , 9, 1923	4.6 15
726	Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the Atherosclerosis Risk in Communities study. <b>2019</b> , 17, 818-826	0
725	Depression and Cardiovascular Risk: Epidemiology, Mechanisms, and Implications. <b>2019</b> , 185-196	
724	Cardiovascular disease in the QUEST-RA study, 10 years later. <b>2019</b> , 21, 242	2
723	References. <b>2019</b> , 415-510	
722	. <b>2019</b> ,	7
721	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions?. <b>2019</b> , 33, 759-762	12
720	Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin. <b>2019</b> , 34, 315-322	1

719	Effect of <i>Helicobacter pylori</i> infection on the risk of acute coronary syndrome: A systematic review and meta-analysis. <b>2019</b> , 98, e18348	13
718	A 6-Week Worksite Positivity Program Leads to Greater Life Satisfaction, Decreased Inflammation, and a Greater Number of Employees With A1C Levels in Range. <b>2019</b> , 61, 357-372	1
717	The relationship of CRP and cognition in cognitively normal older Mexican Americans: A cross-sectional study of the HABLE cohort. <b>2019</b> , 98, e15605	11
716	Systemic inflammation is elevated among both HIV-uninfected and HIV-infected young MSM. <b>2019</b> , 33, 757-759	11
715	Impact of $\beta$ -thalassemia trait carrier state on inflammatory status in patients with newly diagnosed hypertension. <b>2019</b> , 20, 284-289	1
714	Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. <b>2019</b> , 71, 1004-1018	33
713	Foetal hypoxia impacts methylome and transcriptome in developmental programming of heart disease. <b>2019</b> , 115, 1306-1319	8
712	Relation of Neutrophil to Lymphocyte Ratio to Risk of Incident Atrial Fibrillation. <b>2019</b> , 123, 396-401	14
711	Novel biomarkers of cardiovascular disease: Applications in clinical practice. <b>2019</b> , 56, 33-60	37
710	Retrograde and oscillatory shear rate in young anabolic androgenic steroid users. <b>2019</b> , 29, 422-429	3
709	Inflammatory Markers and Novel Risk Factors. <i>Contemporary Cardiology</i> , <b>2019</b> , 87-98	0.1
708	The periodontal stem/progenitor cell inflammatory-regenerative cross talk: A new perspective. <b>2019</b> , 54, 81-94	34
707	Assessment of Relationship Between C-Reactive Protein to Albumin Ratio and Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome. <b>2019</b> , 70, 361-368	44
706	Beta 2-Microglobulin and the Severity of Coronary Stenosis in Patients With Acute Coronary Syndrome. <b>2019</b> , 28, 575-582	5
705	Imaging inflammation in atherosclerotic plaques: Just make it easy!. <b>2019</b> , 26, 1705-1708	5
704	Association Between Systemic Inflammation, Carotid Arteriosclerosis, and Autonomic Dysfunction. <b>2020</b> , 11, 50-59	7
703	Early life adversity exposure and circulating markers of inflammation in children and adolescents: A systematic review and meta-analysis. <b>2020</b> , 86, 30-42	38
702	Daily intake of heat-killed <i>Lactobacillus plantarum</i> L-137 improves inflammation and lipid metabolism in overweight healthy adults: a randomized-controlled trial. <b>2020</b> , 59, 2641-2649	14



701	The intestinal microbiota fuelling metabolic inflammation. <b>2020</b> , 20, 40-54	301
700	Long- and short-term association of low-grade systemic inflammation with cardiovascular mortality in the LURIC study. <b>2020</b> , 109, 358-373	7
699	High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. <b>2020</b> , 116, 91-100	26
698	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <b>2020</b> , 41, 111-188	2236
697	Risks of Cardiovascular Disease and Beyond in Prescription of Nonsteroidal Anti-Inflammatory Drugs. <b>2020</b> , 25, 3-6	11
696	Distinct inflammatory mediator patterns in young black and white adults: The African-predict study. <b>2020</b> , 126, 154894	4
695	Meta-analysis of C-Reactive Protein and Risk of Angina Pectoris. <b>2020</b> , 125, 1039-1045	2
694	Lp-PLA and dual antiplatelet agents in intracranial arterial stenosis. <b>2020</b> , 94, e181-e189	4
693	Inflammation and atherosclerosis: what is on the horizon?. <b>2020</b> , 106, 80-85	25
692	Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men. <b>2020</b> , 10, 17040	0
691	Pathophysiology of Cardiovascular Complications in COVID-19. <i>Frontiers in Physiology</i> , <b>2020</b> , 11, 575600 4.6	21
690	Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. <b>2020</b> , 102, 152195	2
689	Inflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia. <b>2020</b> , 177, 25-52	4
688	Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. <b>2020</b> , 9, e014990	10
687	Management of multivessel coronary artery disease in patients with non-ST-elevation myocardial infarction: a complex path to precision medicine. <b>2020</b> , 11, 2040622320938527	8
686	CircRNA ZNF609 in peripheral blood leukocytes acts as a protective factor and a potential biomarker for coronary artery disease. <b>2020</b> , 8, 741	15
685	A prospective follow-up study of the relationship between high-sensitivity C-reactive protein and primary liver cancer. <b>2020</b> , 20, 1168	1
684	Cardiorespiratory fitness improves prediction of mortality of standard cardiovascular risk scores in a Latino population. <b>2020</b> , 43, 1167-1174	3

683	A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications. <b>2020</b> , 309, 16-26	31
682	Genetic parameters and associated genomic regions for global immunocompetence and other health-related traits in pigs. <b>2020</b> , 10, 18462	5
681	Association of dietary inflammatory potential with cardiometabolic risk factors and diseases: a systematic review and dose-response meta-analysis of observational studies. <b>2020</b> , 12, 86	12
680	Resistance to Antiplatelet Therapy Is Associated With Symptoms of Cerebral Ischemia in Carotid Artery Disease. <b>2020</b> , 54, 712-717	2
679	Heat Shock Proteins and Periodontitis [Cross-Reaction Between Bacterial and Human HSP in Periodontal Infection Linking with Cardiovascular Diseases. <b>2020</b> , 19	2
678	Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial. <b>2020</b> ,	4
677	The Clinical Effect of Psychological Nursing on Patients Undergoing Coronary Angiography Based on Gold Nanoparticle Contrast Agents. <b>2020</b> , 20, 6577-6583	1
676	Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus. <b>2021</b> , 45, 553-556	1
675	Single-Cell Transcriptomics Reveals That Metabolites Produced by sp. nov. BD3526 Ameliorate Type 2 Diabetes in GK Rats by Downregulating the Inflammatory Response. <b>2020</b> , 11, 568805	1
674	Exploring the relationship between fatigue and circulating levels of the pro-inflammatory biomarkers interleukin-6 and C-reactive protein in the chronic stage of stroke recovery: A cross-sectional study. <b>2020</b> , 9, 100157	2
673	Human Immunodeficiency Virus Is Associated With Higher Levels of Systemic Inflammation Among Kenyan Adults Despite Viral Suppression. <b>2021</b> , 73, e2034-e2042	2
672	Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. <b>2020</b> , 1	6
671	GlycA: A New Biomarker for Systemic Inflammation and Cardiovascular Disease (CVD) Risk Assessment. <b>2020</b> , 5,	14
670	Aspirin to Reduce Risk for Sudden Cardiac Death in Athletes With Elevated C-Reactive Protein Levels. <b>2020</b> , 133, 1014-1016	2
669	Periodontal therapy and cardiovascular risk. <b>2020</b> , 83, 107-124	27
668	Risk factors for cardiovascular disease from a population-based screening study in Tianjin, China: a cohort study of 36,215 residents. <b>2020</b> , 8, 444	4
667	Twilight, the Dawn of a New Era of Aspirin-Free PCI?. <b>2020</b> , 75, 2425-2429	5
666	Do Centenarians Die Healthier than Younger Elders? A Comparative Epidemiological Study in Spain. <b>2020</b> , 9,	5

665	PET Scan with Fludeoxyglucose/Computed Tomography in Low-Grade Vascular Inflammation. <b>2020</b> , 15, 207-213	5
664	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <b>2020</b> , 18, 2287-2295	5
663	C-Reactive Protein and Its Structural Isoforms: An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond. <b>2020</b> , 94, 499-520	27
662	Von der Haut zum Gefäßsystem   Psoriasis und das kardiovaskuläre Risiko. <b>2020</b> , 14, 205-211	1
661	Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress. <b>2020</b> , 32, 101500	45
660	Subclinical Inflammation Is Associated With Reductions in Muscle Oxygenation, Exercise Capacity and Quality of Life in Adults With Type 2 Diabetes. <b>2020</b> , 44, 422-427	0
659	Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. <b>2020</b> , 41, 2952-2961	32
658	Rheumatoid Arthritis as a Risk Factor for Coronary Artery Calcification and Obstructive Coronary Artery Disease in Patients with Chest Pain: A Registry Based Cross-Sectional Study. <b>2020</b> , 12, 679-689	4
657	Correlation Between Oral Health and Systemic Inflammation (COHESION): A Randomized Pilot Follow-Up Trial of a Plaque-Identifying Toothpaste. <b>2020</b> , 133, 994-998	0
656	The case for statin use to reduce perioperative adverse cardiovascular and cerebrovascular events. <b>2020</b> , 124, 525-534	0
655	The Impact of Oral Health on Work Performance of Japanese Workers. <b>2020</b> , 62, e59-e64	3
654	Cardiovascular Health Effects of Shift Work with Long Working Hours and Night Shifts: Study Protocol for a Three-Year Prospective Follow-Up Study on Industrial Workers. <b>2020</b> , 17,	11
653	Association of Childhood Psychosocial Environment With 30-Year Cardiovascular Disease Incidence and Mortality in Middle Age. <b>2020</b> , 9, e015326	18
652	Mindfulness with paced breathing reduces blood pressure. <b>2020</b> , 142, 109780	4
651	Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options. <b>2020</b> , 37, 1829-1865	8
650	Outcomes of Acute Myocardial Infarction in Patients with Rheumatoid Arthritis. <b>2020</b> , 133, 1168-1179.e4	8
649	Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). <b>2020</b> , 41, 2262-2271	28
648	Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy: further evidence fuelling the dual target concept. <b>2020</b> , 41, 2962-2964	4

647	Plaque vulnerability and adverse outcomes: The long road to fight atherosclerosis. <b>2020</b> , 50, e13253	3
646	Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models. <b>2020</b> , 22, 90	6
645	Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety. <b>2020</b> , 11, 422	80
644	Soluble pattern recognition molecules: Guardians and regulators of homeostasis at airway mucosal surfaces. <b>2020</b> , 50, 624-642	13
643	Prediction and early detection of cardiovascular disease in South Asians with diabetes mellitus. <b>2020</b> , 14, 385-393	2
642	Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. <b>2020</b> , 9,	0
641	Cardiovascular Disease Risk Assessment: Insights from Framingham. <b>2013</b> , 8, 11-23	146
640	Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. <b>2021</b> , 7, 97-106	6
639	Imaging and Targeting Coronary Artery Inflammation. <b>2021</b> , 34, 1217-1243	4
638	Mechanistic Insights to Target Atherosclerosis Residual Risk. <b>2021</b> , 46, 100432	12
637	Joint effect of blood pressure and C-reactive protein and the risk of sudden cardiac death: A prospective cohort study. <b>2021</b> , 326, 184-188	1
636	Immunomodulation of the NLRP3 Inflammasome in Atherosclerosis, Coronary Artery Disease, and Acute Myocardial Infarction. <b>2021</b> , 14, 23-34	23
635	Global assessment of C-reactive protein and health-related outcomes: an umbrella review of evidence from observational studies and Mendelian randomization studies. <b>2021</b> , 36, 11-36	11
634	Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. <b>2021</b> , 48, 804-812	4
633	The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. <b>2021</b> , 133, 28-41	4
632	Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target population. <b>2021</b> , 28, 152-158	14
631	Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. <b>2021</b> , 99, 335-348	15
630	Assessing the relationship between high-sensitivity C-reactive protein and kidney function employing mendelian randomization in a Japanese community based J-MICC Study. <b>2021</b> ,	

629	Prognostic role of neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing to pharmaco-invasive strategy. <b>2021</b> , 34, 99-99	1
628	Drugs Resistance in Heart Diseases. <b>2021</b> , 295-334	
627	Evaluation on blood coagulation and C-reactive protein level among children with mycoplasma pneumoniae pneumonia by different chest imaging findings. <b>2021</b> , 100, e23926	0
626	[Analysis of the causes of repeat stenosis of the coronary arteries after elective stenting in patients with stable angina pectoris]. <b>2021</b> , 93, 59-65	
625	The prothrombotic state in cancer. <b>2021</b> , 105, 213-242	0
624	Blood platelets in the development of sepsis, septic shock and multiple organ failure syndrome. <b>2021</b> , 22, 1085-1096	1
623	Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes. <b>2020</b> , 7, 631398	6
622	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. <b>2021</b> , 27, 263-275	3
621	Methotrexate and Cardiovascular Disease in Patients With Rheumatoid Arthritis: Insights and Novel Speculations. <b>2021</b> , 48, 793-795	0
620	Cardiovascular Risk Factors from Another Point of View. <b>2021</b> , 6, 27-31	
619	Cardiovascular Outcomes With Anti-Inflammatory Therapies: Review of Literature. <b>2021</b> , 47, 100840	
618	Plasma C-reactive protein is lower among marijuana using HIV-negative individuals but not among persons living with HIV. <b>2021</b> , 11, 4816	3
617	MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation. <b>2021</b> , 10,	5
616	Preliminary algorithm for a personalized diagnosis of cardiovascular disease and dependent renal complications using decision tree. <b>2021</b> , 87, 175-189	
615	Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions. <b>2021</b> , 26, 1-13	6
614	Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. <b>2021</b> , 77, 1670-1680	9
613	Atherosclerosis: Cholesterol Management. 1-36	
612	Hs-CRP as an important inflammatory risk marker of CAD in diabetes mellitus patients. <b>2021</b> , 8, 22-24	

611	Coronary heart disease risk: Low-density lipoprotein and beyond. <b>2021</b> ,	6
610	Protective Role of Platelets in Myocardial Infarction and Ischemia/Reperfusion Injury. <b>2021</b> , 2021, 5545416	0
609	Inflammation and Cardiovascular Disease: The Future. <b>2021</b> , 16, e20	10
608	Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. <b>2021</b> , 128, 1728-1746	46
607	Hemostatic factors, inflammatory markers, and risk of incident venous thromboembolism: The Multi-Ethnic Study of Atherosclerosis. <b>2021</b> , 19, 1718-1728	1
606	Looking for the Achilles heel of atheromatosis: could it be immunotherapy?. <b>2021</b> , 13, 557-560	0
605	Red Hair Color Is Associated with Elevated CRP Levels among US Women. <b>2021</b> , 141, 1342-1344	
604	Prognostic Role of High Sensitivity C-Reactive Protein in Patients With Acute Myocardial Infarction. <b>2021</b> , 8, 659446	3
603	Single-cell dissection of live human hearts in ischemic heart disease and heart failure reveals cell-type-specific driver genes and pathways.	2
602	Diabetes and inflammatory diseases: An overview from the perspective of Ca <sup>2+</sup> /3'-5'-cyclic adenosine monophosphate signaling. <b>2021</b> , 12, 767-779	0
601	Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. <b>2021</b> , 161, 105776	2
600	C-Reactive Protein Levels and Clinical Prognosis in LAA-Type Stroke Patients: A Prospective Cohort Study. <b>2021</b> , 2021, 6671043	3
599	Design, Synthesis, and Activity Evaluation of Stereoconfigured Tartarate Derivatives as Potential Anti-inflammatory Agents and. <b>2021</b> , 64, 9550-9566	1
598	Inflammation in heart disease: do researchers know enough?. <b>2021</b> , 594, S8-S9	
597	Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction. <b>2021</b> , 15, 556-568	2
596	The combined effect of blood pressure and C-reactive protein with the risk of mortality from coronary heart and cardiovascular diseases. <b>2021</b> , 31, 2051-2057	0
595	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. <b>2021</b> ,	
594	Anti-Inflammatory Drugs in Patients with Ischemic Heart Disease. <b>2021</b> , 10,	0

593	Associations between bone mineral density in different measurement locations and coronary artery disease: a cross-sectional study. <b>2021</b> , 16, 100		3
592	Possible Gender Difference in the Association Between Abdominal Obesity, Chronic Inflammation, and Preclinical Atherosclerosis in the General Population. <b>2021</b> , 62, 837-842		0
591	Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy. <b>2021</b> , 25, 8087-8094		2
590	Systemic inflammation as a driver of health disparities among sexually-diverse and gender-diverse individuals. <b>2021</b> , 129, 105215		10
589	Relative Predictive Value of Circulating Immune Markers in US Adults Without Cardiovascular Disease: Implications for Risk Reclassification. <b>2021</b> , 96, 1812-1821		1
588	C-reactive protein: pathogenetic characteristics and possible therapeutic target. <b>2021</b> , 26, 4138		3
587	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. <b>2021</b> , 27, 1382-1392		0
586	High Sensitivity C-reactive Protein in Patients with Coronary Artery in-stent Restenosis: A Case-control Study. <b>2021</b> , 15, 29-37		
585	Elevated Serum Inflammatory Markers in Subacute Stroke Are Associated With Clinical Outcome but Not Modified by Aerobic Fitness Training: Results of the Randomized Controlled Trial. <b>2021</b> , 12, 713018		1
584	Guilt, shame and their associations with chronic diseases in Czech adults. <b>2021</b> , 1-10		0
583	Novel glycoproteins identify preclinical atherosclerosis among women with previous preeclampsia regardless of type 1 diabetes status. <b>2021</b> , 31, 3407-3414		1
582	Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study. <b>2021</b> , 1		3
581	Mortality in Eosinophilic Esophagitis - a nationwide, population-based matched cohort study from 2005 to 2017. <b>2021</b> , 126,		0
580	The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis. <b>2021</b> , 2021, 7712587		3
579	Inflammation and ischemic heart disease: The next therapeutic target?. <i>Revista Portuguesa De Cardiologia</i> , <b>2021</b> , 40, 785-785	1	3
578	Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers. <b>2021</b> , 12, 681455		0
577	Metabolic Comorbidities in Vitiligo: A Brief Review and Report of New Data from a Single-Center Experience. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
576	Cynandione A and PHA-543613 inhibit inflammation and stimulate macrophageal IL-10 expression following $\alpha$ nAChR activation. <b>2021</b> , 190, 114600		2

575	Randomized trial of vitamin D versus placebo supplementation on markers of systemic inflammation in hypertensive patients. <b>2021</b> , 31, 3202-3209		2
574	Short-Term and Lifelong Exercise Training Lowers Inflammatory Mediators in Older Men. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 702248	4.6	0
573	Inflammation and Stroke Risk: A New Target for Prevention. <b>2021</b> , 52, 2697-2706		11
572	Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. <b>2021</b> , 64, 2701-2712		1
571	Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy: what is next?. <b>2021</b> , 36, 776-783		
570	Cardiovascular Disease Risk Assessment in Diabetes. <b>2021</b> , 22, 168-173		
569	Therapeutic radiation exposure of the abdomen during childhood induces chronic adipose tissue dysfunction. <b>2021</b> , 6,		0
568	Association between histological severity of Helicobacter pylori infection and cardiovascular risk scores in the Korean population. <b>2021</b> , 333, 124-130		1
567	Sleep duration, baseline cardiovascular risk, inflammation and incident cardiovascular mortality in ambulatory U.S. Adults: National health and nutrition examination survey. <b>2021</b> , 8, 100246		1
566	Exploring the Links between Personality and Immune Function. <b>2022</b> , 184, 111179-111179		2
565	Inflammatory cardiovascular risk markers and silent myocardial ischemia in type 2 diabetic patients. <b>2021</b> , 10-10		
564	Prognostic Significance of Abnormal Ankle-Brachial Index Among Long-term Hemodialysis Patients in Kinshasa, the Democratic Republic of the Congo. <b>2021</b> , 12,		0
563	Individualised Risk Assessments for Recurrent Venous Thromboembolism: New Frontiers in the Era of Direct Oral Anticoagulants. <b>2021</b> , 2, 64-78		0
562	Targets Atherosclerosis Plaques in Human Coronary Arteries DC-SIGN (CD209). <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 579010	8.4	2
561	Biomarkers. 1		1
560	Sexual Dimorphism in Cardiovascular Disease. <b>1999</b> , 187-217		3
559	Uremic toxicity. <b>2004</b> , 15-55		4
558	Pathogenesis of Atherosclerosis. <b>2013</b> , 377-386		1



557	The role of linoleic acid in endothelial cell gene expression. Relationship to atherosclerosis. <b>1998</b> , 30, 415-36	16
556	Role of coenzyme Q and superoxide in vitamin E cycling. <b>1998</b> , 30, 491-507	20
555	Direct Estrogen Effects on the Cardiovascular System. <b>2002</b> , 99-119	1
554	Lipids, Inflammatory Cytokines, and Endothelial Cell Injury. <b>2000</b> , 203-220	2
553	Endothelial Dysfunction, Inflammation, and Exercise. <b>2009</b> , 131-147	1
552	A microchip-based assay for interleukin-6. <b>2007</b> , 385, 131-44	11
551	From Vulnerable Plaque to Vulnerable Patient. <b>2011</b> , 13-38	4
550	Comprehensive Non-contrast CT Imaging of the Vulnerable Patient. <b>2011</b> , 375-391	1
549	Inflammation, C-Reactive Protein, and Vulnerable Plaques. <b>2007</b> , 611-620	2
548	The role of inflammation in head and neck cancer. <b>2014</b> , 816, 107-27	61
547	Atherosclerosis: an Inflammatory Disease. <b>2001</b> , 1-21	2
546	Predicting Mortality from Profiles of Biological Risk and Performance Measures of Functioning. <b>2014</b> , 119-135	2
545	Cardiovascular Dysfunction Following Spinal Cord Injury. <b>2017</b> , 325-361	2
544	Sex and Gender Differences in Psychosocial Risk Factors for Ischemic Heart Disease. <b>2017</b> , 203-220	1
543	Epidemiology of Atherosclerotic Vascular Disease. <b>2002</b> , 3-16	1
542	Anatomie und Pathologie der Koronararterien. <b>2000</b> , 209-553	2
541	Vaskuläre Erkrankungen. <b>1999</b> , 954-1093	1
540	Links Between Biomarkers and Mortality. <b>2011</b> , 381-398	15

539	Outcome following Stroke. <b>2004</b> , 35-57	3
538	Sudden Cardiac Death. <b>2004</b> , 720-731	9
537	Lipids III: Plasma Lipoproteins. <b>2002</b> , 429-451	1
536	Atherosclerosis in Systemic Lupus Erythematosus. <b>2001</b> , 255-265	1
535	Atherosclerosis and Familial Mediterranean Fever. <b>2001</b> , 335-337	1
534	Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors. <b>2012</b> , 731-805	4
533	Cardiac Injury, Atherosclerosis, and Thrombotic Disease. <b>2011</b> , 249-258	1
532	[High sensitivity C protein as an independent risk factor in people with and without history of cardiovascular disease]. <b>2015</b> , 85, 124-35	7
531	Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review. <b>2020</b> , 75, 2726-2737	18
530	Learning about the structure and biology of human lipoprotein [a] through dissection by enzymes of the elastase family: facts and speculations. <b>1997</b> , 38, 2193-2206	29
529	Lipid Management. <b>2007</b> , 13, 40-47	0
528	Air pollution. <b>2005</b> , 480-494	1
527	Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay. <b>1999</b> , 45, 2136-2141	457
526	Acute Coronary Syndromes. <b>2009</b> , 535-596	9
525	Nontraditional cardiovascular risk factors. <b>1999</b> , 317, 193-207	38
524	Metabolic risk factors for coronary heart disease: current and future prospects. <b>1999</b> , 14, 176-85	17
523	Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. <b>2000</b> , 11, 382-7	153
522	Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. <b>2001</b> , 13, 341-4	59

521	Acute phase proteins and the systemic inflammatory response. <b>1999</b> , 27, 452-3	10
520	Inflammation and Infection in Clinical Stroke. <b>2002</b> , 1399-1419	69
519	Is C-reactive protein an independent risk factor for essential hypertension?. <b>2001</b> , 19, 2107	6
518	Novel risk factors for coronary heart disease: emerging connections. <b>2000</b> , 14, 91-103	6
517	The vulnerable coronary plaque. <b>2000</b> , 15, 1-12	8
516	Pretransplant systemic inflammation and acute rejection after renal transplantation. <b>2000</b> , 69, 869-74	34
515	Inflammation and acute stroke. <b>1998</b> , 11, 45-9	83
514	Biological basis for statin therapy in stroke prevention. <b>2000</b> , 13, 57-62	17
513	C-reactive protein and cardiorespiratory fitness in young adults. <b>2005</b> , 12, 216-220	25
512	New and old cardiovascular risk factors: C-reactive protein, homocysteine, cysteine and von Willebrand factor increase risk, especially in smokers. <b>2005</b> , 12, 542-7	13
511	Is high-sensitivity C-reactive protein associated with carotid atherosclerosis in healthy Koreans?. <b>2005</b> , 12, 548-54	11
510	Physical performance is associated with markers of vascular inflammation in patients with coronary heart disease. <b>2006</b> , 13, 356-362	6
509	Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. <b>2005</b> , 17, 234-41	22
508	Statin therapy in rheumatoid arthritis. <b>2005</b> , 98, 534-40; quiz 541, 572	8
507	Correlation of high-sensitivity C-reactive protein and plasma fibrinogen with individual complications in patients with type 2 diabetes. <b>2006</b> , 99, 23-7	14
506	C-reactive protein and cold-pressor tolerance in the general population: the Tromsø Study. <b>2017</b> , 158, 1280-1288	26
505	C-reactive protein: the harbinger of cardiovascular diseases. <b>2008</b> , 101, 525-33	4
504	Venous and arterial disease in inflammatory bowel disease. <b>2013</b> , 28, 1095-113	49

503	Innate immunity, local inflammation, and degenerative disease. <b>2002</b> , 2002, re3		43
502	<i>Helicobacter pylori</i> and Gastrointestinal Disorders. 191-206		2
501	The Association of <i>Chlamydia pneumoniae</i> and Atherogenesis. 105-123		2
500	A <i>Chlamydia pneumoniae</i> component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. <b>1998</b> , 66, 5067-72		131
499	Invasion of human coronary artery cells by periodontal pathogens. <b>1999</b> , 67, 5792-8		229
498	Inflammatory responses and coronary heart disease. <b>1998</b> , 316, 953-4		13
497	Multivessel myocardial infarction: a window to future treatments of myocardial infarction. <b>2010</b> , 2, 82-8		3
496	Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. <b>1997</b> , 17, 3208-14		49
495	Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. <i>Circulation</i> , <b>1997</b> , 96, 2914-9	16.7	101
494	Mechanisms precipitating acute cardiac events: review and recommendations of an NHLBI workshop. National Heart, Lung, and Blood Institute. Mechanisms Precipitating Acute Cardiac Events Participants. <i>Circulation</i> , <b>1997</b> , 96, 3233-9	16.7	79
493	Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. <b>2007</b> , 27, 1087-94		40
492	Systemic Inflammatory Response in Cardiac Allograft Vasculopathy. <i>Circulation</i> , <b>2000</b> , 102,	16.7	4
491	A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. <b>1998</b> , 101, 353-63		384
490	Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. <b>2001</b> , 107, 1481-9		114
489	C-reactive protein: a critical update. <b>2003</b> , 111, 1805-12		1134
488	C-reactive protein: a critical update. <b>2003</b> , 111, 1805-1812		2388
487	Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. <b>1999</b> , 103, 571-7		379
486	Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. <b>2017</b> , 127, 83-93		84

485	Novel biomarkers for cardiovascular risk prediction. <b>2017</b> , 14, 135-150	109
484	Cardiopulmonary Consequences of Particle Inhalation. <b>2000</b> , 653-670	3
483	CMR plaque characterization. <b>2005</b> , 116-127	1
482	Prognostic value of low and moderately elevated C-reactive protein in acute coronary syndrome: a 2-year follow-up study. <b>2013</b> , 19, 777-86	7
481	Application of Isobaric Tags for Relative and Absolute Quantification (iTRAQ) Coupled with Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry in Quantitative Proteomic Analysis for Discovery of Serum Biomarkers for Idiopathic Pulmonary Fibrosis. <b>2018</b> , 24, 4146-4153	9
480	Oxidative Stress and C-Reactive Protein in Patients with Cerebrovascular Accident (Ischaemic Stroke): The role of Ginkgo biloba extract. <b>2012</b> , 12, 197-205	13
479	Non-invasive measurement of brachial-ankle pulse wave velocity is associated with serum C-reactive protein but not with alpha-tocopherol in Japanese middle-aged male workers. <b>2004</b> , 27, 173-80	32
478	Nonfasting Lipemia and Inflammation as Cardiovascular Disease Risks After SCI. <b>2009</b> , 14, 15-31	5
477	Suppression of Proatherogenic Inflammatory Cytokines as a Therapeutic Countermeasure to CVD Risks Accompanying SCI. <b>2011</b> , 16, 14-32	6
476	C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. <b>2008</b> , 3, e1395	64
475	Immune responses accelerate ageing: proof-of-principle in an insect model. <b>2011</b> , 6, e19972	25
474	Maternal diet supplemented with methyl-donors protects against atherosclerosis in F1 ApoE(-/-) mice. <b>2013</b> , 8, e56253	25
473	Time variability of C-reactive protein: implications for clinical risk stratification. <b>2013</b> , 8, e60759	32
472	HDL-apoA-I exchange: rapid detection and association with atherosclerosis. <b>2013</b> , 8, e71541	43
471	Early inflammatory markers are independent predictors of cardiac allograft vasculopathy in heart-transplant recipients. <b>2014</b> , 9, e113260	10
470	Attenuated age-impact on systemic inflammatory markers in the presence of a metabolic burden. <b>2015</b> , 10, e0121947	3
469	Plasma C-Reactive Protein and Clinical Outcomes after Acute Ischemic Stroke: A Prospective Observational Study. <b>2016</b> , 11, e0156790	33
468	Impact of arteriovenous fistula blood flow on serum il-6, cardiovascular events and death: An ambispective cohort analysis of 64 Chinese hemodialysis patients. <b>2017</b> , 12, e0172490	4

467	Serum biomarkers in patients with ossification of the posterior longitudinal ligament (OPLL): Inflammation in OPLL. <b>2017</b> , 12, e0174881	22
466	Comparisons of microbiota-generated metabolites in patients with young and elderly acute coronary syndrome. <b>2020</b> , 24, 175-182	1
465	C-reactive protein and immunoglobulin-E response to coronary artery stenting in patients with stable angina. <b>2003</b> , 44, 593-600	5
464	Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). <b>2018</b> , 13, 38-41	7
463	Prognostic value of C-reactive protein/albumin ratio in ST-segment elevation myocardial infarction. <b>2020</b> , 11, 168-171	1
462	Virtual Histology Intravascular Ultrasound Assessment of Carotid Artery Disease:The Carotid Artery Plaque Virtual Histology Evaluation (CAPITAL) Study. <b>2007</b> , 14, 676-686	47
461	Amount of physical activity necessary for a normal level of high-sensitivity C-reactive protein in ELSA-Brasil: a cross-sectional study. <b>2020</b> , 138, 19-26	1
460	[The influence of estrogen and progestogen replacement on growth hormone activity in women with hypopituitarism]. <b>2008</b> , 52, 901-16	3
459	C-Reactive protein predicts acute myocardial infarction during high-risk noncardiac and vascular surgery. <b>2011</b> , 66, 773-6	9
458	Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients?. <b>2001</b> , 12, 814-821	90
457	Inflammation, Malnutrition, and Cardiac Disease as Predictors of Mortality in Hemodialysis Patients. <b>2002</b> , 13, S28-S36	300
456	The impact of the cumulative burden of LDL-c and hs-CRP on cardiovascular risk: a prospective, population-based study. <b>2020</b> , 12, 11990-12001	4
455	Aspirin induces autophagy inhibition of the acetyltransferase EP300. <b>2018</b> , 9, 24574-24575	10
454	The use of neutrophil lymphocyte ratio to predict complications post cardiac surgery. <b>2019</b> , 7, 778	17
453	Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. <b>2005</b> , 1, 55-71	80
452	Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. <b>2006</b> , 2, 221-37	55
451	Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events. <b>2012</b> , 26, 217	2
450	Risk Factors for Ischemic Heart Disease. <b>2019</b> , 14, 86-94	4

449	Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life. <b>2010</b> , 4, 24-9	12
448	[Predictors of mortality in dialysis patients--association between malnutrition, inflammation and atherosclerosis (MIA syndrome)]. <b>2004</b> , 57, 149-52	4
447	[Oxidized LDL and C-reactive protein as markers for detection of accelerated atherosclerosis in type 2 diabetes]. <b>2006</b> , 59, 160-4	2
446	[Oxidized LDL and C-reactive protein level in relation to carotid intima-media thickness in population with risk factors for atherosclerosis]. <b>2009</b> , 137, 140-5	3
445	Relationship between periodontal disease and diabetic complications. <b>2013</b> , 54, 336-345	1
444	COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events. <b>2020</b> , 68, 5-8	3
443	Inflammation imaging to define vulnerable plaque or vulnerable patient. <b>2020</b> , 64, 21-34	2
442	Advances in biomarker for stroke patients: from marker to regulator. <b>2017</b> , 1, 32-42	7
441	Evaluation of Neutrophil-lymphocyte and Platelet-lymphocyte Ratios as Predictors of 30-day Mortality in Patients Hospitalized for an Episode of Acute Decompensated Heart Failure. <b>2019</b> , 38, 452-460	8
440	Frequency of Heparin-Induced Thrombocytopenia. <b>2007</b> , 67-116	17
439	Physiological correlates of bereavement and the impact of bereavement interventions. <b>2012</b> , 14, 129-39	73
438	Serum high sensitivity C-reactive protein levels in obese middle school boys. <b>2006</b> , 49, 617	2
437	Pro-inflammatory gene expression in adipose tissue of patients with atherosclerosis. <b>2017</b> , 66, 633-640	8
436	Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities. <b>2020</b> , 9,	4
435	The effect of shift work on high sensitivity C-reactive protein level among female workers. <b>2019</b> , 31, e5	6
434	Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug. <b>2005</b> , 11, 1040-3	6
433	An elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneous coronary intervention. <b>2003</b> , 18, 154-60	8
432	Relationship between peripheral leukocyte count and the severity of stable angina determined by coronary angiography. <b>2004</b> , 19, 99-103	1

431	Significance of inflammatory markers in diabetic patients with stable coronary artery disease. <b>2009</b> , 24, 212-9	6
430	Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. <b>2009</b> , 76, 37-44	7
429	[C-reactive protein and carotid intima-media thickness in a population of middle-aged Koreans]. <b>2009</b> , 42, 29-34	5
428	Association of Serum Total Bilirubin with Serum High Sensitivity C-reactive Protein in Middle-aged Men. <b>2011</b> , 32, 327-33	12
427	Association between Resting Heart Rate and Inflammatory Markers (White Blood Cell Count and High-Sensitivity C-Reactive Protein) in Healthy Korean People. <b>2017</b> , 38, 8-13	8
426	Inflammatory markers among adolescents and young adults with bipolar spectrum disorders. <b>2015</b> , 76, 1556-63	47
425	Evaluation of the C-reactive protein serum levels in periodontitis patients with or without atherosclerosis. <b>2010</b> , 21, 326-9	14
424	Inverse Correlation between Serum C-Reactive Protein and Magnesium Levels in Smokers and Nonsmokers. <b>2015</b> , 7, 271-4	1
423	Association of Elevated C-Reactive Protein with Severe Periodontitis in Hypertensive Patients in Lagos, Nigeria: A Pilot Study. <b>2018</b> , 9, S95-S99	1
422	Relationship between C-reactive Protein and Screening Test Results of Gestational Diabetes in Pregnant Women Referred to Health Centers in Isfahan in 2013-2014. <b>2019</b> , 24, 360-364	4
421	Effect of yoga training on inflammatory cytokines and C-reactive protein in employees of small-scale industries. <b>2017</b> , 6, 76	15
420	Residual Cardiovascular Risk—Inflammation the Primary Cause?. <b>2018</b> , 08, 59-69	3
419	Aspirin resistance: Fact or fiction? A point of view. <b>2010</b> , 2, 280-8	11
418	Adipose tissue and vascular inflammation in coronary artery disease. <b>2014</b> , 6, 539-54	32
417	The Concept of Risk and the Emerging Discipline of Periodontal Medicine. <b>1999</b> , 1, 42-59	12
416	Potential role of interleukin-18 in patients with rheumatoid arthritis-associated carotid intima-media thickness but not insulin resistance. <b>2014</b> , 1, 135-139	2
415	Relationship between periodontitis and cardiovascular diseases: A literature review. <b>2014</b> , 3, 1	2
414	Acute phase reactants as novel predictors of cardiovascular disease. <b>2012</b> , 2012, 953461	49



413	Impact of C-reactive protein on the likelihood of carotid atherosclerosis in Japanese adults. <b>2006</b> , 13, 175-82	8
412	Derivatives of reactive oxygen metabolites correlates with high-sensitivity C-reactive protein. <b>2008</b> , 15, 206-12	38
411	Progression of atherosclerosis in hemodialysis patients: effect of adiponectin on carotid intima media thickness. <b>2008</b> , 15, 213-8	10
410	Effect of a Probiotic Preparation (VSL#3) on CardiovascularRisk Parameters in Critically-Ill Patients. <b>2013</b> , 5, 67-70	13
409	Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention. <b>2016</b> , 5, e28997	8
408	Assessment of serum leptin, pregnancy-associated plasma protein A and CRP levels as indicators of plaque vulnerability in patients with acute coronary syndrome. <b>2012</b> , 23, 330-5	10
407	Increased carotid intima-media thickness associated with high hs-CRP levels is a predictor of unstable coronary artery disease. <b>2013</b> , 24, 270-3	7
406	Overall and Gender-specific Associations between C-reactive Protein and Stroke Occurrence: A Cross-sectional Study in US. <b>2016</b> , 18, 355-357	2
405	Effect of a new international reference preparation for proteins in human serum (certified reference material 470) on results of the College of American Pathologists Surveys for plasma proteins. <b>2000</b> , 124, 1496-501	23
404	Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. <b>2002</b> , 126, 1281-95	55
403	Hypercoagulation testing in ischemic stroke. <b>2007</b> , 131, 890-901	38
402	Correlation between C-reactive protein in peripheral vein and coronary sinus in stable and unstable angina. <b>2015</b> , 104, 202-8	3
401	Levels of High-Sensitivity C-Reactive Protein in Heart Transplant Patients With and Without Periodontitis. <b>2019</b> , 17, 123-127	2
400	Protective effect of vitamin E against diabetes-induced oxidized LDL and aorta cell wall proliferation in rat. <b>2015</b> , 19, 117-23	6
399	Hypoalbuminaemia--a marker of cardiovascular disease in patients with chronic kidney disease stages II-IV. <b>2008</b> , 5, 366-70	27
398	Risk factors for cardiovascular disease: one down, many more to evaluate. <b>1999</b> , 131, 62-3	32
397	Mediators of Inflammation in Patients with Coronary Artery Disease. <b>2000</b> , 467-487	
396	Arteriosklerose. <b>2000</b> , 115-188	

- 395 Evaluation of Platelet Membrane Glycoproteins in Ischemic Heart Disease. **2000**, 601-619
- 394 Arteriosclerosis and Its Risk Factors. **2000**, 19-28
- 393 The Newer Coronary Risk Factors. **2000**, 179-191
- 392 Hypercoagulative syndrome: Molecular markers for the identification of cardiovascular patients at risk. **2000**, 21-27
- 391 Grundprinzipien medikamentöser Therapie und allgemeiner Lebensweise. **2000**, 331-338
- 390 Antibiotika zur Reokklusionsprophylaxe. **2000**, 55-68
- 389 Human Studies of Antioxidants and Vascular Function. **2000**, 213-243
- 388 Prevalence of Chlamydia pneumoniae in human coronary plaques with acute coronary syndrome. **2000**, 84-90
- 387 Autoantibodies to Endothelial Cells and Oxidized LDL in Human Atherosclerosis and Hypertension. **2001**, 161-171
- 386 C-reactive Protein is Prognostic Marker of Inflammation in Atherothrombosis. **2001**, 203-220 1
- 385 Defensins. **2001**, 73-85
- 384 Die koronare Herzerkrankung [eine entzündliche oder infektiöse Krankheit?]. **2001**, 99-109
- 383 Host Response Differences to Infection May Affect Disease susceptibility in atherosclerotic patients. **2001**, 119-126
- 382 Clinical evidence of inflammation as a risk factor in ischemic stroke. **2001**, 13-26
- 381 Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T. **2001**, 85, 571-575
- 380 Aging of Joints and Skeletal System: Influence of Gender and Physical Activity. **2001**, 209-230
- 379 Coronary Artery Disease and Endothelial Function. **2002**, 887-912
- 378 Reducing Neuroinflammation. **2002**, 65-93

- 377 Monitoring and Assessment of Perioperative Vital Functions in Major Non-Cardiac Surgery. **2002**, 777-787
- 376 Metabolic Syndrome X and low-grade systemic inflammation. **2002**, 61-93
- 375 Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall. **2002**, 81-98
- 374 Atherosclerotic Lesions: Vulnerability. **2002**, 327-339
- 373 Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets). **2002**, 55-80
- 372 Role of Inflammatory Response and Thrombosis in Acute Coronary Syndromes. **2002**, 46-61
- 371 Immune-mediated inflammatory disorders. **2002**, 30, 1-3
- 370 Inflammation and Cardiovascular Disease. **2003**, 3-18
- 369 The Newer Coronary Risk Factors. **2003**, 193-211
- 368 Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. **2003**, 67-73
- 367 A biomarker of inflammation in cardiovascular disease. **2003**, 9-20
- 366 Lipoxins and Aspirin-Triggered 15-epi-Lipoxins: Mediators in Anti-inflammation and Resolution. **2003**, 281-285
- 365 C-Reactive Protein for Primary Risk Assessment. **2003**, 279-290
- 364 Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement. **2003**, 305-317
- 363 The clinical and vasoprotective effect of aspirin in patients long receiving therapy with angiotensin-converting enzyme inhibitors. **2003**, 9, 10-13
- 362 Novel Atherosclerotic Risk Factors and Management. **2003**, 41-58
- 361 Atherogenesis and Coronary Heart Disease.
- 360 Unanswered questions about the use of statins. **2003**, 228-240

- 359 Epidemiology of Coronary Calcification. **2004**, 213-222
- 358 Endothelial Cell Biology: Inflammatory Biomarkers and Risk of Transplant Atherosclerosis. **2004**, 591-605
- 357 Serum Biomarkers in Prediction of Stroke Risk and Outcome. **2004**, 257-278
- 356 Gender and Its Impact on Risk Factors for Cardiovascular Disease. **2004**, 193-214 1
- 355 Risk Detection and Primary Prevention in Women. **2004**, 29-45
- 354 Markers of myocardial damage and inflammation in patients with coronary artery disease. **2004**, 23, 249-253
- 353 Prävention der koronaren Herzerkrankung. **2004**, 1119-1147
- 352 Collagen Vascular and Infectious Diseases. **2004**, 575-601
- 351 The Insulin Resistance Syndrome.
- 350 The Role of P2Y12 Blockade in Acute Coronary Syndromes and in the Catheterization Laboratory. **2004**, 411-434
- 349 B-Type Natriuretic Peptides in Acute Coronary Syndromes. **2004**, 323-338
- 348 Bedside Platelet Monitoring. **2004**, 495-520
- 347 Statins and Plaque Stabilization. **2004**, 521-562
- 346 Imaging of High-Risk Atherosclerotic Plaque by Intravascular Ultrasound. **2004**, 67-83
- 345 Treatment of Vulnerable Plaques. **2004**, 164-202
- 344 Arteriosclerosis. **2005**, 620-629
- 343 Determination of high sensitivity C-reactive protein: Clinical and analytical quality. **2005**, 24, 85-93 1
- 342 Vascular Inflammation as a Cardiovascular Risk Factor. **2005**, 577-604

341 Coagulation, thrombosis, and coronary heart disease. **2005**, 466-479

340 Chronic infection and circulating markers of inflammation. **2005**, 448-465

339 Pathophysiology. **2005**, 31-54

338 Carotid Imaging. **2005**, 77-110

337 Statins. **2005**, 425-450

336 [Relationship between nutritional status and some inflammatory markers]. **2006**, 134, 54-9

335 ??. **2006**, 48, 101-105

1

334 Atherosclerosis coronaria. **2006**, 18-28

333 Analytic Issues for Clinical Use of C-Reactive Protein. **2006**, 223-235

332 Statins and Toxicity. **2006**, 273-295

331 Statins, Inflammation, and Cardiomyopathy: Old Pathways, New Targets. **2006**, 155-166

330 Anticoagulation and Antiplatelet Agents. **2006**, 501-524

329 Stroke Prevention. **2006**, 545-584

328 Kardiovaskulární onemocnění a dysfunkce parenchymatů srdce. **2006**, 48, 331-332

327 Inflammatory Mediators and C-Reactive Protein. **2006**, 441-462

326 Acute Myocardial Infarction. **2006**, 611-646

325 The risk factor profile of patients undergoing cardiovascular surgery and their relatives. **2006**, 48, 379-383

1

324 Angiotensin II and Inflammation. **2007**, 91-110

- 323 Inflammatory Markers are Associated with Microvascular Complications in Type 2 Diabetes. **2007**, 31, 472 1
- 322 EFFECT OF EXERCISE TRAINING ON SERUM HIGH-SENSITIVITY C-REACTIVE PROTEIN CONCENTRATION IN HEALTHY MIDDLE-AGED AND ELDERLY SUBJECTS. **2007**, 56, 179-190
- 321 Risk Factors for Cardiovascular Disease and Arterial Thrombosis. **2007**, 371-378
- 320 The Effect of Weight Reduction Diet on C-Reactive Protein Level in Obese-Adult Subjects. **2008**, 9, 17-23 3
- 319 CORONARY ARTERY DISEASE. **2009**, 321-365
- 318 Periodontal disease: Chronic low-grade inflammation accelerating aging. **2009**, 29, 186-189
- 317 3.???CRP??????????? ??????????????????????(N Engl J Med 2006)??????????. **2009**, 40, 171S-172S
- 316 Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. **2009**, 293-340
- 315 Thyroid and Cardiovascular Risk. **2009**, 151-165 1
- 314 Inflamaci3n y riesgo cardiovascular en di3lisis peritoneal. **2009**, 361-377
- 313 The Association between Serum GGT within Normal Range and Cardiovascular Risk Factors, Metabolic Syndrome of Premenopausal and Postmenopausal Women. **2009**, 13, 171-181
- 312 The Link Between Inflammation and Thrombosis. **2010**, 39-61
- 311 Evaluation of risk markers fluctuation during an initial therapy with rosiglitazon in patients suffering from metabolic syndrome. **2009**, 9, 320-8
- 310 The Effect of Aerobic Gymnastic Exercise on Physical Fitness and Inflammatory Markers in Hemiplegic Disabled after Cerebral Stroke. **2009**, 17, 109-126 1
- 309 Peritoneal Dialysis Prescription and Adequacy. **2010**, 432-445
- 308 Medical Management of Acute Coronary Syndromes. **2010**, 867-882
- 307 Anatomia patologica. **2010**, 27-37
- 306 1.?????????????????. **2010**, 41, 90-94

305 COMPARISON OF ATHEROSCLEROTIC RISK FACTORS BETWEEN DONORS WITH ASSOCIATED ACUTE NON-HEMOLYTIC TRANSFUSION REACTIONS AND DONORS WITHOUT ASSOCIATION. **2010**, 56, 697-701

304 Inflammation, Thrombosis and Vascular Biology: Translating Ideas into Cardiovascular Research and Therapy. **2010**, 4, 20-23

303 Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood. **2011**, 53-66

302 Inflammation, thrombosis and vascular biology: translating ideas into cardiovascular research and therapy. **2010**, 4, 20-2

301 Implications of genetic polymorphisms in inflammation-induced atherosclerosis. **2010**, 4, 30-7 8

300 Inflammatory Markers and Novel Risk Factors. **2011**, 107-123

299 Recent advances in preventing cardiovascular disorders by managing lipid levels. **2010**, 2, 66 1

298 Newer Coronary Risk Factors. **2011**, 113-139

297 Advanced Lipid Testing. **2011**, 77-103

296 Novel Biomarkers and the Assessment of Cardiovascular Risk. **2011**, 54-63

295 Biomarkers in Acute Ischemic Heart Disease. **2011**, 101-112

294 Risk Stratification in Unstable Angina and NonST-Segment Elevation Myocardial Infarction. **2011**, 181-193

293 Inflammation and Immunity as Targets for Drug Therapy in Acute Coronary Syndrome. **2011**, 271-288

292 Insulin Resistance, Dyslipidemia, Type 2 Diabetes Mellitus and Metabolic Syndrome. **2011**, 277-332

291 Biomarkers of Stroke. **2011**, 13, 57

290 Circulating levels of inflammatory biomarkers associated with ischemic stroke subtype. **2011**, 33, 564-571

289 Molecular genetics of atherosclerosis and acute coronary syndromes. **2011**, 35-43

288 Atherogenesis and Inflammation. 10-29

- 287 Stable Angina. **2012**, 1-18
- 286 Prognostic Implications of Depression in Ischemic Syndromes. **2012**, 147-167
- 285 Historical Reflections on the Inflammatory Aspects of Atherosclerosis. **2012**, 1-17
- 284 Atherosclerosis in Rheumatic Diseases. **2012**, 497-512 0
- 283 Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines. **2011**, 10, 81-88
- 282 Coagulation Disorders: Inflammation and Thrombosis. **2012**, 770-774
- 281 A case of pseudoaneurysm formed 10 years after segmental liver resection for hepatocellular carcinoma. **2012**, 53, 55-63
- 280 Cardiovascular Disease. **2012**, 478-549
- 279 Krankheiten des Herzens. **2012**, 335-393
- 278 [C reactive protein in women with coronary heart disease and its association with depression]. **2012**, 58, 158-72 1
- 277 Aspirin. 12-25
- 276 The Role and Potential of Surrogate Outcomes in Clinical Trials: Have We Made Any Progress in the Past Decade?. **2013**, 3-19 1
- 275 Inflammation, Chronic Disease, and Cancer: Is Psychological Distress the Common Thread?. **2013**, 13-30
- 274 Inflammation and atherothrombosis. **2013**, 828-836
- 273 Elevated levels of inflammatory cytokines and high-sensitivity C-reactive protein in periodontitis patients in Kosovo: A pilot study. **2013**, 03, 32-38
- 272 A Hierarchy of Healing: The Therapeutic Order. **2013**, 18-33 1
- 271 High Sensitivity CRP Predicts Long-Term Mortality in Patients with Atrial Fibrillation and Evident Acute Coronary Syndrome. **2013**, 04, 137-144
- 270 C-Reactive Protein in Cardiovascular Disease. **2013**, 3-18



269 Aspirin as Primary Prevention of Acute Coronary Heart Disease Events. **2014**, 4, 5357-5367

268 Chronic Kidney Disease and Cardiovascular Risk. **2014**, 49-61

267 Immunologie. **2014**, 63-103

266 Sudden Cardiac Death in Adults. **2014**, 981-991

265 Integration of Biomarkers with Plaque Imaging. *Contemporary Cardiology*, **2014**, 203-214 0.1

264 HIGH SENSITIVITY C - REACTIVE PROTEIN AS A PROGNOSTIC MARKER IN ACUTE STROKE. **2014**, 3, 2675-2679 5

263 Inflammatory Activity in the Pathogenesis of Unstable Angina. **1997**, 23-31

262 Are C-Reactive Protein and Fibrinogen Risk Factors?. **1997**, 13-21

261 New Biochemical Markers for Heart Diseases. **1998**, 281-294 1

260 Dietary Lipid Guidelines for Infants and Children. **1998**,

259 Linking Biochemical, Pathologic, and Clinical Events in Acute Coronary Syndromes. *Contemporary Cardiology*, **1999**, 19-56 0.1 1

258 Activated Protein C Resistance, Factor V Leiden, and Venous Thromboembolism. **1999**, 37-53

257 The Spectrum of Myocardial Ischemia. *Contemporary Cardiology*, **1999**, 3-18 0.1

256 Das Herz des alternden Menschen. **1999**, 67-125

255 Very Early C-Reactive Protein Levels after Acute Myocardial Infarction Predict Early Outcome and Late Prognosis. **2015**, 06, 547-553

254 Cardiovascular Disease. **2015**, 25-53

253 Lipid and Inflammation in Atherosclerosis. **2015**, 37-63

252 Cardiovascular and Metabolic Syndrome Impact on Uristatin. **2015**, 157-170

- 251 New Risk Factors of Cardiovascular Disease. **2015**, 3-19
- 250 Bereavement and the Risk of Cardiovascular Disease. **2015**, 1-18
- 249 Investigation of serum antibody titers for periodontopathic bacteria in diabetic patients. **2015**, 56, 414-422
- 248 Correlation of Ceruloplasmin with Biomarkers of Cardiac Remodelling and Myofibrosis in Patients with Acute Decompensated Heart Failure Referred to a Tertiary Nurse Lead Heart Failure Clinic. **2015**, 05, 971-975
- 247 Biomarkers of Coronary Plaque Composition and Vulnerability. **2015**, 1-17
- 246 Bereavement and the Risk of Cardiovascular Disease. **2016**, 229-246 0
- 245 Biomarkers of Coronary Plaque Composition and Vulnerability. **2016**, 897-913
- 244 Lifestyle Factors that can Induce an Independent and Persistent Low-Grade Systemic Inflammatory Response: A Wholistic Approach. **2016**, 3, 34-48 0
- 243 The Role of High-sensitivity C-reactive Protein as a Cardiovascular Risk Marker in Essential Hypertension. **2016**, 02, 23-28
- 242 A STUDY OF HIGH SENSITIVITY C-REACTIVE PROTEIN (hs-CRP) LEVELS IN CEREBROVASCULAR ACCIDENT (STROKE). **2016**, 5, 4655-4660
- 241 Ankle-Brachial Index as a Predictor of Mortality in Hemodialysis: A 5-Year Cohort Study. **2017**, 108, 204-211 5
- 240 The Relationship between Metabolic Syndrome Risk Factors and High Sensitive C-reactive Protein in Abdominal Obesity Elderly Women. **2017**, 49, 121-127 3
- 239 Relationship between platelet-to-lymphocyte ratio and cardiac syndrome X. **2017**, 39, 570-575
- 238 Risk factors for acute coronary events in patients with rheumatoid arthritis. **2017**, 44, 164-171 1
- 237 Evaluation of Sperm DNA Fragmentation amongst Infertile Black Africans. A Nigerian Study. **2018**, 08, 297-316 2
- 236 C-Reactive Protein (CRP) Latex Agglutination Test. **2018**, 59-62 0
- 235 Hematological Analyses of Both Postoperative Inflammation and Fibrinolysis-coagulation Disorder in Patients with Abdominal Aortic Aneurysm between Vascular Prosthesis Replacement and Endovascular Repair. **2018**, 58, 21-26
- 234 TO STUDY THE RELATIONSHIP BETWEEN MICROALBUMINURIA AND ISCHAEMIC HEART DISEASE IN NON-DIABETIC SUBJECTS. **2018**, 7, 2562-2565

233 ASPIRINA NA PREVENÇÃO PRIMÁRIA DE EVENTOS CARDIOVASCULARES EM PACIENTES DIABÉTICOS: UMA REVISÃO.

232 Biomarkers for unstable atherosclerotic plaques in carotid arteries. **2019**, 17, 290-294

231 The Effects of Menopausal Hormone Therapy on Serum Level of C-reactive Protein in Postmenopausal Korean Women. **2019**, 25, 49-54 0

230 C-reactive protein, a disintegrin and metalloproteinase 17 protein, and cathepsin D in chronic periodontitis with type 2 diabetes mellitus. **2019**, 43, 169-179

229 Changes of cardiac troponin I and hypersensitive C-reactive protein prior to and after treatment for evaluating the early therapeutic efficacy of acute myocardial infarction treatment. **2020**, 19, 1121-1128

228 A Hierarchy of Healing. **2020**, 11-24.e4

227 Relationship Between Oral Health and Clinical Osteoporosis Among Hospitalized Patients with and Without Diabetes. **2020**, 12, e7145

226 [Primary Prevention of Acute Stroke]. **2020**, 109, 277-289

225 Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections. **2020**, 212-228

224 Secondary prevention after acute coronary syndrome. **2020**, 66, 236-241

223 C-reactive protein and cardiovascular disease: From animal studies to the clinic (Review). **2020**, 20, 1211-1219 3

222 [C-reactive protein and its associations with cardiometabolic risk factors and echocardiographic indicators of heart failure: results of "Know your heart" study in Arkhangelsk]. **2020**, 60, 68-75 0

221 Can High-Sensitivity C-Reactive Protein Levels Predict Functional Outcome Following Epidural Steroid Injection in Patients with Lumbar Disc Disease?. **2020**, 0

220 C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease: Inflammatory Disorders and Atherosclerosis. *Contemporary Cardiology*, **2021**, 565-583 0.1 1

219 Inflammation and Atherosclerotic Cardiovascular Disease. *Contemporary Cardiology*, **2021**, 289-333 0.1

218 C-Reactive Protein and Incident Hypertension in Black and White Americans in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Cohort Study. **2021**, 34, 698-706 1

217 Comparison of Familial, Polygenic and Biochemical Predictors of Mortality. **2020**, 23, 307-315 0

216 Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. **2021**, 19, 323-342 8

- 215 A Preliminary Study of the Relationship between Oral and Vascular Function in the Elderly Population. **2020**, 29, 161-164 2
- 214 Adult Stem Cells: Mesenchymal Stromal Cells, Endothelial Progenitor Cells, and Pericytes. **2020**, 109-149 0
- 213 The acute phase response and C-reactive protein. **2020**, 2199-2207
- 212 Encyclopedia of Behavioral Medicine. **2020**, 1187-1189
- 211 Multiple Faces of C-Reactive Protein: StructureFunction Relationships. **2020**, 1-34
- 210 Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis. **2021**, 12, 774808 2
- 209 Cardiorespiratory fitness, white blood cell count, and mortality in men and women. **2021**, 1
- 208 Krankheiten des Herzens. **2008**, 311-373
- 207 Coronary Artery Disease. **2005**, 107-150
- 206 Kardiovaskuläre Risikofaktoren und deren therapeutische Beeinflussung. **2006**, 1-26
- 205 Herderkrankungen aus mund-, kiefer- und gesichtschirurgischer Sicht. **2006**, 47-68
- 204 Vaskuläre Erkrankungen. **2006**, 941-1073
- 203 The Problems of Childhood Obesity and the Metabolic Syndrome. **2006**, 153-168
- 202 Uremic Toxins in Chronic Renal Failure. **2006**, 71-103 1
- 201 Atherosclerosis and coronary heart disease. **1999**, 1-22
- 200 Prevention of Atherosclerosis: Endothelial Function, Cholesterol, and Antioxidants. **1999**, 77-106
- 199 Mechanisms of Sudden Cardiac Death. **2005**, 323-351
- 198 Risk Factors. **2005**, 475-516

197	Multivariable Evaluation of Candidates for Cardiovascular Disease. <b>2005</b> , 3-18	
196	Pathogenesis of Atherosclerosis. <b>2005</b> , 409-418	
195	Inflammation and Infection in Coronary Artery Disease. <b>2006</b> , 29-45	
194	Paradoxical modulation of influenza by intranasal administration of non-replicating adenovirus particles. <b>2020</b> , 15, e0241266	
193	The Evolution and Future Direction of The Cardiac Biomarker.	
192	C reactive protein and acute phase of ischaemic stroke. <b>2001</b> , 322, 1605-6	
191	Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis. <b>1999</b> , 344 Pt 1, 7-13	6
190	Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. <b>2000</b> , 352 Pt 3, 693-9	10
189	Ways to make "usual" and "successful" aging synonymous. Preventive gerontology. <b>1997</b> , 167, 206-15	9
188	Retinal emboli and cardiovascular disease: the Beaver Dam Eye Study. <b>2003</b> , 101, 173-80; discussion 180-2	10
187	Respiratory infection in lipid-fed rabbits enhances sudanophilia and the expression of VCAM-1. <b>1997</b> , 151, 1009-17	18
186	Microbes, inflammation and atherosclerosis: will old pathology lessons guide new therapies?. <b>2001</b> , 112, 215-22; discussion 222-3	4
185	Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins. <b>1999</b> , 5, 117-28	11
184	Reduction of C-reactive protein and the use of anti-hypertensives. <b>2007</b> , 3, 975-83	22
183	Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. <b>2007</b> , 12, 17-28	58
182	Role of plaque inflammation in acute and recurrent coronary syndromes. <b>2004</b> , 12, 106-109	6
181	Periodontitis as a risk factor for cardiovascular disease: the role of anti-phosphorylcholine and anti-cardiolipin antibodies. <b>2008</b> , 12, 144-9	17
180	Association of serum C-reactive protein and indices of body fat distribution and overweight in Mexican American children. <b>2003</b> , 95, 545-52	38

179	Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins. <b>2005</b> , 97, 1600-7	8
178	Nonobese, exercising children diagnosed with dyslipidemia have normal C-reactive protein. <b>2009</b> , 5, 65-9; quiz 70-2	1
177	Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future. <b>2008</b> , 3, 293-302	1
176	Haptoglobin: A major susceptibility gene for diabetic vascular complications. <b>2002</b> , 7, 113-9	9
175	PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. <b>2009</b> , 36, 530-9	9
174	Variation in high-sensitivity C-reactive protein levels over 24 hours in patients with stable coronary artery disease. <b>2010</b> , 37, 42-8	20
173	Modulatory Effect of Inflammation on Blood Pressure Reduction via Therapeutic Lifestyle Change. <b>2009</b> , 9, 175-80	
172	Association of cardiac rehabilitation with improvement in high sensitive C-reactive protein post-myocardial infarction. <b>2012</b> , 14, 49-50	2
171	Association between Periodontopathogens and CRP Levels in Patients with Periodontitis in Serbia. <b>2011</b> , 5, 10-6	5
170	Relation of resistin levels with C-reactive protein, homocysteine and uric acid in smokers and non-smokers. <b>2011</b> , 16, 1273-9	7
169	Changes in plasma IL4, TNF $\alpha$ and CRP in response to regular passive smoking at home among healthy school children in Khartoum, Sudan. <b>2012</b> , 12, 41-7	10
168	Evaluation of serum C-reactive protein levels in subjects with aggressive and chronic periodontitis and comparison with healthy controls. <b>2012</b> , 9, 261-5	7
167	Treating chronic periodontitis: current status, challenges, and future directions. <b>2010</b> , 2, 79-91	26
166	High-sensitivity C-reactive protein levels and treadmill exercise test responses in men and women without overt heart disease. <b>2013</b> , 18, 124-8	3
165	The effects of cyclooxygenase and nitric oxide synthase inhibition on cardiodynamic parameters and coronary flow in isolated rat hearts. <b>2013</b> , 18, e102-10	2
164	Influence of periodontal disease on systemic disease: inversion of a paradigm: a review. <b>2013</b> , 6, 126-30	17
163	High sensitivity C-reactive protein levels in Acute Ischemic Stroke and subtypes: A study from a tertiary care center. <b>2013</b> , 12, 92-7	13
162	Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals. <b>2010</b> , 11, 884-900	25

161	Association of Ca <sup>2+</sup> PO <sub>4</sub> product with levels of serum C-reactive protein in regular hemodialysis patients. <b>2012</b> , 1, 55-9	1
160	Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. <b>2014</b> , 140, 392-400	4
159	Polymorphisms in the PTX1 may not be associated with ischemic stroke susceptibility. <b>2014</b> , 7, 3992-9	
158	Stress and support for parents of youth with bipolar disorder. <b>2012</b> , 49, 104-10	7
157	Association of COX-2 -765G>C genetic polymorphism with coronary artery disease: a meta-analysis. <b>2015</b> , 8, 7412-8	7
156	Anticoagulants and Statins As Pharmacological Agents in Free Flap Surgery: Current Rationale. <b>2015</b> , 15, e51	6
155	Using biomarkers to improve the preoperative prediction of death in coronary artery bypass graft patients. <b>2010</b> , 42, 293-300	9
154	The Role of IL-33 in the Inflammation Process of Asthma and Atherosclerosis. <b>2011</b> , 22, 79-91	3
153	Predictive role of adiponectin and high-sensitivity C-reactive protein for prediction of cardiovascular event in an Iranian cohort Study: The Isfahan Cohort Study. <b>2016</b> , 12, 132-137	2
152	Mid-term Risk Stratification of Patients with a Myocardial Infarction and Atrial Fibrillation: Beyond GRACE and CHADS. <b>2013</b> , 6, 897	
151	Study of High Sensitive C-Reactive Protein (HS-CRP) After Cardiac Rehabilitation Program in Patients Undergoing Isolated CABG. <b>2016</b> , 12, 143-148	2
150	The effect and safety of diacerein in patients with type 2 diabetes mellitus : a systematic review and meta-analysis. <b>2017</b> , 6, 97-106	4
149	Role of Inflammation in the Pathogenesis of Acute Coronary Syndromes. <b>2003</b> , 14, 51-52	
148	C-reactive protein as a predictor of malignant ventricular arrhythmias in non-ST elevation myocardial infarction. <b>2019</b> , 16, 614-620	1
147	Prediction of Lipoprotein-Associated Phospholipase A2 and Inflammatory Markers in Subclinical Atherosclerosis in Premature Ovarian Failure Patients. <b>2021</b> , 37, 30-37	
146	Dyslipidemia, Not Inflammatory Markers or Adipokines, Contributes Significantly to a Higher SYNTAX Score in Stable Coronary Artery Disease (from the Taichung CAD Study). <b>2021</b> , 37, 232-238	
145	Inflammation and ischemic heart disease: The next therapeutic target?. <b>2021</b> , 40, 785-796	1
144	Glasgow prognostic score can be a prognostic indicator after percutaneous coronary intervention: a two-center study in Japan. <b>2021</b> , 1	1

143	The Role of Inflammation in Post-TAVI Outcomes. <b>2021</b> , 117, 1028-1029	0
142	Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: State-of-the-Art Review.. <b>2021</b> , 3, 619-634	5
141	Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study.. <b>2022</b> , 15, 681-692	0
140	Influence of anti-TNF therapy and homocysteine level on carotid intima-media thickness in rheumatoid arthritis patients.. <b>2022</b> , 23, 59	3
139	Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease. <b>2021</b> , 49, 3000605211060890	0
138	Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. <b>2021</b> , 20, 220	5
137	Curcuma longa extract improves serum inflammatory markers and mental health in healthy participants who are overweight: a randomized, double-blind, placebo-controlled trial. <b>2021</b> , 20, 91	3
136	Combined impact of residual inflammatory risk and chronic kidney disease on long-term clinical outcomes in patients undergoing percutaneous coronary intervention. <b>2021</b> ,	0
135	Statins and Inflammation. <b>2021</b> , 23, 80	3
134	Specific impact of cardiovascular risk factors on coronary microcirculation in patients with subclinical hypothyroidism.	
133	The effect of low-dose combined hormone therapy (oestradiol and norethindrone acetate) on serum C-reactive protein levels and life quality in natural menopause women.. <b>2021</b> , 20, 177-183	
132	Cardiovascular Protection Effect. <b>2021</b> , 397-422	
131	Research Progress of Lp-PLA2: A Marker of Systemic Inflammatory Response. <b>2021</b> , 11, 5112-5118	
130	Anti-inflammatory strategies for atherosclerotic artery disease.. <b>2022</b> ,	1
129	Exploring the association of fibrinogen and CRP with the clinical spectrum of CAD and periprocedural outcomes in patients undergoing percutaneous coronary interventions.. <b>2022</b> , 25, 34-40	
128	Decreasing severity of obesity from early to late adolescence and young adulthood associates with longitudinal metabolomic changes implicated in lower cardiometabolic disease risk.. <b>2022</b> ,	0
127	Influence of Long-term Non-Aspirin NSAID use on Risk of Frailty in Men ≥0 years: The Physicians' Health Study.. <b>2022</b> ,	
126	Relationship between adiponectin multimer levels and subtypes of cerebral infarction.. <b>2022</b> , 17, e0262542	0



125	High-sensitivity C-reactive protein levels and pregnancy outcomes in women with unexplained infertility after ovarian stimulation with intrauterine insemination in a multicenter trial.. <b>2022</b> , 3, 57-62	0
124	Dissecting the IL-6 pathway in cardiometabolic disease: a Mendelian randomization study on both IL6 and IL6R.. <b>2021</b> ,	0
123	Inflammation, Chronic Disease, and Cancer: Is Psychological Distress the Common Thread?. <b>2022</b> , 1-19	
122	Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management. 16,	0
121	Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members.. <b>2022</b> , 10,	
120	Roles and mechanisms of puerarin on cardiovascular disease:A review.. <b>2022</b> , 147, 112655	2
119	Serial cardiac biomarker assessment in adults with congenital heart disease hospitalized for decompensated heart failure.. <b>2022</b> , 7,	2
118	Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.. <b>2022</b> , 11,	0
117	Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. <b>2003</b> , 249, 67-73	5
116	ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND GLYCOSYLATED HEMOGLOBIN IN TYPE-2 DIABETES MELLITUS: AN INDIAN PERSPECTIVE. <b>2022</b> , 4-7	
115	Transitional Changes in the Structure of C-Reactive Protein Create Highly Pro-Inflammatory Molecules: Therapeutic Implications for Cardiovascular Diseases.	
114	Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications.. <b>2022</b> , 130, 578-592	0
113	Association between maternal gestational diabetes mellitus and high-sensitivity C-reactive protein levels in 8-year-old children: the Yamanashi Adjunct Study of the Japan Environment and Children's Study (JECS).. <b>2022</b> ,	
112	Cardiovascular Inflammaging: Mechanisms and Translational Aspects.. <b>2022</b> , 11,	4
111	Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia: A long-term nationwide study.. <b>2022</b> ,	
110	Interleukin 6 in diabetes, chronic kidney disease and cardiovascular disease: mechanisms and therapeutic perspectives.. <b>2022</b> ,	2
109	Transcranial sonography depicts a larger substantia nigra echogenic area in renal transplant patients on calcineurin inhibitors than on rapamycin.. <b>2022</b> , 23, 108	
108	High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort.. <b>2022</b> , 21, 46	0

107	Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies.. <b>2022</b> , 17, e0264437	0
106	Molecular Basis for Paradoxical Activities of Polymorphonuclear Neutrophils in Inflammation/Anti-Inflammation, Bactericide/Autoimmunity, Pro-Cancer/Anticancer, and Antiviral Infection/SARS-CoV-II-Induced Immunothrombotic Dysregulation.. <b>2022</b> , 10,	0
105	ALB-dNLR Score Predicts Mortality in Coronary Artery Disease Patients After Percutaneous Coronary Intervention.. <b>2022</b> , 9, 709868	0
104	High-Sensitivity C-Reactive Protein and Ischemic Stroke in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study.. <b>2022</b> , 2022, 9711712	0
103	Association of Residual Inflammatory Risk with Stroke Recurrence in Patients with Acute Ischemic Stroke or TIA.. <b>2022</b> ,	
102	Recent advances in the development of active hybrid molecules in the treatment of cardiovascular diseases.. <b>2022</b> , 62, 116706	0
101	Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases.. <b>2022</b> , 108165	2
100	ROLE OF HS CRP AND LIPID ABNORMALITIES AS RISK FACTOR IN CORONARY ARTERY DISEASE. <b>2021</b> , 37-39	
99	Adipose tissue macrophages and atherogenesis $\square$ synergy with cholesterolaemia. <b>2021</b> , S535-S549	1
98	The role of the mineralocorticoid receptor in immune cells in in cardiovascular disease.. <b>2021</b> ,	2
97	Neuroinflammation, diabetes, and COVID-19: Perspectives coming from Ca <sup>2+</sup> /cAMP signalling.. <b>2021</b> ,	
96	Neuroinflammation as a Key Driver of Secondary Neurodegeneration Following Stroke?. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3 5
95	Association Between Occupational Sitting With High Sensitivity C-Reactive Protein: The Jackson Heart Study. 155982762110597	0
94	Plasma lipopolysaccharide-binding protein is a biomarker for future venous thromboembolism: Results from discovery and validation studies.. <b>2022</b> ,	0
93	A timeline of Ca <sup>2+</sup> /cAMP signalling: From basic research to potential therapeutics for dementia.. <b>2022</b> ,	0
92	Table_1.XLSX. <b>2018</b> ,	
91	Image_1.TIF. <b>2020</b> ,	
90	Image_2.TIF. <b>2020</b> ,	

89	Image_3.TIF. <b>2020</b> ,		
88	Image_4.TIF. <b>2020</b> ,		
87	Table_1.XLSX. <b>2020</b> ,		
86	Table_2.XLSX. <b>2020</b> ,		
85	Table_3.XLSX. <b>2020</b> ,		
84	Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study.. <b>2022</b> , 19, e1003911		3
83	Adipose tissue macrophages and atherogenesis - a synergy with cholesterolaemia.. <b>2021</b> , 70, S535-S549		
82	Atherogenesis and Inflammation. <b>2022</b> , 1-20		
81	Why there are so many contradicted or exaggerated findings in highly-cited clinical research?. <i>Contemporary Clinical Trials</i> , <b>2022</b> , 118, 106782	2.3	
80	The Impact of a Plant-Based Diet on Indices of Cardiovascular Health in African Americans: A Cross-Sectional Study.. <i>Applied Physiology, Nutrition and Metabolism</i> , <b>2022</b> ,	3	0
79	Progress in the Treatment of Acute Coronary Syndromes. <i>Circulation</i> , <b>2000</b> , 102,	16.7	
78	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. <b>2013</b> , 332-397		1
77	Characterization of coronary atherosclerotic plaques and the significance of vessel calcification. 40-46		
76	Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?. <i>Basic Research in Cardiology</i> , <b>2022</b> , 117, 28	11.8	1
75	Elevated C-reactive protein among symptomatic youth with bipolar disorder.. <i>Journal of Psychopharmacology</i> , <b>2022</b> , 36, 645-652	4.6	0
74	Cardiovascular Risk Assessment in Primary Prevention. <i>Contemporary Cardiology</i> , <b>2022</b> , 3-19	0.1	
73	High-Sensitivity C-Reactive Protein. <i>Contemporary Cardiology</i> , <b>2022</b> , 347-375	0.1	
72	Distinct Immunological Profiles Help in the Maintenance of Salivary Secretory IgA Production in Mild Symptoms COVID-19 Patients. <i>Frontiers in Immunology</i> , <b>2022</b> , 13,	8.4	2

71	Letter to the editor regarding the article: Inflammation and Ischemic heart disease: the next therapeutic target? <i>Revista Portuguesa De Cardiologia</i> , <b>2022</b> ,	1	0
70	Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 5680	6.3	3
69	Effect of anterior approach compared to posterolateral approach on readiness for discharge and thrombogenic markers in patients undergoing unilateral total hip arthroplasty: a prospective cohort study. <i>Archives of Orthopaedic and Trauma Surgery</i> ,	3.6	1
68	Relationship between C-reactive protein/albumin ratio and dipper/nondipper pattern in normotensive individuals. <i>Blood Pressure Monitoring</i> , Publish Ahead of Print,	1.3	
67	Novel predictive risk factor for erectile dysfunction: Serum high-sensitivity C-reactive protein. <i>Andrology</i> ,	4.2	
66	An overview of prognostic value of neurologic and cardiac biomarkers in patients with COVID-19 sequelae. <i>Hormone Molecular Biology and Clinical Investigation</i> , <b>2022</b> ,	1.3	0
65	A study on adiponectin, uric acid, and C-reactive protein in prediabetic and diabetic subjects. <i>BLDE University Journal of Health Sciences</i> , <b>2022</b> , 7, 89	0.1	
64	Ethnopharmacological and therapeutic potential of Terminalia arjuna and Camellia sinensis against cardiovascular diseases: Evidence and experimental studies. <b>2022</b> , 651-669		
63	Comparative evaluation of salivary and serum high-sensitive C-reactive protein in acute myocardial infarction. <i>Journal of Pharmacy and Bioallied Sciences</i> , <b>2022</b> , 14, 127	1.1	
62	Commercial Hormone Replacement Therapy Jeopardized Proinflammatory Factors in Experimental Rat Models. <i>Open Access Macedonian Journal of Medical Sciences</i> , <b>2022</b> , 10, 977-981	1	
61	The usefulness of C-reactive protein to predict improving left ventricular function after aortic valve replacement in patients with aortic regurgitation. <i>American Heart Journal Plus</i> , <b>2022</b> , 17, 100169		
60	Risk Factors Predisposing to Angina in Patients with Non-Obstructive Coronary Arteries: A Retrospective Analysis. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 1049	3.6	1
59	Role of Inflammation in Cardiac Remodeling After Acute Myocardial Infarction. <i>Frontiers in Physiology</i> , 13,	4.6	0
58	Community Acquired Pneumonia and Cardiac Diseases: A Fatal Association. <i>The Indian Journal of Chest Diseases &amp; Allied Sciences</i> , <b>2022</b> , 56, 153-156		3
57	Cardiovascular Disease in Myeloproliferative Neoplasms. <b>2022</b> , 4, 166-182		1
56	CHARACTERISTICS OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS. <b>2015</b> , 33-35		
55	Extracellular Vesicles, Inflammation, and Cardiovascular Disease. <b>2022</b> , 11, 2229		0
54	Cardiology co-management of rheumatoid arthritis patients with coronary artery disease as an intervention reduces hospitalization rates and adverse event occurrence.		0

53	Understanding the role of alternative macrophage phenotypes in human atherosclerosis. 1-17	
52	Causal Association of Thyroid Signaling with C-Reactive Protein: A Bidirectional Mendelian Randomization. <b>2022</b> , 2022, 1-8	
51	Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions.	4
50	High inflammatory burden predicts cardiovascular events in patients with axial spondyloarthritis: a long-term follow-up study. <b>2022</b> , 14, 1759720X2211224	0
49	Biomarkers: Tools for discriminating MODY from other diabetic subtypes. <b>2022</b> , 26, 223	0
48	Systemic Immune-Inflammation Index Predicts Long-Term Outcomes in Patients with Three-Vessel Coronary Disease After Revascularization: Results from a Large Cohort of 3561 Patients. Volume 15, 5283-5292	0
47	Combined assessment of frailty and nutritional status can be a prognostic indicator after percutaneous coronary intervention.	1
46	Targeting innate immunity-driven inflammation in CKD and cardiovascular disease.	2
45	C-reactive protein, immunothrombosis and venous thromboembolism. 13,	3
44	Effects of combination of obesity, diabetes, and hypoxia on inflammatory regulating genes and cytokines in rat pancreatic tissues and serum. 10, e13990	0
43	Stroke and Carotid Artery Disease. <b>2022</b> , 1207-1226	0
42	Roles of Oxidative Stress and Inflammation in Vascular Endothelial Dysfunction-Related Disease. <b>2022</b> , 11, 1958	3
41	Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities. 13,	2
40	Prognostic Impact of Statins on Patients With Peripheral Artery Disease With Elevated C-Reactive Protein Levels. <b>2022</b> ,	0
39	Inflammation in chronic kidney disease [Something old, something new. <b>2022</b> ,	0
38	Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review. <b>2022</b> ,	0
37	Er den observerte sammenhengen mellom periodontitt og hjerte- og karlidelser kausal?. <b>2003</b> , 113,	0
36	A Robust Framework Combining Image Processing and Deep Learning Hybrid Model to Classify Cardiovascular Diseases Using a Limited Number of Paper-Based Complex ECG Images. <b>2022</b> , 10, 2835	0

- 35 Rapid Drop in Coronary Heart Disease Mortality in Czech Male Population—What Was Actually behind It?. **2022**, 10, 2871 ○
- 34 Refinando o Risco Cardiovascular: Olhando Abaixo da Superfície do Círculo. **2022**, 119, 921-922 ○
- 33 Associations of systemic inflammation and social support with suicidal ideation in patients with acute coronary syndrome and stroke. **2023**, 323, 101-107 ○
- 32 Exploring biomarkers in routine diagnostics for the risk stratification of older patients in the Chest Pain Unit: a prospective cohort study. **2022**, 12, e056674 ○
- 31 Persistent Asthma Is Associated With Carotid Plaque in MESA. **2022**, 11, 1 ○
- 30 The IL-1 Family and Its Role in Atherosclerosis. **2023**, 24, 17 1
- 29 Drug-Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors). ○
- 28 Citri Reticulatae Pericarpium (Chenpi) Protects against Endothelial Dysfunction and Vascular Inflammation in Diabetic Rats. **2022**, 14, 5221 ○
- 27 Aspirin: The end of a myth. **2023**, ○
- 26 A Hidden Organism, Chlamydia in the Age of Atherosclerosis. ○
- 25 One-year nutrition counselling in the context of a Mediterranean diet reduced the dietary inflammatory index in women with breast cancer: a role for the dietary glycemic index. **2023**, 14, 1560-1572 ○
- 24 Associations among cardiorespiratory fitness, C-reactive protein, and all-cause mortality in men and women. 108155892211491 ○
- 23 Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives. **2023**, 24, 2079 ○
- 22 Cardiovascular Disease Causes Proinflammatory Microvascular Changes in the Human Right Atrium. ○
- 21 Cholesterol Reduction to Prevent CAD: What do the Data Show?. **2000**, 108, 40-52 ○
- 20 Destructive Periodontal Diseases, Systemic Inflammation and Atherosclerotic Complications: The Emerging Role of the Dental Profession. **2009**, 37, 773-777 ○
- 19 Recent advancements of nanomodified electrodes —Towards point-of-care detection of cardiac biomarkers. **2023**, 152, 108440 ○
- 18 ANGPTL4 stabilizes atherosclerotic plaques and modulates the phenotypic transition of vascular smooth muscle cells through KLF4 downregulation. **2023**, 55, 426-442 ○

- 17 Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: A bibliometric analysis of 1990-2022. **2022**, 10, 0
- 16 Cardiovascular disease and bone health in aging female rheumatic disease populations: A review. **2023**, 19, 174550572311552 0
- 15 Pre-Race Aspirin to Enhance Primary Prevention of Marathon-Related Cardiac Arrest: Confronting Pheidippides' Legacy. **2023**, 0
- 14 A Scoping Review on COVID-19-Induced Cardiovascular Complications. **2023**, 3, 348-369 0
- 13 Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. **2023**, 401, 1293-1301 1
- 12 Baseline inflammatory status affects the prognostic impact of statins in patients with peripheral arterial disease. 0
- 11 Koronare Herzkrankheit [Begutachtung]. **2022**, 1-25 0
- 10 Correlation between neutrophil-to-lymphocyte ratio after percutaneous coronary intervention and the size of infarction in patients with acute myocardial infarction. **2022**, 5, 468 0
- 9 Inflammation in Chronic Periodontitis and Significant Systemic Diseases. **2010**, 38, 247-257 0
- 8 The Protective Role of TREM2 in the Heterogenous Population of Macrophages during Post-Myocardial Infarction Inflammation. **2023**, 24, 5556 0
- 7 Awareness and Knowledge of Pneumococcal Vaccination in Cardiology Outpatient Clinics and the Impact of Physicians' Recommendations on Vaccination Rates. **2023**, 11, 772 0
- 6 C-reactive protein and high-sensitivity C-reactive protein levels in asymptomatic intestinal parasite carriers from urban and rural areas of Gabon. 0
- 5 Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4+ T cells. **2023**, 22, 0
- 4 The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients. **2023**, 29, 107602962311695 0
- 3 The bidirectional association between atrial fibrillation and myocardial infarction. 0
- 2 Predictive value of high sensitivity C-reactive protein in three-vessel disease patients with and without type 2 diabetes. **2023**, 22, 0
- 1 Fitness Attenuates Long-term Cardiovascular Outcomes in Women with Ischemic Heart Disease and Metabolic Syndrome. **2023**, 100498 0